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ABSTRACT 
 
Introduction: Sub-arachnoid haemorrhage (SAH) occurs when a cerebral artery 
ruptures and blood leaks out into the sub-arachnoid space.  This is often a catastrophic 
event for the individual and morbidity and mortality rates are significantly influenced 
by early intervention.  This makes the role of the clinical biochemistry laboratory in 
early diagnosis vitally important, as delays in diagnosis can have a major clinical 
impact. 
The cerebrospinal fluid (CSF) of healthy individuals is optically clear.  It has, 
however, been recognised for over a century that it can become coloured 
(xanthochromia) following a cerebrovascular incident such as a SAH.   This has made 
the main role of the clinical biochemistry laboratory in SAH diagnosis that of 
detecting xanthochromia in the CSF.   
The majority of laboratories which offer a xanthochromia screening service use the 
national guidelines that are based upon ultra-violet scanning spectrophotometry (350 
nm to 600 nm).  This analytical technique is not without its problems: it is subjective, 
has a possibility of inter-operator variability and due to the specialised nature of the 
test can take many hours or even days for a result to be issued. 
This project aimed to improve the current laboratory service by investigating: 
turnaround times, users opinions of the current service and potential alternative 
analytical methods.   
 
Methods: An audit of the current analytical provision was used to assess its 
effectiveness and in order to elucidate the service users’ perception.  This was 
effected by a questionnaire that was distributed to service users across three different 
NHS Trusts in England and Wales.   
In an attempt to improve the laboratory service, alternatives to scanning 
spectrophotometry were investigated.  These were selected through consideration of 
the nature of SAH i.e. blood is released into the subarachnoid space and the brain is 
damaged.  Laboratory analysis therefore needed to focus on detecting the presence of 
blood and/or its breakdown products, any change in CSF constituents that arise as a 
direct consequence of blood being introduced in to the subarachnoid space or a 
specific analyte which would only be present if brain damage occurred. 
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Investigation of current research into subarachnoid haemorrhage identified the 
following analytes as potential alternatives: CSF diazo bilirubin, CSF Ferritin, CSF 
protein S100 and serum protein S100. 
 
Results: The audit revealed the average turnaround time for reporting xanthochromia 
results to be 26 hours, with almost 20% of samples being reported as equivocal.  The 
service user’s questionnaire revealed a general lack of awareness of current United 
Kingdom National External Quality Assurance Scheme (UKNEQAS) guidelines for 
the ‘Analysis of cerebrospinal fluid for bilirubin in suspected Subarachnoid 
haemorrhage’ and a lack of understanding regarding the timing of lumbar punctures.  
Additionally, one third of users felt that the turnaround time for results was 
inadequate.   
CSF protein S100 was found to be unsuitable due to the difficulty in achieving a 
suitable balance between sensitivity and specificity; at a cut-off of 0.40 μg/l 
sensitivity is 80% and specificity is 4%, at a cut-off of 1.60 μg/l sensitivity is 40% and 
specificity is 94%.  Serum protein S100 was found to be unsuitable due to the 
difficulty in achieving a suitable balance between sensitivity and specificity at 
appropriate cut-offs (66 % and 73%, respectively, at a cut-off of 0.09 µg/l).  When the 
CSF diazo bilirubin and CSF ferritin were compared to current laboratory practises 
using pre-defined criteria then CSF diazo bilirubin was found to be the analyte of 
choice to base new guidelines upon.  CSF diazo bilirubin was then used as an initial 
‘rule-out’ step in a new set of guidelines for the determination of SAH utilising CSF 
analysis.  
 
Conclusion: The new guidelines employ CSF diazo bilirubin analysis as a ‘rule-out’ 
step with all samples that are above the cut-off (300 nmol/l) being processed through 
the UKNEQAS guidelines.  In order for the guidelines to be introduced and accepted, 
local training and education programmes for laboratory and clinical staff will need to 
be developed and implemented and they will need to be disseminated through 
publication of articles in journals relevant to both the clinical biochemistry 
community and requesting clinicians. 
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Chapter 1 
Literature review and research background 
  2 
1.1. Sub-arachnoid haemorrhage 
 This first chapter affords the reader details of what a sub-arachnoid 
haemorrhage (SAH) is and how it is currently diagnosed and treated.  Appendix 1 lists 
the terms used to search for relevant literature to review for this chapter. 
 
1.1.1. What is a sub-arachnoid haemorrhage? 
SAH occurs when a cerebral artery ruptures and blood leaks out into the sub-
arachnoid space.  There are three membranes that cover the brain and the spinal cord, 
known collectively as the meninges.  They are the pia mater (inner membrane), the 
arachnoid mater (middle membrane) and the dura mater (outer membrane).  Blood 
vessels, supplying blood to the brain lie in the sub-arachnoid space, between the pia 
mater and the arachnoid mater, surrounded by cerebrospinal fluid (CSF). 
The most common cause of SAH is the rupture of an aneurysm (80-90%), 
other causes include; trauma, dissection of vertebral and carotid arteries, 
arteriovenous dura mater and spinal malformations, rupture of mycotic aneurysm, 
sickle cell disease,  coagulopathy, cocaine abuse and pituitary apoplexia (Crespo, 
1998, p.4).  
An aneurysm is a localised dilation or ballooning of a blood vessel by more 
than 50% of the diameter of the vessel and rupture can lead to instantaneous death. 
Aneurysms most commonly occur in arteries within the Circle of Willis (Figure 1.1) 
and in the aorta (an aortic aneurysm).  The larger an aneurysm becomes, the more 
likely it is to burst.  Aneurysms are also described according to their shape: saccular 
or fusiform. A saccular aneurysm resembles a small sack; a fusiform aneurysm is  
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Figure 1.1:  The Circle of Willis (From: Grey’s Anatomy of the Human body, 
Philadelphia: Lea and Febiger, 1918).  
 
shaped like a spindle.   Saccular aneurysms occur  around  arterial  bifurcation  points; 
they vary in size from 5 to 20 mm in diameter and are the result of processes, which 
affect only part of the circumference of the vessel wall. Their lumen is connected with 
the lumen of the affected vessel through an opening, which varies in size.  As a 
consequence, flow through the aneurysm is turbulent and thrombosis is common.  
The Circle of Willis is a circle of arteries that supply the brain, named after an 
English physician, Thomas Willis.  The arrangement of the brain’s arteries into the 
Circle of Willis creates redundancies in the cerebral circulation.  If any one of the 
arteries that make up or supply the circle become blocked or narrowed, blood flow 
from the other blood vessels can normally maintain cerebral perfusion. 
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1.1.2. Aetiology and epidemiology of SAH 
The combined worldwide incidence of SAH is about six cases per 100,000 
patient years (Linn et al., 1996, p.628).  Cerebral aneurysms have been identified in 
2.3% of autopsies, with prevalence in the adult population estimated at 2% that may 
possibly increase with age (Rinkel et al., 1998, p.253 & p.255).  There is a 
geographical worldwide variation in incidence, with Finland and Japan consistently 
demonstrating the highest incidence rates (Wood & Nowitzke, 2005, p.770).  The 
underlying reason for the geographical incidence is unclear but may reflect 
differences in genetic and environmental factors in different populations. 
The average age of patients with SAH is substantially lower than for other 
types of stroke, peaking in the fifth and sixth decade (Qureshi et al., 2001, p.609; 
Wood & Nowitzke, 2005, p.771).  Gender also influences the incidence of SAH with 
women having a 1.6 times higher risk than men (Linn et al., 1996, p.626; Macpherson 
et al., 2011, p.3).  
Race has a variable effect on incidence, with black people living in a 
developed country having a risk 1.8 times that of whites (Kissela et al., 2004, p.428).  
When this is compared to the risk of SAH in blacks living in a developing country, 
there is a five times higher risk in a developed country such as the United Kingdom, 
compared to a developing country such as Barbados (Wolfe et al., 2006, p.1988).  
This may be due to significantly higher rates of hypertension, diabetes, smoking and 
heavy alcohol use in the developed country population (Kissela et al., 2004, p.428; 
Wolfe et al., 2006, p.1989). 
A number of modifiable risk factors are linked to an increased incidence of 
SAH, including cigarette smoking, excessive alcohol intake, coffee consumption and 
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hypertension (Qureshi et al., 2001, p.610; Isaksen et al., 2002, p.186; Feigin et al., 
2005, p.2778; Shiue et al., 2012. p.93). 
There are a few specific heritable disorders of connective tissue associated with an 
increased risk of SAH (polycystic kidney disease and Ehlers-Danlos syndrome) but 
these patients only account for a minority of all SAH (van Gijn & Rinkel, 2001, 
p.250).   
The incidence of SAH appears to have a circadian and seasonal rhythm; the 
occurrence of SAH is increased from 8 am to 4 pm independent of sex, age, and 
hypertension, possibly in relation to increases in blood pressure in the early morning 
and early afternoon (Nyquist et al., 2006. p.192).  Increased incidence during the 
winter months is thought to be linked to increased cardiovascular stresses such as 
stress of physical activity in extremes of temperature and specific effects of abrupt 
temperature changes or temperature extremes on the blood pressure and 
cardiovascular system.  These cardiovascular stresses can lead to fluctuations in blood 
pressure, blood coagulability and cardiovascular performance (Nyquist et al., 2006. 
p.192).  Conversely a more recent study (Cowperthwaite & Burnett, 2011, p. 135) 
found that neither seasonal nor weather trends influenced the incidence of SAH 
Around 2% of patients presenting to an emergency department with the ‘worst 
headache of their life’ will have suffered SAH (Morgenstern et al., 2001, p.538).  
 
1.1.3. Symptoms of SAH 
The classic presentation of SAH is an unusually severe almost instantaneous 
headache in the back of the head accompanied by loss of consciousness or focal 
deficits (a problem in nerve function that affects a specific location or a specific 
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function). Almost a third of patients present with a headache as their only symptom 
and only half of these report it to be instantaneous (Linn et al.,1998, p.792).   
In the days or weeks leading up to SAH, thunderclap or warning headaches 
may develop in seconds, achieve maximum intensity in minutes and last hours to 
days.  These are termed ‘warning’ or ‘sentinel’ leaks and occur in 30–50% of subjects 
(Newton & Oman, 2005).  These sentinel leaks are mild but the rebleeding which 
follows is usually severe. 
Neck stiffness (meningism) is fairly common but can take 3–12 hours to 
develop.  Less common presentations associated with SAH such as vomiting and low 
grade fever, neck pain, symptoms of sciatica, confusion, agitation or restlessness 
make clinical diagnosis difficult. 
 
1.1.4. Diagnostic investigation of SAH 
SAH diagnosis is notoriously difficult despite the widespread availability of 
neuroimaging equipment.  The difficulty stems from the variety of clinical 
presentations, the limitations of computed tomography (CT), and the difficulty in 
performing and correctly interpreting the results of lumbar puncture, Table 1.1 
(Edlow, 2002, p.32). 
The time of day at which a patient attends the accident and emergency 
department and has their CT scan performed, can have a significant impact on the 
diagnostic value of the CT scan.  Strub et al (2007, p.1680) found that the second 
most common pattern of haemorrhage that was misdiagnosed by radiology staff ‘out-
of-hours’ (5 pm – 7 am) was SAH, accounting for 33% of misdiagnosis due to 
misidentified haemorrhage.  
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Table 1.1: Reasons for error in diagnosis in SAH (Edlow, 2002, p.33). 
 
Variety of clinical presentations of SAH 
 Not evaluating patients with unusual (for the patient) headaches 
 Failure to appreciate that the headache can improve spontaneously or with 
non-narcotic analgesics 
 Over-reliance on the classic presentation with misdiagnosis of; 
o Viral syndrome, viral meningitis and gastroenteritis 
o Migraine and tension-type headache 
o Neck pain (rarely, back pain) 
o Psychiatric diagnoses 
 Focus on the secondary head injury (resulting from syncope) 
 Focus on electrocardiographic abnormalities 
 Focus on elevated blood pressure 
 Lack of knowledge of presentation of the un-ruptured aneurysm 
Limitations of CT 
 CT scans are less sensitive with increasing time from onset of the headache 
 CT scan can be falsely negative with small volume bleeds (spectrum bias) 
 Interpretation factors (expertise of clinician reading the scan) 
 Technical factors (Have thin cuts been taken at the base of the brain? Is there 
motion artefact?) 
 CT can be falsely negative for blood at haematocrit level of less than 30% 
Difficulty in performing and correctly interpreting the results of lumbar puncture 
 Failure to do lumbar puncture in patients with negative, equivocal or sub-
optimal CT scans 
 Failure to recognise that xanthochromia may be absent very early (< 12 hours) 
and very late (> 2 weeks) 
 Failure to realise that visual inspection for xanthochromia is less sensitive than 
measurement by spectrophotometry 
 Failure to properly distinguish traumatic tap from true subarachnoid 
haemorrhage 
 
Modern CT imaging of patients reporting worst headache symptoms fails to 
detect approximately 2% of those who have suffered SAH (Morgenstern et al., 1998, 
p.303; Gee et al., 2012).  Patients who present with decreased levels of consciousness 
due to significant SAH uniformly have CT scans positive for blood.  Third generation 
CT scanners are reported to have 100% sensitivity and specificity for identifying SAH 
if carried out within 6 hours of onset (McCormack, 2012, p.27), although these 
scanners are not universally routinely available in the United Kingdom.  This 
sensitivity and specificity can only be achieved if the scans are interpreted by an 
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experienced radiologist and beyond six hours the sensitivity and specificity decreases 
dramatically. 
Lumbar puncture should be performed in all patients whose clinical 
presentation suggests SAH and whose CT scan is negative, equivocal or technically 
inadequate.  Published research suggests that < 50% of patients who present to the 
emergency department with a severe headache and have a negative CT go on to have 
a lumbar puncture (Morgenstern et al., 1998, p. 298;  O’Neill et al., 2005, p. 152).   
The CSF of healthy individuals is optically clear, but for over a century it has 
been recognised that it can become coloured (xanthochromia) following a 
cerebrovascular incident such as SAH.   This has made the traditional role of the 
laboratory in SAH diagnosis that of detecting xanthochromia in the CSF.  Until the 
mid-1950’s xanthochromia could only be assessed qualitatively by visual 
interpretation.  The introduction of spectrophotometry brought with it the ability to 
measure pigments present in coloured CSF. 
Xanthochromia is by definition the yellow discolouration indicating the 
presence of bilirubin in the CSF.  Following haemorrhage red cells undergo lysis (due 
to the low osmolarity of CSF) and phagocytosis, releasing oxyhaemoglobin, which is 
metabolised by haem oxygenase in the arachnoid and choroid plexus to form bilirubin 
(Roost et al., 1972, p.975).  At least 12 hours are required to reach peak enzyme 
activity following SAH (Roost et al., 1972, p.975), therefore the minimum period for 
CSF xanthochromia detection is 12 hours after onset of symptoms.  Xanthochromia 
indicates in-vivo haemorrhage, whereas detection of red blood cells and 
oxyhaemoglobin cannot differentiate in-vivo haemorrhage from blood introduced into 
the CSF due to a traumatic lumbar puncture.   
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There is conflicting advice within the available literature regarding the ‘three-
tube’ test in which the comparative ‘bloodiness’ of consecutively collected CSF tubes 
is used to determine if there is an SAH or it is a ‘traumatic tap’.  On the one hand 
there is clear advice that when used appropriately the ‘three-tube’ test can provide an 
indication of the occurrence of a traumatic tap (Shah & Edlow, 2002, p.69), whereas 
others present clear evidence that a decrease in red blood cells in consecutive tubes 
also occurs if there has been a previous bleed (Heasley et al., 2005, p.823).  Other 
research which also focuses on the significance of blood in the CSF, has utilised urine 
test strips to exclude cerebral spinal fluid blood (Marshall & Hejamanowski, 2011, p. 
63).  This was a small pilot study which gave a sensitivity of 91% and specificity of 
58%.   
If the patient presents late, 100% still have xanthochromia at two weeks post 
haemorrhage, 70% after three weeks and 40% after four weeks (Vermeulen & van 
Gijn, 1990, p.369).  Upon closer examination of this research, xanthochromia detected 
at two, three and four weeks post haemorrhage was found as a consequence of 
repeated lumbar punctures.  There is a danger here that the xanthochromia detected at 
two weeks and later could be attributable to blood introduced into the cerebro-spinal 
space during the initial lumbar puncture. 
Cerebral angiography is the accepted ‘gold standard’ in the diagnosis of SAH 
and must be performed in a specialist centre: a catheter is inserted into a main artery 
(usually leg), threaded through the main vessels of the abdomen and chest until 
positioned in the desired artery - contrast dye is injected into one or both of the carotid 
or vertebral arteries in the neck.  Cerebral angiography is not however, without its 
risks; in 0.9–1.4% of cases there are transient and reversible neurological 
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complications and in 0.5–0.7% there is permanent neurological deficit (Dion et al., 
1987, p.1002; Wilinsky et al., 2003, p.526).   
Neurological complications consist mainly of:  hemiparesis, aphasia, blindness 
and ataxia and are considered transient if they last less than 24 hours, reversible if 
they resolve within one week and permanent if they persist for more than one week 
post procedure (Kaufmann et al., 2007, p.814).  Dion et al. (1987, p.1002) monitored 
patients for 72 hours post procedure.  Whereas Wilinsky et al. (2003, p.526) only 
monitored patients for 24 hours post procedure.  In both of these studies it is assumed 
that any event following the cerebral angiography is attributable to it even though the 
culprit may well have been the primary disease (Dion et al., 1987, p.1002).  Risk 
factors which increased the likelihood of a neurological event within 24 hours where 
the length of the procedure itself, systolic hypertension prior to commencement of the 
procedure, presence of cardiovascular disease and increasing age (Dion et al, 1987, 
p.1000; Wilinsky et al., 2003, p.525).  Risk factors 24-72 hours post procedure 
included increasing age and diabetes mellitus (Dion et al, 1987, p.1000). 
Some studies have also identified factors which decrease the risk of 
neurological complications, the primary one being the level of experience the operator 
undertaking the cerebral angiography (Kaufmann et al., 2007, p.817). 
A number of potential mechanisms for complications following cerebral 
angiography have been proposed, including thromboembolism from the catheters and 
guide wires and disruption of atherosclerotic plaques (Wilinsky et al., 2003, p.526). 
There are a number of different grading systems used for the classification of 
SAH severity.  The two most widely used are that of Hunt and Hess (Hunt & Hess, 
1968, p.14) and the World Federation of Neurological Surgeons (WFNS) (Drake, 
1988, p.985), both of which are described in Table 1.2.  The WFNS scale is the scale  
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Table 1.2: The two most widely used grading scales for the classification of SAH 
severity; Hunt and Hess (1968, p.14) and the World Federation of Neurological 
Surgeons (Drake, 1988, p.985). 
 
Hunt and Hess grading scale 
Scale Symptom 
1 Asymptomatic, mild headache, slight nuchal 
(nape of the neck) rigidity 
2 Moderate to severe headache, nuchal rigidity, no 
neurological deficit other than cranial nerve palsy 
3 Drowsiness/confusion, mild focal neurologic 
deficit 
4 Stupor, moderate-severe hemiparesis, possibly 
early decerebrate rigidity & vegetative 
disturbances 
5 Deep coma, decerebrate rigidity, moribund 
appearance 
World Federation of Neurological Surgeons 
Grade Glasgow Coma 
Scale 
Motor deficit 
I 15 Absent 
II 14–13 Absent 
III 14–13 Present 
IV 12–7 Present or absent 
V 6-3 Present or absent 
 
currently preferred as it is based upon the sum score of the Glasgow Coma Scale 
(GCS), a very reliable method of evaluating the level of consciousness, and the 
presence of focal neurological signs (Suarez et al., 2006, p.387).  The higher the 
WFNS scale, the worse the prognosis. 
The GCS is a means of assessing the severity of brain impairment.  It 
examines three different factors; eye response, verbal response and motor response.  
The scale is from 3 (a deep coma) to 15 (a light coma with a better prognosis). 
 
1.1.5. Treatment and outcomes of SAH 
The medical treatment of patients with aneurysmal SAH is directed towards 
the prevention and management of neurological (aneurysm rebleeding, 
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hydrocephalus, cerebral vasospasm, ischaemia and seizures) and systemic 
complications (hyponatraemia, cardiac arrhythmia, myocardial damage and 
neurogenic pulmonary oedema) (Feigin & Findlay, 2006, p.305).  
There are two sets of guidelines which have been published recently for the 
management of SAH, one from the Neurocritical Care Society (Diringer et al., 2011, 
p.211) and the second from the American Heart Association/American Stroke 
Association (Connolly et al., 2012).  These guidelines not only  focus on the 
neurological and systemic complications stated above but they also consider the 
location at which patients should be treated, both coming to the same conclusion that 
SAH should preferably be treated at high volume centres (35 - 60 cases per year) as 
this was associated with better outcomes. 
SAH should be evaluated and treated as an emergency with initial priorities 
focussing on the maintenance of the patient’s airway and cardiovascular function.  
The patient should be transferred to a neurology unit as soon as practical to optimise 
care.  Once airway and cardiovascular function have been stabilised the main goals 
are prevention of re-bleeding and the prevention and management of vaso-spasm.  
Pain management, sedation and control of hypertension are important in preventing 
re-bleeding.  Avoidance of hypovolaemia, hypotension and hyponatraemia are 
important in preventing delayed cerebral ischaemia. 
Frequent checking of the GCS and pupillary responses as well as vigilance for 
focal neurological deficits is essential, as a drop of just one point in GCS may be the 
first sign of a complication.  Careful monitoring of blood pressure, fluid balance, heart 
rhythm and respiratory function are crucial due to the risk of developing cardiac 
arrhythmia and pulmonary oedema. 
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Once SAH has been diagnosed it is important to determine the cause by 
further investigation; three quarters of spontaneous cases are due to ruptured 
aneurysms, 20% have no identifiable cause (at least half of which are due to 
idiopathic or non-aneurysmal perimesencephalic SAH), the remainder are due to a 
variety of rare disorders; arteriovenous malformations of the brain or spine, arterial 
dissections, sympathomimetic drugs, tumours, vasculitis. 
As twenty % of people with SAH have multiple aneurysms, a CT scan can be 
crucial in identifying which one has ruptured, and the pattern of blood on the CT scan 
may suggest the location of the aneurysm Table 1.3 (Al-Shahi et al., 2006, p.237). 
Mortality rates following SAH in the community are 12%, and 10% of those 
who reach hospital alive die within 24 hours.  The majority of deaths occur within the 
first three weeks post SAH and almost all are due to rebleeding (Al-Shahi et al., 2006, 
p.238).  One year after SAH two thirds of previously employed people have returned 
to work, over 50% report problems with memory, mood or neuropsychological 
function, 10% are dependant in activities of daily living and 4% require institutional 
care (Hackett & Anderson, 2000, p.660).    
 
Table 1.3: The relationship between blood patterns found in CT scans and the 
location of the aneurysm. 
 
 
Most common 
blood pattern 
 
 
 
Least common 
blood pattern 
Anterior communicating artery complex – blood in the 
interhemispheric fissure 
Internal carotid artery 
Middle cerebral artery - blood in the sylvanian fissure 
Vertebrobasilar circulation 
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Once the patient has been stabilised, the next phase of treatment is to secure 
the aneurysm.  The main purpose of securing or occluding the aneurysm is to prevent  
re-bleeding.  There are a number of factors which need to be taken into 
account when determining if treatment is possible, including; age, WFNS grade, co-
morbidity, time from onset of SAH and the aneurysms vascular anatomy. 
Neurosurgical clipping became standard treatment for SAH in the 20
th
 century 
but it has now been superseded by endovascular occlusion using detachable coils.  
Clipping is still utilised for patients with large aneurysms and coiling is used in the 
elderly or those with a poor grade WFNS classification (Connolly et al., 2012, p.11).  
If the aneurysm is suitable for treatment, coiling has an absolute risk reduction of 
about 7% for dependency or death at one year, with benefit sustained to seven years.  
Evidence for the durability of coiling beyond seven years is still awaited.  Aneurysmal 
occlusion is attempted as soon as practicable (within 3-4 days) to prevent re-bleeding. 
SAH is a medical emergency requiring expeditious surgical intervention, but 
for this to be carried out within an effective time frame it needs to be diagnosed 
swiftly and correctly.  The most readily accessible imaging method available for 
emergency admissions is CT scanning, but due to the inherent problems with 
correctly identifying an SAH with a head CT further diagnostic support is required.  
Problems include; decreasing sensitivity with increasing time from onset of headache, 
scan may be falsely negative with small volume bleeds, expertise of the clinician 
reading the scan and technical factors (Edlow, 2002, p.33).  This is where the clinical 
biochemistry laboratory is invaluable in that it can analyse CSF for the breakdown 
products produced following an SAH. 
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1.2. Role of the clinical biochemistry laboratory 
in the diagnostic investigation of SAH 
Traditional visual assessment of CSF samples for xanthochromia is subject to 
confounding factors, including visual detection limits of the naked eye (Marden et al., 
2001, p.54; Bradley et al., 2003, p.74), high CSF protein concentration (Jerrard et al., 
2001, p.173), or haemolysed red blood cells from a traumatic tap (Shah & Edlow, 
2002, p.70).  Until relatively recently CSF xanthochromia in the majority of clinical 
biochemistry departments was assessed either visually or by a variety of ‘in-house’ 
methods based on spectrophotometry.  In 1998, Chalmers and Kiley (1998, p.1740) 
proposed a method which simplified the process of scanning spectrophotometry for 
CSF xanthochromia.  In 2001 Chalmers (2001, p.147) followed this with further 
research which refined the process.  Following the publication of these two papers a 
working group was formed to develop guidelines on CSF sampling, transport, 
handling, analysis and interpretation (Beetham, 2004, p.528).  The outcome of this 
working group was the introduction of National guidelines for the analysis of CSF 
bilirubin by scanning spectrophotometry in suspected SAH (UKNEQAS, 2003, p.481) 
by the United Kingdom National External Quality Assurance Scheme (UKNEQAS, 
see Appendix 2).  These guidelines standardised the spectrophotometric investigation 
of CSF for xanthochromia and reduced subjectivity as compared to visual 
investigation. 
There are currently 171 laboratories within the United Kingdom who 
subscribe to the UKNEQAS for CSF Haem pigments Quality Assurance Scheme.  
This scheme provides quality assurance for determination of CSF bilirubin in 
suspected SAH in line with UKNEQAS Guidelines.  This means that there are at least 
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171 laboratories in the UK which provide CSF bilirubin analysis in suspected SAH in 
line with UKNEQAS Guidelines. 
The introduction of the UKNEQAS Guidelines has removed the inaccuracies 
of visual examination in that the human eye cannot differentiate between a 
xanthochromia negative CSF sample and a ‘borderline’ positive sample (Bradley et 
al., 2003, p.74).  It has also consolidated the variety of different methods of 
spectrophotometry that were being employed by a number of laboratories. 
Scanning spectrophotometry is still not the answer; it is still subjective and has 
a possibility of inter-operator variability, is dependent upon which system is used 
within the laboratory and whether the baseline is positioned or drawn manually 
following spectrophotometric scanning of the CSF sample (Figure 1.2).  This could 
have a major impact when dealing with borderline samples in that there is a very real 
potential for the laboratory to report both false positives and false negatives. 
 
Figure 1.2:  Example of a spectrophotometric scan of CSF for xanthochromia 
determination, the sample was scanned from 350 nm to 550 nm.  The baseline was 
then applied from 360 nm to 520 nm. 
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Predicted CSF   =    CSF total protein (g/l)   x   serum bilirubin (mol/l)   x   0.042 
  Absorbance         Serum total protein (g/l) 
 
Equation 1.1: Calculation of serum bilirubin’s contribution to CSF bilirubin 
 
More recently there have been moves towards utilising software to interpret 
sepctrophotometric scans, automatically positioning the baseline and providing 
interpretation based upon the UKNEQAS guidelines.  This is available as a 
commercial product (NorthStar Scientific) and as a ‘free’ web interface (Collett et al., 
2012, p.182), neither of these products will account for pre-analytical error and 
neither are CE marked. 
There is also concern that when employing the UKNEQAS Guidelines, too 
much emphasis is placed upon the presence of oxyhaemoglobin and its possible 
interference and that the calculation (Equation 1.1) used to estimate serum bilirubin’s 
contribution to CSF bilirubin overestimates by up to 15%, which could lead to false 
negatives (Chalmers, 2003, p.132; Brunt, 2006, p.165).  The authors of the 
UKNEQAS guidelines endorse the use of the equation as it avoids using a reporting  
phrase such as ‘false-positives may occur in hyperbilirubinaemic patients’ 
which has the potential to underemphasise the likelihood of SAH (Beetham et al., 
2006, p.166). 
There are also issues relating to high CSF proteins which result in the 
interpretive comment ‘interpret with caution’ being issued.  These high CSF proteins 
are seen in cases of meningitis and as the clinical signs of SAH and meningitis are not 
dissimilar there is a very real possibility of xanthochromia requests being undertaken 
on patients with meningitis and the results clouding the diagnostic process. 
The future skills mix of pathology also needs to be considered.  Currently the 
majority of   analytical   tasks   (including   scanning   spectrophotometry   for   
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xanthochromia analysis) are undertaken by Health and Care Professions Council 
(HCPC) registered Biomedical Scientists.  This is very likely to change with more 
support worker grades becoming involved and also the introduction of the associate 
practitioner (an intermediate grade between support worker and registered 
professional).  If this were to happen then the analytical process for determining 
xanthochromia in CSF needs to become less technically demanding in order to 
accommodate the changing skills mix of pathology. 
There are also concerns regarding the range and sophistication of scanning 
spectrophotometers in use around the UK.  For example; Southampton University 
Hospital NHS Trust report some CSF samples as ‘uninterpretable’, due to the 
negative absorbances which cannot be assessed with their current equipment (Nuala 
O’Connell, personal communication, June 2008).  This could potentially be another 
source of problems related to clinical biochemistry laboratories provision for 
xanthochromia analysis. 
In order to address these issues, with an aim to improving the xanthochromia 
service provided by clinical biochemistry laboratories, a number of areas need to be 
investigated. 
 
1.3. Aims and objectives of research project 
The aim of this research is to enhance clinical biochemistry service provision 
of the analysis of CSF bilirubin in determining the occurrence of SAH.  In order to 
meet this aim the research project has the following objectives: 
1. To examine processes and identify problems with the current laboratory 
service for detection of SAH, through surveying requesting clinicians and 
examining the current UKNEQAS National Guidelines. 
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2. To develop an alternative laboratory test(s), which could be used to identify 
patients who have suffered an SAH, utilising cerebral spinal fluid and/or 
serum samples. 
3. To compare the alternative laboratory test(s) with existing laboratory practice 
i.e. the UKNEQAS National Guidelines. 
4. To present an alternative or supplement to the current UKNEQAS National 
Guidelines for the laboratory diagnosis of SAH which is accessible to all 
laboratories; timely, feasible and employs commonly used analytical 
equipment. 
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Chapter 2 
Current laboratory service provision for the 
detection of sub-arachnoid haemorrhage 
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2.1. Introduction 
This chapter satisfies objective one of this research ‘To examine processes and 
identify problems with the current laboratory service for detection of SAH, through 
surveying requesting clinicians and examining the current UKNEQAS National 
Guidelines.’  Appendix 1 lists the terms used to search for relevant literature to review 
for this chapter. 
 
 
2.1.1. Background 
An audit (2004/2005 – Appendix 3) of the clinical biochemistry services 
within Swansea NHS Trust revealed that the average turn-around time for reporting 
xanthochromia results was 26 hours and almost 20% of the samples were reported as 
equivocal (in the majority of cases this was due to the presence of ‘significant’ 
amounts of oxyhaemoglobin as a direct result of traumatic lumbar puncture).  The 
average turn-around time was overly long as the service provided at the time only 
covered normal laboratory hours (9 am – 5 pm) Monday to Friday.  This was due to 
the limited number of staff who had sufficient technical expertise to undertake this 
analysis. 
This average turn-around time of 26 hours does not fit with the laboratory’s 
ethos to report requests on acute admissions within a time frame more suited to the 
clinical need and length of analysis rather than the availability of suitably trained 
staff.  There is some suggestion from outside the laboratory that the relatively long 
turnaround time for CSF xanthochromia is in some instances delaying patient 
discharge and thus contributing towards ‘bed blocking’ within the NHS. 
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In 2000 the Government committed to reducing waiting times in accident and 
emergency (A&E) departments (Department of Health, 2000 , p.103).  At the end of 
March 2003 a pre-announced audit of A&E waiting times in England was carried out 
by the Department of Health; the target was that 90% of patients should be seen 
within four hours (British Medical Association, 2003, p.1).  There were concerns 
raised that Trusts would throw unsustainable resources at the time period to be 
audited and possibly cancel elective work to meet the A&E target.  As a consequence 
the British Medical Association (BMA) carried out a survey of A&E consultants 
regarding the audit week.  The results of the BMA survey revealed that 72% of 
responding departments introduced special arrangements, including: use of agency 
staff, double and extended shifts and cancellation of operations.  The week before the 
audit only 55% of departments met the Government’s 90% target.  This increased to 
85% during the week of the audit and then fell again to 63% the week after.  The 
major concern with these findings was that resources provided during the audit week 
were unsustainable and rather than meeting Government targets there should be more 
focus on developing long-term improvements in capacity (British Medical 
Association, 2003, p.6). 
In February 2004 a new incentive scheme aimed at reducing A&E waiting 
times was introduced by the Government (British Medical Association, 2005, p.1).  
Targets for the scheme require 97% of patients to be seen, treated or discharged 
within four hours.  A survey carried out by the BMA in 2005 (British Medical 
Association, 2005, p.2) indicated that of those A&E departments who failed to meet 
the targets for the period ending December 2004, 30% cited a delay in accessing 
diagnostic services as a major reason for missing the targets.  In order to meet these 
targets, patients, such as those suspected of SAH, are admitted as in-patients due to 
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necessary delays in sample collection, i.e. 12 hours post event is the optimum time 
required to determine the presence of bilirubin in the CSF.  As the average laboratory 
turn-around time for CSF bilirubin by scanning spectrophotometry analysis in 
Swansea NHS Trust was 26 hours this results in a considerable amount of 
unwarranted time for a hospital bed to be occupied, i.e. bed blocking.  In Swansea 
NHS Trust, over the internal audit period, this could equate to one hospital bed being 
unnecessarily occupied for up to 160 days. 
In 2004 the Association of Clinical Biochemists (ACB) conducted a national 
audit of CSF testing in suspected SAH (Holbrook et al, 2007, p.443).  Questionnaires 
were sent out electronically via regional audit committees, therefore it is not possible 
to ascertain exactly how many questionnaires were issued.  Eighty four replies were 
received from across Northern Ireland, Scotland, Wales and England.  Of those who 
responded 67% performed scanning spectrophotometry on-site, 22% referred samples 
to another laboratory and 6% did not offer a service.  The 6% who did not offer a 
service served a total population of over 2 million.  Of the sites which did provide an 
on-site scanning spectrophotometry service, 57% provided a 24 hour service, although 
34% of these qualified this as only after consultation with a clinical biochemist ‘out of 
hours’, the remaining 33% only provided a service within ‘core-hours’ (Holbrook et 
al, 2007, p.444).  These results clearly demonstrate the variability across the UK in 
the service provision for CSF testing in suspected SAH.  The data provided in this 
audit also indicated that where scanning spectrophotometry did occur, the UKNEQAS 
Guidelines were not always being strictly adhered to.  Of course as this audit was 
carried out in the autumn of 2004, this nationwide picture will undoubtedly have 
changed during the intervening nine years. 
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Under the current Guidelines there are fourteen possible interpretative 
comments, it may not always be clear from the comments what the laboratory is 
trying to convey to the requesting clinicians.  Remarks made by the ‘reporting team’ 
at Swansea NHS Trust indicate that they do receive a number of enquiries regarding 
these comments, as to what the information provided actually means for the patient. 
 
2.1.2. Surveying the opinion of requesting clinicians 
Although not the main thrust of this research, the perception of requesting 
clinicians regarding the laboratory service for xanthochromia analysis would provide 
valuable information.  In healthcare, quantitative surveys are used in the following 
areas (McColl & Thomas, 2000, p.8): 
 Epidemiology e.g. health needs assessments, health and lifestyle 
surveys, surveys of specific disease groups 
 Health services research e.g. trials of health care interventions, health 
technology assessment, assessment of health-related behaviour, quality 
of life 
 Audit e.g. patient satisfaction surveys 
As this part of the research is an audit of user views and satisfaction of the 
service provided it is therefore ideally suited to the quantitative survey approach.   
In quantitative survey research there are three common modes of data 
collection; self-completion questionnaires, face-to-face interviews and telephone 
interviews.  All of these have their advantages and disadvantages, for example self-
completion questionnaires are good for avoiding distortion due to interviewer effects, 
but there is poor control over who completes the questionnaire, whereas face-to-face 
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interviews are good for open ended questions but are expensive to undertake (McColl 
et al., 1998, p.52).  
A self-completion questionnaire was selected for this research as it is an 
efficient use of time, provides anonymity for the respondent, ensures that all 
respondents receive identical questions, and can be used to gather information on both 
knowledge and opinion (Dillman, 1978, p.80; Munn & Drever, 2004, p.2). 
 
2.1.3. Xanthochromia service provision within project NHS Trusts 
In order to inform the questionnaire development it was important to establish 
what sort of xanthochromia detection service was provided by the NHS Trusts in the 
immediate vicinity of those included in the project (Table 2.1). 
Regardless of the fact that this was just a small snapshot of service provision 
in 2008, it does clearly illustrate the variation in service provision that still existed.  
Of most concern is that there were still laboratories which offered no service or only 
assessed xanthochromia visually. 
 
2.2. Questionnaire development & distribution 
 The questionnaire (Appendix 4) was designed with a simple introduction 
outlining the aims of the survey and why it had been initiated i.e. to improve service 
provision and as part of a doctoral research project.  The first three points related to 
the individual’s grade, speciality and base as these may influence the results provided.  
There were nine questions in total, the majority of which were tick boxes and a final 
section for additional comments.  Individual questions were written in such a way as 
to adhere to the general principles of question wording, for example; use of simple  
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Table 2.1 – Xanthochromia service provision in NHS Trust’s in the immediate vicinity 
of those included in the project. 
 
Trust Number 
of beds 
Service provision 
Southampton University 
Hospitals NHS Trust 
1100 Scanning spectrophotometry; 24 hours per day 
Portsmouth Hospitals 
NHS Trust 
1200 Scanning spectrophotometry Mon-Fri 9 am -      
5 pm; Sent to Southampton Hospital outside of 
these hours 
Isle of Wight NHS 
Primary Care Trust; St 
Mary’s Hospital 
300 No on-site service;  
All requests sent to Southampton Hospital 
Bath Royal United 
Hospital NHS Trust 
700 Scanning spectrophotometry Mon-Fri 9 am -5 
pm; Outside of these hours only on advice of 
clinical scientist 
Swindon & Marlborough 
NHS Trust 
800 Scanning spectrophotometry Mon-Fri 9 am -      
5 pm; Only by special arrangement over the 
weekend 
Poole Hospital NHS 
Foundation Trust 
800 Scanning spectrophotometry 24 hours per day 
The Royal Bournemouth 
& Christchurch NHS 
Foundation Trust 
900 Scanning spectrophotometry 24 hours per day 
Dorset County Hospitals 
NHS Foundation Trust 
400 No service offered 
Carmarthenshire NHS 
Trust 
750 No on-site service other than visual assessment; 
selected samples referred by post to Swansea 
NHS Trust 
Pembrokeshire & Derwen 
NHS Trust 
330 Only visual assessment offered 
Ceredigion & Mid Wales 
NHS Trust 
230 No on-site service; selected samples referred by 
courier to Swansea NHS Trust 
North Glamorgan NHS 
Trust 
740 No on-site service; 
All requests posted to Cardiff Hospital 
Cardiff & Vale NHS 
Trust 
1900 Scanning spectrophotometry Mon-Fri 9 am -5 
pm; Outside of these hours only on advice of 
clinical scientist – suitably experienced BMS 
called in. 
Gwent Healthcare NHS 
Trust 
1400 Scanning spectrophotometry 24 hours per day; 
Do not routinely correct for serum bilirubin 
 
 
language, avoiding acronyms, abbreviations and technical jargon, keeping questions 
brief and avoiding ambiguity (McColl et al., 1998, p.50).  The questionnaires were 
piloted with the clinical leads for the three clinical biochemistry services involved 
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(Bro-Morgannwg, Salisbury and Swansea NHS Trusts), to test for simplicity of 
design and relevance. 
The  questionnaire was issued to all relevant consultants and junior doctors 
within three Acute NHS trusts, across five hospitals; consisting of Swansea NHS 
Trust, BroMorgannwg NHS Trust (neighbouring trust) and Salisbury NHS Trust 
(comparison from England for standardisation).  It was important for the 
questionnaires to be distributed across three NHS trusts as there would be differences 
in service provision, as demonstrated by the ACB audit (Holbrook et al, 2007, p.444) 
and as detailed in Table 2.2.  The aim of the questionnaire was to establish the effects 
of sample turnaround time upon patient management and if interpretative details 
provided with the results were clear and comprehensible. 
 Questionnaire distribution at the three hospitals covered by Swansea 
NHS Trust clinical biochemistry services was determined by an audit of all 
xanthochromia requests over the preceding 12 months.  All those clinicians who had 
made a request were sent a hard copy of the questionnaire, 46 in total.  There was also 
an e-mail distribution to the entire Trust to target any other clinicians involved.  
Questionnaire distribution for Bro-Morgannwg NHS Trust and Salisbury NHS 
Trust were on the advice of the lead clinical scientist.  The clinician’s questionnaire 
results were analysed using descriptive statistics; all clinician’s comments are listed 
due to diversity and lack of any major themes. 
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Table 2.2 – Clinical biochemistry laboratories surveyed as part of the research, 
including hospitals and the level of xanthochromia service provided. 
 
Pathology Service Hospitals surveyed Service provided 
Swansea NHS Trust 
clinical biochemistry 
services 
Morriston Hospital 
Neath Port Talbot 
Hospital 
Singleton Hospital 
Monday – Friday 9 am – 5 
pm.  Out of hours service 
only if deemed necessary by 
a clinical scientist, use of 
specialist collection kits for 
light protection. 
Bro-Morgannwg NHS 
Trust clinical 
biochemistry services 
Princess of Wales Monday – Friday 9 am – 5 
pm.  Out of hours service 
only if deemed necessary by 
a clinical scientist 
Salisbury NHS Trust Salisbury District General 
Hospital 
24 hour  Onsite service, 
dependant on experience of 
on-call staff. 
 
 
 2.3. Analysis of Questionnaire  
2.3.1. Questionnaire returns 
A total of 24 questionnaires were returned, 23 via the postal service and 1 via 
e-mail (a further 5 responses from Salisbury were lost in transit); 5 responses were 
received from Bro Morgannwg NHS Trust and 19 from Swansea NHS Trust. 
 
2.3.2. Evaluation of returns by staff group and speciality 
 The majority (58%) of respondents were consultants and the most common 
area of expertise of all respondents (67%) was medicine. 
 
2.3.3. Evaluation of Questions 
 The following section provides an overview of the results obtained from the 
questionnaire, for a more detailed description of the results obtained see appendix 5. 
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One third of respondents (n = 8) were aware of the UKNEQAS Guidelines regarding 
the laboratory investigation of CSF xanthochromia and almost 60% (n = 14) were 
aware that the minimum time from onset of symptoms to lumbar puncture was 12 
hours. 
More than half of all respondents (n = 13) did not request CSF xanthochromia 
as part of a diagnostic protocol, just over one third (n = 9) did and two did not 
understand the question.  Over the preceding twelve months six respondents had 
requested CSF xanthochromia five times or more, five had requested if four times, 
four had requested it three times, seven had requested it twice and two had requested 
it on only one occasion. 
All respondents, regardless of speciality or location stated that the patient had 
had a negative or equivocal CT scan result before undergoing lumbar puncture.  
Almost two thirds of respondents (n = 15) stated that the CSF collection kit for 
xanthochromia was readily available in the wards and departments, one quarter (n = 
6) stated it was not and three did not know.  Almost two thirds of respondents (n = 15) 
stated that the CSF collection kit instructions were clear and easy to follow one stated 
they were not and one third (n = 8) did not respond. 
Almost two thirds of respondents (n = 15) felt that the turn-around time of the 
results was within a clinically acceptable time frame and the remainder (n = 9) stated 
that it was not.  Twenty respondents felt that the accompanying interpretation was 
clear and informative, two stated that it was not and two did not respond.  Twenty one 
respondents (n = 21) stated that they received all of the results that they expected, one 
did not and two did not respond. 
 
 
  30 
2.3.4. Clinicians comments 
 In total nine clinicians provided additional comments at the end of the 
questionnaire regarding the service provided for CSF xanthochromia analysis.  Two 
clinicians raised concerns over the transport of ‘precious’ samples between sites and 
the potential consequences of them going astray.  There were two comments 
regarding the lack of an out of hours service.  One clinician was particularly 
concerned about ‘equivocal’ samples, this was deemed as ‘fence sitting’ and that there 
were a large proportion of ‘false equivocals’ which were ‘angiography negative, as 
expected’. 
  
2.4. Discussion 
2.4.1. Questionnaire returns 
 There were a total of fifty four questionnaires posted to requesting clinicians 
in Swansea and Bridgend giving an overall response rate of 43%.  Mail questionnaires 
are renowned for their poor response rates, usually achieving no better than a 20% 
response rate (Bourque & Fielder, 2002, p.15).  The response rate achieved in this 
research (43%) is better than expected and probably reflects the educational and 
intelligence level of the receiving audience, as this has been shown to have a 
significant effect (Lynn, 1996, p.6).   
Almost all experts in survey design recommend the use of follow up reminders 
(McColl et al., 1998, p. 53).  Heberlein and Baumgartner (1978, p.459) demonstrated 
a 20% increase in response rate with a first reminder and a further 12 and 10% 
increase, respectively, with a second and third reminder.  If a reminder strategy of this 
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type had been employed in this research it could have potentially improved the 
response rate to over 60%.  
The Trust wide e-mail in Swansea elicited a very poor response with only one 
return being received.  This may be due to the transitory nature of some clinician’s 
posts and their reliance on a constant personal e-mail address.  All staff now having 
access to an ‘All Wales’ e-mail account which would mean that any future 
questionnaires sent out to the entire Trust/Health Board by e-mail may produce a 
better response.  Electronic distribution could have been improved by hosting the 
questionnaire on a survey website such as Survey Monkey and advertising the 
questionnaire on the Trust/Health Board Intranet site. 
 
2.4.2. Returns by staff group and speciality 
 Almost two thirds (58%) of respondents were consultants, this probably 
reflects the way in which the questionnaires were distributed; i.e. to the requesting 
clinicians over the preceding twelve months and it is more often than not the 
consultant stated on the form rather than the requesting doctor.  This could have been 
addressed through discussion with the consultants involved and identifying how best 
to reach the relevant clinicians within their team. 
Over two thirds (67%) of all respondents were from medicine, this probably 
reflects the patients route into hospital.  Headaches and other similar symptoms will 
as a rule arrive in the A&E Unit or are admitted straight on to a Medical Admissions 
Unit via a primary care referral.  These units combined with the symptoms would 
require attention from medicine in order to establish a diagnosis which can be 
referred, where required, to the appropriate team. 
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2.4.3 Question responses 
 Only one third of respondents were aware of the UKNEQAS guidelines.  How 
can clinicians’ collect appropriate specimens and access the service provided by 
clinical biochemistry departments appropriately if they are unaware of the guidelines 
upon which they are based?  This could possibly be an education issue which could be 
rectified within a Trust, but once clinicians change post replacement staff could be 
just as unaware.  To ensure that information regarding the UKNEQAS guidelines was 
accessible to all clinicians at all times, a link to the Trust/Health Board pathology 
intranet site could be included as part of the lumbar puncture collection kit.  This 
questionnaire has only looked at two individual NHS Trusts, this could well be a UK 
wide issue. 
 Less than half of all respondents appreciated that the minimum time for 
lumbar puncture was 12 hours.  A third (33.4%) of respondents stated that the 
minimum time was less than 12 hours, particularly worrying as carrying out the 
lumbar puncture too early could lead to false negative results.  Of less concern from a 
diagnostic point of view was the 12.6% who thought that it was more than 12 hours.  
Delaying a lumbar puncture by a few hours would not adversely affect the 
xanthochromia result but it could impact upon patient treatment whether the diagnosis 
was SAH or not.   This again, is an educational issue which needs to be addressed. 
Just over one third (37.5%) of xanthochromia requests were made as part of a patient 
pathway, suggesting that diagnostic protocols are not widely used or that the question 
was misunderstood.  More detailed information on this issue could be gathered in 
further questionnaires.  
Clinicians in medicine request xanthochromias more than clinicians in other 
disciplines with neurosurgery coming a close second.  This reflects the routes by 
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which patients arrive i.e. initially medicine via A&E and Medical Admissions Units.  
Neurosurgery is probably high in this research due to the neruosurgery unit at 
Swansea which receives admissions from across Mid and West Wales. 
 All respondents stated that the patient had a negative or equivocal CT scan 
result before undergoing lumbar puncture.  This is consistent with the UKNEQAS 
guidelines recommendations which suggests that the respondents may be aware of the 
UKNEQAS guidelines but do not know what they are called. 
 One quarter of respondents stated that a CSF collection kit was not available 
on the ward, if correct this needs to be addressed in order to protect sample integrity.  
It may simply be a problem of wards not re-ordering when stocks run out or the kits 
are not always put in to the lumbar puncture trays. 
 This level of ‘missing’ collection kits is not borne out by the condition of the 
samples received in the laboratory, as they are very rarely received not in collection 
kit sample containers.  An in-house audit showed that only 0.6% of xanthochromia 
requests were not light protected upon arrival in the laboratory between April 2004 
and March 2005.  The high percentage of questionnaire returns from consultants may 
well explain this, as junior doctors are more likely to be performing the lumbar 
punctures on the wards and the consultant may not be aware of the conditions under 
which samples are taken for individual patients. 
 Only one respondent felt that the instructions on the CSF collection kit for 
xanthochromia were unclear.  This is almost certainly a reflection of how well the 
instructions have been written, and it is possible that this one respondent may have 
experienced difficulty accessing CSF kits. 
Although almost two thirds of respondents felt that the turnaround time was 
acceptable, this still means that more than one third felt that it was not, and this is an 
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unacceptably high figure.  This may be a reflection of those requests made over 
weekends, especially Bank Holiday weekends.   
 Over 80% of respondents felt that the results and accompanying interpretation 
were clear and informative.  This appears to be an excellent response until you 
consider that 8% felt that it was not, additionally the clinical scientists report regularly 
receiving queries regarding the interpretation of xanthochromia results, indicating that 
the reports are not always clear. 
 Only one respondent did not receive all the results they expected, but did not 
expand on which results they did expect. 
 
2.4.4. Clinicians comments 
 The two main concerns raised through individual comments, were the lack of 
an out of hours service, therefore increasing turnaround time, and the general feeling 
that reporting a sample as ‘equivocal’ wasn’t good enough especially if this would 
mean putting a patient at risk while undergoing angiography. 
 
2.5. Conclusion 
 The questionnaire itself has raised some interesting points many of which are 
pertinent to the overarching aim of this research project.  A further questionnaire 
would be beneficial in the future to probe the opinion of service users in more depth, 
but careful consideration would need to be given to the method of targeting specific 
groups of users to ensure those at the ‘coal face’ were indeed the ones responding.  
Alternative methods of accessing the questionnaire could improve responses e.g. 
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Survey Monkey, an on-line survey tool which removes the need to send out physical 
copies of questionnaires and provides an electronic interface. 
 Achieving the best response rate possible in any future questionnaires needs to 
have greater importance attached to it.  Mangione (1995, p.60) recommended a 
number of strategies to improve response rates, some of which are outlined in table 
2.3.  Whilst some of these strategies where employed in this research, such as a good 
respondent letter and a self addressed envelope, this element of using questionnaires 
in research needs to be incorporated into the planning stages.  As such, each of the 
strategies highlighted in Table 2.3 needs to considered and where possible and 
appropriate, become an integral part of the questionnaire design. 
The overall lack of awareness of the UKNEQAS Guidelines needs attention.  
This could be tackled at a local level with clinicians’ continuous professional 
development (CPD) meetings, but it is important to establish if this is a local or 
national issue.  If this is a national issue then educational papers need to be carefully 
directed at journals with a high circulation in the relevant disciplines; in this research 
it is medicine and neurology, the nationwide picture may be quite different.  An 
article published in 2011 in the British Medical Journal ‘Investigating suspected 
subarachnoid haemorrhage in adults’ (Brown, et al., 2011, p.1083) discusses lumbar 
punctures following a negative CT scan, but fails to mention the laboratories’ 
involvement or reference the UKNEQAS guidelines.  This is just one example of why 
the medical profession may be unaware of the UKNEQAS guidelines. 
The lack of understanding regarding the timing of lumbar punctures needs to 
be addressed to ensure that requesting clinicians receive the correct results.   A simple 
solution may be to review the instructions in the CSF kit and insert a clear statement 
about timing of lumbar punctures. 
  36 
Table 2.3 – Strategies to improve questionnaire response rates (Mangione, 1995, 
p.60) 
 
Strategy 
A good respondent letter; 
 Not too long 
 Professional letterhead 
 Clear contact details for queries 
 ‘Grabber’ as first sentence; encourage respondent to read letter 
 Why the questionnaire is important 
 Who is being asked to participate 
 Whether it is confidential and/or anonymous 
 Emphasise that participation is voluntary 
 Make it clear how the questionnaire is to be returned 
 Relevant language 
Return postage; 
 Also include a self-addressed envelope 
Confidentiality/Anonymity 
 Respondents more likely to respond if they feel their answers are confidential 
or anonymous 
Reminders 
 Single most important technique 
 Important to send out several reminders paying attention to timing 
 Aim for non-responders to receive a reminder by day 14 post distribution (as 
returns drop off between days 10 and 14) 
 The 14 day pattern repeats itself and further reminders should be timed 
accordingly 
 In order to achieve 75% response rate aim for three reminders post 
distribution 
 Each reminder should focus on a slightly different issue  
 
Diagnostic protocols do not appear to be widely used, but this may actually be 
a problem with the terminology used within the question.  It would be useful to clarify 
this through discussion with clinicians in different disciplines before further 
questionnaires were issued.  
An unacceptably large proportion, one third, of respondents felt that the 
turnaround time for results was inadequate, this part of the service therefore needs 
urgent attention.  This may be directly related to when the samples are received in the 
laboratory; an in-house audit of xanthochromia requests showed that 27% of requests 
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were received over the weekend period.  If this is the case then this could be 
addressed by changing the service provision over the weekend, which is complicated 
by the amount of training required to perform spectrophotometric scans adequately, or 
by offering an alternative or supplementary test which may ‘rule-out’ a large 
proportion of samples. 
On reflection, although this relatively small survey gathered some significant 
and interesting data, it would have better served the role of a pilot study.  The 
information gathered from this initial questionnaire could then have been used to 
produce a more detailed questionnaire with a robust method of distribution to the 
target audience.  This would have produced results of greater impact to this research.  
 
2.6. Questionnaire findings versus current 
UKNEQAS Guidelines 
 It is clear from the questionnaire findings that general awareness of the 
UKNEQAS Guidelines needs to be improved to ensure that users access the service 
appropriately.  It will also be important to establish if the introduction of the 
Guidelines has improved the patient outcomes – are less undergoing angiography?  
The Guidelines themselves discuss the hours of service that should be available i.e. 
that it should be determined by: 
 Local need 
 Tertiary centre’s referral policy 
 Access to beds 
 Availability of angiography 
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What hours of service would the laboratory need to provide in order to meet 
the above criteria?  The results of the questionnaire would suggest that local need is 
not being met.  An alternative or supplement to scanning spectrophotometry could 
improve this. 
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Chapter 3 
Alternatives to scanning spectrophotometry 
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3.1. Introduction 
 This chapter partially satisfies objective two of this research ‘To develop an 
alternative laboratory test(s), which could be used to identify patients who have 
suffered an SAH, utilising cerebral spinal fluid and/or serum sample.’ through its 
investigation of a suitable laboratory test.  Appendix 1 lists the terms used to search 
for relevant literature to review for this chapter. 
 
3.2. Potential alternatives to scanning 
spectrophotometry  
In order to explore alternative laboratory tests the nature of SAH needs to be 
considered i.e. blood is released into the subarachnoid space and the brain is damaged.  
Therefore the laboratory analysis needs to focus on detecting the presence of blood 
and/or its breakdown products i.e. any change in CSF constituents that arises as a 
direct consequence of blood being introduced in to the subarachnoid space or a 
specific analyte which would only be present if brain damage occurred. 
Traditionally the laboratory investigated the likelihood of SAH having 
occurred by examining the CSF sample for xanthochromia.  Xanthochromia is the 
yellow discolouration due to the presence of bilirubin, which is produced as a 
consequence of the enzymatic breakdown of oxyhaemoglobin (released from red 
blood cells upon lysis). 
The majority of laboratories have already moved away from the visual 
examination of CSF for xanthochromia to scanning spectrophotometry (UKNEQAS 
National Guidelines, 2003, p.481) but this appears to have certain inherent problems, 
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for example turnaround time has been greatly increased.  An in-house audit revealed 
the average time in Swansea to be 26 hours (Appendix 3).  Scanning 
spectrophotometry is not only time consuming but also requires a significant level of 
technical expertise, and a recent audit by the ACB clearly indicates that this service is 
not available in all clinical biochemistry laboratories (Holbrook et al., 2007, p.444).  
Some of this may be due to the complex nature of determining whether a sample is 
positive, negative or inconclusive.  A simplified approach would be to analyse the 
bilirubin content of the CSF directly on an automated analyser, routinely used for 
measuring serum bilirubin.  This may prove to be a suitable alternative to scanning 
spectrophotometry and the majority of laboratories would be able to provide this 
service. 
In order to establish the ability of laboratories to analyse bilirubin in CSF 
using an automated analyser, the UKNEQAS returns for serum bilirubin (part of the 
UKNEQAS for clinical chemistry scheme) were analysed to determine which 
methods were employed around the UK.  This revealed that the majority (67.8%) of 
laboratories enrolled on the UKNEQAS scheme employed a diazo method, 19.1% 
used an oxidation method and 13.1% used a dry slide method.  The details of 
individual methods are provided in Table 3.1.  The method routinely used for 
bilirubin analysis within the laboratory at Swansea is a diazo method; therefore the 
analysis of bilirubin in CSF using an automated analyser will be referred to as ‘CSF 
diazo bilirubin’. 
Iron, present in haemoglobin, can reach toxic levels in the body.  In order to 
prevent this, ferritin binds iron therefore preventing toxicity.  Following SAH red 
blood cells are released into the CSF, these subsequently lyse releasing haemoglobin, 
which is bound by ferritin.  Keir et al. (1993, p.161) found that following 
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haemorrhage there was intrathecal production of ferritin as CSF levels were much 
higher than those found in the patient’s serum.  Ferritin has also been found to be 
present in the CSF for 2-3 weeks post-bleed (Watson, 1998, p.685; Petzold et al., 
2011 p.492).  Therefore CSF ferritin levels could indicate if bleeding into the CSF had 
occurred.  
 
Table 3.1: Bilirubin methods, and any identified issues, used on automated analysers 
in clinical biochemistry laboratories in the UK.  Details of the methods currently in 
use were obtained by examination of the UKNEQAS Clinical Chemistry Scheme 
returns (August 2008 returns). 
 
Method type Supplier Method 
specifics 
Issues 
Dry slide Ortho Clinical 
Diagnostics  (J&J) 
Diazo based; 
Dappen et al. 
(1983, p.37) 
modified by Lo et 
al. (1984, p.970) 
At low bilirubin 
concentration 
increasing 
haemolysis causes 
a significant 
positive bias 
(Weiss et al., 1984, 
p.1312) 
Diazo Abbott reagents Winsten & Cehelyk 
(1969, p.441) 
Increasing 
haemolysis has a 
negative bias 
(Abbott, 2006, p.4; 
Beckman Coulter, 
2005, p.8; 
Olympus, n.d., p.2)  
 Beckman reagents Jendrassik & Gróf 
(1938, p.81) 
Olympus reagents Jendrassik &Gróf 
(1938, p.81) 
modified by 
Doumas et al. 
(1973, p.984) 
Roche Integra 
reagents 
Wahlefeld et al. 
(1972, p.11) 
Uses a ‘new’ 
diazonium ion that 
reduces 
interference from 
haemolysis (Roche, 
2005, p.1) 
Roche 
MODULAR
TM
 
reagents 
Oxidation Olympus reagents O’leary et al. 
(1993, p.175) 
No significant 
interference from 
haemolysis up to 5 
g/l (O’leary et al., 
1993, p.178) 
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Although expressed to a lower extent in a variety of other tissues, protein S100 
 and  dimers are predominantly found in glia and Schwann cells of the brain.  If 
the brain cells are damaged protein S100 is released.  Analysis of protein S100 could 
be used to look more specifically for brain tissue damage rather than the presence of 
blood in the CSF.  Protein S100 only has a half-life of 2 hours in the blood due to its 
clearance by the kidneys (Usui et al., 1989, p.1944), but the rate of CSF turnover (6-8 
hours) would give it a much longer half-life in CSF.  CSF and serum protein S100 
levels could be used to determine if brain damage had occurred.  
 
3.2.1. CSF diazo bilirubin 
Following searches of scientific literature three published papers were found 
regarding the direct measurement of CSF bilirubin on an automated analyser in SAH 
diagnosis (Ungerer et al., 2004, p.1854; Chao et al., 2007, p.140; Ahmed et al., 2009, 
p.283).  In all three of these papers CSF bilirubin was evaluated using the Jendrassik-
Gróf (1938, p.81) diazo bilirubin method on automated analysers (Aeroset and 
Architect C8000 - Abbott Laboratories), and results were compared to scanning 
spectrophotometry.  All three groups concluded that it was suitable as a screening test 
but noted that there was interference from oxyhaemoglobin and that individual 
laboratories would need to validate their own analytical performance (Florkowski et 
al., 2008, p.617).  A further group is investigating the potential of a prototype point of 
care device to determine and quantify CSF bilirubin (Beyette et al, 2011, p.773).  
The UKNEQAS guidelines proffer the view that the analysis of bilirubin in 
CSF, using a diazo method, should not be used for the detection of SAH as it has not 
been adequately validated (Cruickshank et al., 2008, p.239).  The special advisory 
group which developed the guidelines could not recommend it as a screening method 
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as it was not CE marked and had concerns that performing this assay may delay the 
spectrophotometric analysis and interpretative reporting of CSF samples with 
increased bilirubin (Cruickshank, 2008, p.618) 
In this research the method of Whalefeld et al. (1972, p.11) was employed to 
investigate the applicability of CSF diazo bilirubin analysis, in SAH diagnosis on an 
automated analyser (MODULAR
TM
 P unit – Roche diagnostics).  This method suffers 
from less interference due to the presence of haemolysis as compared to the 
Jendrassik-Gróf method and as this is an automated assay there is the possibility of 
making results available 24 hours a day.  Initial investigations were aimed at 
validating this assay for use with CSF.  This involved assessing the ideal sample to 
reagent volume ratio to achieve sufficient sensitivity as compared to scanning 
spectrophotometry and assessing interference from oxyhaemoglobin.  Further 
investigations were aimed at examining the cut-off values for the direct analysis 
method.  If published research (Ungerer et al., 2004, p.1854; Chao et al., 2007, p.140) 
is compared to the CSF bilirubin calculated from the UKNEQAS guidelines cut-off 
(>0.007 AU) then there is a large discrepancy which needs to be accounted for. 
 
3.2.2. CSF ferritin 
There have been relatively few studies published regarding CSF ferritin and 
SAH diagnosis and only two which compared results to both scanning 
spectrophotometry and clinical outcome (O’Connell & Watson, 2003, p.272; Watson 
et al., 2008, p.190).  The research of O’Connell & Watson (2003) and Watson et al. 
(2008) found CSF ferritin to be a good negative predictor, but there were some false 
positives.  O’Connell and Watson (2003, p.272) identified three false positives (12%; 
n=24) using a cut-off of 12µg/l and giving a sensitivity of 100% and a specificity of 
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78%.  Watson et al. (2008, p.190) identified 20 false positives (8%; n= 236) and three 
false negatives (18%; n=16) using the same cut-off and giving a sensitivity of 81% 
and a specificity of 91%.  Watson et al. (2008, p.190) also investigated a cut-off of 
6.4µg/l which gave a sensitivity of 100% and a specificity of 48% (exact figures are 
not provided).   
Results from previous research (unpublished work) indicated that CSF ferritin 
may have a role to play as a screening tool in the diagnosis of SAH, which could be 
made available 24 hours a day. 
One potential difficulty highlighted as a result of the literature searches is that 
CSF ferritin has been found to be increased in both viral and bacterial meningitis 
(Kim et al., 2003, p.273).  This is further complicated by the similarities in clinical 
presentation between meningitis and SAH.  In order to investigate this further, CSF 
microbiology reports were examined to rule out the diagnosis of meningitis. 
CSF ferritin was analysed on the Roche MODULARTM E unit by an 
electrochemiluminescence immunoassay.  This assay has already been validated for 
use with CSF (unpublished work), but work was undertaken to assess interference 
from oxyhaemoglobin.   
 
3.2.3. CSF and serum protein S100 
A review of the literature on protein S100 revealed that the majority of 
published research concerns its use in determining brain damage during on-bypass 
cardiac surgery, although there were a small number of studies regarding its use in 
SAH diagnosis and monitoring.  One group (Wiesmann et al., 1997, p.1159) found 
serum levels of protein S100 were elevated, as compared to normal controls, up to 
seven days after onset of SAH symptoms, whereas Yoon et al. (2008, p.311) found 
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levels had normalised by day seven.  This was a prospective study which also 
indicated that protein S100 levels correlated well with the neurological outcome 
measured at six months post-SAH.  Two further groups (Persson et al., 1988, p.120; 
Kay et al., 2003, p.242) found that CSF levels of protein S100 were elevated 
following SAH, reflecting the severity of the SAH and the outcome in most patients.   
Protein S100 was analysed on the Roche MODULAR
TM
 E unit by an 
electrochemiluminescence immunoassay.  This assay detects both  and  dimers.  
Initial investigations were aimed at validating this assay for use with CSF and also 
included assessing interference from oxyhaemoglobin.  
A potential problem with the analysis of protein S100 is its relatively short 
half-life in serum of only 1-2 hours.  To further investigate this, comparisons were 
made between serum and CSF protein S100 levels (longer half-life due to CSF 
turnover rate of 6-8 hours) in order to determine which may be the more suitable 
sample. 
 
3.2.4. Suitable CSF sample type 
 Under UKNEQAS Guidelines the laboratory receives two separate CSF 
samples.  One is collected into fluoride oxalate preservative for the analysis of 
glucose and protein.  This is the first sample collected from the lumbar tap.  The other 
sample is collected into a plain sample container which is light protected for scanning 
spectrophotometry.  This is the fourth sample collected from the lumbar tap (samples 
two and three are sent to microbiology for analysis).  It is essential to establish if both 
sample types are equally suitable in all alternative analyses as it would be simpler and 
less time consuming if all analyses could be carried out on one sample alone.  
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Additionally it would address the concerns raised by the UKNEQAS special advisory 
group regarding potential delay in reporting results (Cruickshank, 2008, p.618). 
 More importantly, if the fluoride oxalate sample proved suitable this would 
then protect the plain sample from unnecessary light degradation and therefore 
provide the opportunity of performing scanning spectrophotometry if required.   
 
3.3. Materials and methods 
3.3.1. Sample selection 
An audit was performed of CSF samples received by Swansea NHS Trust 
clinical biochemistry service between April 2004 and March 2005 in order to 
determine the numbers received for xanthochromia or oligoclonal band analysis (for 
the diagnosis of multiple sclerosis).  Based on the results it was expected that samples 
from around 100 patients suspected of having an SAH, and 100 controls (CSF 
samples received for oligoclonal band analysis), would be received in the laboratory 
during the study period. 
All CSF samples were visually assessed for xanthochromia, analysed directly 
for CSF diazo bilirubin and then scanned spectrophotometrically.  Where possible 
both plain and fluoride oxalate CSF samples were collected for each subject and 
control included in the study.  The samples were subsequently frozen (-20° C) until 
the final clinical outcome of the subject was ascertained from their clinical notes.  
Samples were then anonymised and analysis for ferritin and protein S100 was 
performed. 
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The control group consisted of CSF samples collected from patients in whom 
SAH and xanthochromia were not expected (i.e. requests for oligoclonal band 
analysis in the diagnosis of multiple sclerosis).  The samples were anonymised and 
subjected to the same analyses. 
 
3.3.2. Ethical approval 
Ethical approval for this research was obtained from the Local Research 
Ethics Committee; Iechyd Morgannwg Health Local Research Ethics Committee 
(Appendix 6).  Consent from individual patients was not required as only existing, 
anonymised samples were being utilised. 
 
3.3.3. Visual assessment of xanthochromia 
Visual assessment of CSF for xanthochromia was performed immediately 
upon arrival in the laboratory.  Samples were centrifuged at 3000 rpm for 6 min and 
then examined against a white background.  Individual operators determined the 
presence or absence of xanthochromia based on the presence or absence of CSF 
discolouration as compared to the white background. 
 
3.3.4. Spectrophotometric assessment of xanthochromia  
Scanning spectrophotometry was performed on a CE 3041 (CECIL 
Instruments Limited) spectrophotometer.  Samples were scanned between 350 nm and 
600 nm and auto-scaled.  After visual assessment of the scan, information regarding 
the positioning of the base line was programmed in to the spectrophotometer and a 
baseline applied to form a tangent between 350 and 400 nm and again between 430 
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and 530 nm.  Perpendiculars to this baseline were then calculated by the 
spectrophotometer in absorbance units at 415 nm (net oxyhaemoglobin absorbance - 
NOA) and 476 nm (net bilirubin absorbance – NBA) (Chalmers, 2001, p.147).   
In line with the then current UKNEQAS Guidelines (2003, p.484), the NBA 
cut-off value of 0.007 AU was used, i.e. anything greater than this was classified as 
positive for xanthochromia, subject to further interpretation in relation to NOA, serum 
bilirubin and CSF protein. 
Figure 3.1. is a digital scan of a typical spectrum used to obtain the 
information required, showing the baseline to be used and the perpendicular at 415 
nm to measure oxyhaemoglobin. 
 
3.3.5. Analytical methods 
The CSF diazo bilirubin was analysed on a MODULAR
TM
 P unit (Roche) 
using the method of Wahlefeld et al. (1972, p.11).  Total bilirubin, in the presence of a 
solubilising agent, is coupled with a diazonium ion in a strongly acidic medium (pH 
1-2) (Equation 3.1.).  The intensity of the colour of the azobilirubin produced is 
proportional to the total bilirubin concentration and is measured photometrically; 
wavelength 546-600 nm. 
In order to compensate for the expected low levels of bilirubin that would be 
present in the CSF samples analysed, the Roche bilirubin method was altered to 
accommodate this.  Reagent volumes remained unchanged whereas sample volume 
was increased seven-fold.  The sensitivity and linearity of the assay where 
investigated using dilutions of serum quality control material Multichem S Plus 1 
(TECHNOPATH), Precinorm (Roche) and Precipath (Roche).  The precision of the 
assay was examined by analysing CSF samples in replicates of five.   
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Figure 3.1. – Digital scan of a spectrum of CSF demonstrating positioning of base 
lines and perpendiculars (at 415 nm). Scanning performed on a CE 3041 (CECIL 
Instruments Limited) spectrophotometer.  Scanning at 600 nm/min from 360 nm to 
520 nm, then auto-scaled. The baseline was manually positioned by the analyst from 
360 nm to 520 nm.  The NOA was then calculated by the spectrophotometer, from the 
absorbance above the baseline at 415 nm. 
 
 
 
 Bilirubin + diazonium ion                        Azobilirubin      Equation 3.1. 
Equation 3.1: The method of Wahlefeld et al. (1972, p.11) uses a solubilising agent to 
couple bilirubin with a diazonium ion in a strongly acidic medium to produce the 
coloured azobilirubin, the intensity of which is measured at 600-546 nm. 
 
The published extinction coefficient for bilirubin is based on measurements at 
453 nm giving a value of 60700 ± 800 (Wells, 1988, p.722).  Investigation of 
discrepancies in cut-off values were therefore aimed at calculating the extinction 
coefficient of bilirubin at 476 nm.  This was achieved using a solution of bilirubin in 
chloroform at 25 °C, scanning the solution between 350 and 600 nm and using Beer-
Lambert’s law to calculate the extinction coefficient at 476 nm.  Additionally the 
limits of detection of the assay where investigated by repeat analysis of saline and 
CSF samples which contained no bilirubin.  A bilirubin free CSF sample was 
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achieved by exposing CSF to light over a period of five days in a refrigerated (4 °C) 
storage tray. 
Ferritin and protein S100 were analysed on a MODULAR
TM
 E Unit (Roche) 
using electrochemiluminescence immunoassay (ELCIA).  A sample volume of 10 μl 
was required to perform the ferritin assay and 20 μl to perform the protein S100 assay.  
The ferritin assay has a linear range of 0.2-1500 ng/ml and the protein S100 assay has 
a linear range of 0.005-39 μg/l.  The suitability of the ferritin and protein S100 assays 
for CSF analysis was confirmed using precision and sensitivity studies. 
 
Ferritin; 
Sandwich principle. Total duration of assay: 18 min. 
• 1st incubation: 10 µl of sample, a biotinylated monoclonal ferritin- specific antibody 
and a monoclonal ferritin-specific antibody labeled with a ruthenium complex*, react 
to form a sandwich complex. 
• 2nd incubation: After addition of streptavidin-coated microparticles, the complex 
becomes  bound to the solid phase via interaction of biotin and streptavidin. 
• The reaction mixture is aspirated into the measuring cell where the microparticles 
are magnetically captured onto the surface of the electrode. Unbound substances are 
then removed with ProCell (2.6% tripropylamine). Application of a voltage to the 
electrode then induces chemiluminescent emission which is measured by a 
photomultiplier. 
• Results were determined via a calibration curve which is instrument-specifically 
generated by 2-point calibration and a master curve provided via the reagent bar code. 
 
* Tris(2,2’-bipyridyl)ruthenium(II) complex (Ru(bpy)) 
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Protein S100; 
Sandwich principle. Total duration of assay: 18 min. 
• 1st incubation: 20 µl of sample, a biotinylated monoclonal protein S100-specific 
antibody and a monoclonal protein S100-specific antibody labeled with a ruthenium 
complex*, react to form a sandwich complex. 
• 2nd incubation: After addition of streptavidin-coated microparticles, the complex 
becomes bound to the solid phase via interaction of biotin and streptavidin. 
• The reaction mixture is aspirated into the measuring cell where the microparticles 
are magnetically captured onto the surface of the electrode. Unbound substances are 
then removed with ProCell (2.6% tripropylamine). Application of a voltage to the 
electrode then induces chemiluminescent emission which is measured by a 
photomultiplier. 
• Results were determined via a calibration curve which is instrument-specifically 
generated by 2-point calibration and a master curve provided via the reagent bar code. 
 
* Tris(2,2’-bipyridyl)ruthenium(II) complex (Ru(bpy)) 
 
 
3.3.6. Effects of oxyhaemoglobin 
 In order to investigate oxyhaemoglobin interference, a sample was prepared 
by washing human erythrocytes in phosphate buffered saline then haemolysing them 
in HPLC grade water using a freeze-thaw method.  The oxyhaemoglobin was diluted 
sufficiently to give an absorbance of < 2.000 AU at 415 nm.  Serial dilutions were 
then performed to give a total of eight samples which were all subject to scanning 
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spectrophotometry and then analysed for CSF diazo bilirubin, ferritin and protein 
S100. 
 To investigate this further a second series of tests were undertaken using a 
pool of CSF samples.  Erythrocytes were washed with phosphate buffered saline, to 
prevent any cross-contamination, and then added to an aliquot of the pooled CSF 
which was then frozen to ensure lysis of the erythrocytes.  Serial dilutions were 
carried out using the same CSF pool to ensure that the analytes remained at a constant 
concentration in order to examine further the specific effects of oxyhaemoglobin. 
 
3.3.7. Analyte stability 
 A short-term and a long-term analyte stability study for CSF ferritin and 
protein S100 were also undertaken.  For the short-term stability study two pools of 
CSF were kept refrigerated (4-8 ºC) and analysed on consecutive days.  For the long-
term stability study two separate pools of CSF were used and four sets of each were 
stored at -40 ºC over a period of 18 months.  One set was analysed with batch one and 
a further set analysed with each of batches two, three and four.   
The purpose of this was to estimate the stability of the analytes under 
investigation to ensure that there was no degradation of samples during the study 
period which could give rise to inaccurate results.  It would also provide information 
on the stability of samples referred from other laboratories via the post. 
 
3.3.8. Analysis of laboratory results 
 The suitability of the proposed alternative tests was determined by assessing 
their sensitivity and specificity at multiple cut-off points.  Sensitivity was based upon 
results from subjects who had suffered an SAH and specificity was based upon results 
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from subjects who had not suffered an SAH, as determined from patients’ clinical 
notes. 
 
3.4. Results 
3.4.1. Subjects 
There were eighty patients with suspected SAH (39 males and 41 females: 
Age range 18 – 82 years with a median of 44 years) and thirty control patients (13 
males and 17 females: Age range 22 – 78 years with a median of 48 years) recruited 
into the study.  Of the subjects recruited with suspected SAH, according to 
UKNEQAS Guidelines (2003); fifty nine were reported as having ‘no evidence to 
support SAH’, six were reported as ‘SAH not excluded’, eight were reported as ‘may 
be consistent with SAH’ and seven were reported as ‘consistent with SAH’.  Of the 
control patients in which SAH was not expected, according to UKNEQAS Guidelines 
(2003); twenty seven were reported as having ‘no evidence to support SAH’ and three 
were reported as ‘SAH not excluded’. 
 
3.4.2. Visual inspection of CSF for xanthochromia 
 As visual inspection of CSF for xanthochromia is the traditional method for 
assessing patient samples for the possibility of SAH, and it is the only method offered 
by a number of pathology laboratories (Holbrook et al., 2007, p.444), it was therefore 
important to assess its efficacy. 
 In this research, visual inspection of CSF had a sensitivity of 40% and a 
specificity of 92% in detecting patients who had suffered an SAH.  These results 
show a similar pattern to the findings of Perry et al. (2006, p.2470) who reported 
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visual inspection to have a sensitivity of 50% and a specificity of 97%, although they 
fail to provide details of how visual inspection was carried out. 
 
3.4.3. Spectrophotometric assessment of xanthochromia using 
UKNEQAS Guidelines 
 In order to facilitate a comparison of the different methods of determining the 
occurrence of SAH it is essential that the results of the UKNEQAS Guidelines 
method for determination of xanthochromia are examined more closely. 
 In this research the method detailed in the UKNEQAS Guidelines (2003) had 
a sensitivity of 80% and a specificity of 95% when only those results reported as 
‘consistent with SAH’ are included.  If all results that cannot exclude SAH, and 
therefore increase the risk of the patient undergoing angiography, are included then 
the sensitivity is 100% and the specificity is 81%.  This is of similar performance to 
the sensitivity (80%) and specificity (100%) obtained by O’Connell and Watson 
(2003, p.272) who used the method of Chalmers (2001, p.147) upon which the 
UKNEQAS Guidelines are based, although the authors do note that two patients (out 
of 24 studied) with negative NBA’s of < 0.007 AU were positive for SAH by 
angiography. 
 
3.4.4. CSF diazo bilirubin 
A precision study was performed to confirm the suitability of the modified 
Roche assay for CSF diazo bilirubin.   For the precision study, CSF samples were 
assayed in replicates of five and the coefficient of variance (CV %) calculated.  
Figure 3.2, shows there is scatter and the range of CVs is 12.4 – 19.2% indicating 
moderate precision for the analysis of CSF at low levels of CSF diazo bilirubin. 
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Figure 3.2: CSF diazo bilirubin precision as performed on the Roche MODULAR 
unit.  CSF samples were analysed in replicates of fives. 
 
The intra assay CV of the CSF diazo bilirubin method was investigated further 
using dilutions of serum quality control material Multichem S Plus 1 
(TECHNOPATH) and Precinorm (Roche) and Precipath (Roche).  These samples 
were analysed in replicates of 15 on separate occasions.  The intra assay CV was 
20.7% at 70 nmol/l, 6.5% at 140 nmol/l, 7.9% at 280 nmol/l , 3.2% at 710 nmol/l and 
4.0% at 4024 nmol/l, the response of the assay was found to be linear from 70 nmol/l 
to 4024 nmol/l, encompassing the area of interest.  
 Figure 3.3 shows one of the spectrophtometric scans of the bilirubin 
chloroform solutions used to calculate the extinction coefficient for bilirubin at 
476nm.  Table 3.2 shows the figures used to calculate the extinction coefficient for 
bilirubin at 476nm, which was found to be 41900 ± 50.  Using Beer Lambert’s Law 
and the extinction coefficient for bilirubin at 476 nm the proposed cut-off value of 
300 nmol/l of bilirubin in CSF would equate to 0.012 AU.  The UKNEQAS 
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guidelines cut-off of 0.007 AU would equate to 167nmol/l of CSF bilirubin 
(Cruickshank et al., 2008, p.238). 
 This leaves a discrepancy of around 130 nmol/l to account for.  To investigate 
this further all of the subjects included in the research which had an NBA of 0.000 
AU were examined and found to have a mean CSF diazo bilirubin of 107 nmol/l ± 63 
nmol/l. 
 
Figure 3.3: Spectrophotometric scan of bilirubin chloroform solution for the 
calculation of the bilirubin extinction coefficient at 476nm. 
 
Table 3.2: Absorbance of bilirubin chloroform solution at 453nm and 476nm used to 
determine the extinction coefficient of bilirubin at 476nm. 
 
Absorbance at 
453nm 
Absorbance at 
476nm 
Concentration 
(nmol/l) 
Concentration 
(mol/l) 
Extinction 
coefficient at 
476nm 
0.0579 0.0400 953 9.53871E-07 41934 
0.2285 0.1575 3764 3.76442E-06 41839 
0.5749 0.3970 9471 9.47117E-06 41916 
   Mean 41896 
 
 
  
 
58 
The total absorbance at 476nm is not available for the subjects included in this 
research with an NBA of 0.000 AU, so a smaller group of anonymised subjects was 
examined and the CSF diazo bilirubin, NBA and total absorbance at 476nm analysed.   
Ten subjects from this second group, which had an NBA of 0.000 AU, Table 3.3, had 
a mean CSF diazo bilirubin of 128 nmol/l (± 26 nmol/l) and a mean total absorbance 
at 476nm of 0.014 AU (SD 0.015 AU). 
The limits of detection of the assay using repeat analysis of saline was 60 
nmol/l (n=20), this was the within batch mean plus 3SD.  When this exercise was 
repeated using CSF samples which were bilirubin free (n=10) the detection limit was 
found to be 158 nmol/l.   
In order to investigate the efficacy of the CSF diazo bilirubin method as 
compared to the UKNEQAS Guidelines, the CSF diazo bilirubin and the NBA of all 
samples used within the research were plotted against each other (Figure 3.4).  The 
graph in Figure 3.4 indicates that the relationship between CSF diazo bilirubin and 
NBA is linear, as might be expected as they should be measuring the same thing.   
 
Table 3.3: CSF diazo bilirubin, NBA and total absorbance at 476nm for ten subjects. 
 
Sample NBA (AU) Total Abs at 
476nm 
CSF diazo 
bilirubin (nmol/l) 
1 0.000 0.010 126 
2 0.000 0.003 79 
3 0.000 0.007 115 
4 0.000 0.008 122 
5 0.000 0.017 163 
6 0.000 0.007 109 
7 0.000 0.012 152 
8 0.000 0.010 137 
9 0.000 0.007 117 
10 0.000 0.055 164 
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.  
Figure 3.4 – Relationship between NBA(AU) and CSF diazo bilirubin (nmol/l).  
 
Furthermore the coefficient of determination R
2 
= 0.994 is excellent, indicating that 
the linear relationship between ‘x’(NBA) and ‘y’(CSF diazo bilirubin) is strong 
 Of the test results included, forty eight (76%) had an NBA of zero, and as a 
CSF bilirubin of zero is improbable it may suggest that scanning spectrophotometry at 
low concentrations may be problematic (Ungerer et. al., 2004, p.1855).  CSF bilirubin 
has a normal range of 30-150 nmol/l, with an average of 90 nmol/l (Gimpel et al., 
1989, p.218).  The average of 90 nmol/l bilirubin equates to an NBA of 0.004 AU and 
only 16 % (n=13) of samples recruited into this research had an NBA of ≥ 0.004 AU, 
which would again appear improbable. 
Table 3.4 details the sensitivity and specificity of potential CSF diazo bilirubin 
‘cut-off’ points, included are the cut-off values used in the research of Chao et al. 
(2007, p.142) of 300 nmol/l and Ungerer et al (2004, p.1854) of 359 nmol/l.   
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Table 3.4: Sensitivity and specificity of potential cut-off points of CSF diazo bilirubin 
for the detection of SAH. 
 
CSF diazo bilirubin cut off (nmol/l) Sensitivity  Specificity 
200 100% 77% 
300 (Chao et al., 2007, p.142) 100% 86% 
359 (Ungerer et al., 2004, p.1854) 100% 90% 
400 100% 92% 
500 100% 94% 
600 100% 96% 
 
The sensitivity and specificity of the 300 nmol/l cut-off in this study, 100% 
and 86% respectively, are superior to the 100% specificity and 75% sensitivity 
obtained by Chao et al. (2007, p.142).  The sensitivity and specificity of the 359 
nmol/l cut-off in this study, 100% and 90% respectively, show a similar  pattern to the 
100% specificity and 92% sensitivity obtained by Ungerer et al. (2004, p.1854).  One 
sample from this study had an NBA of 0.008 AU, which is above the UKNEQAS cut-
off (NBA > 0.007 reported as consistent with SAH), this had a CSF diazo bilirubin of 
303 nmol/l.  Thus setting the cut-off of 300 nmol/l with a sensitivity of 100% and a 
specificity of 86% needs to be considered. 
 In order to compare the diagnostic capability of CSF diazo bilirubin to 
spectrophotometry by the UKNEQAS Guidelines, the cut-off values set at 300 and 
359 nmol/l were applied to the results obtained in this research (Tables 3.5 and 3.6), 
and CSF diazo bilirubin results less than the cut off point reported as ‘not consistent 
with SAH’ and those greater than or equal to the cut-off reported as ‘may be 
consistent with SAH’.   
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Table 3.5:  Comparison of UKNEQAS Guidelines reporting status groupings to the 
proposed CSF diazo bilirubin cut-off of < 300 nmol/l. 
 
UKNEQAS reporting status No. CSF diazo 
bilirubin < 300 
nmol/l 
CSF diazo 
bilirubin ≥ 300 
nmol/l 
Controls 
No evidence to support SAH 27 
29 1 
SAH not excluded 3 
Subjects 
No evidence to support SAH 59 56 3 
SAH not excluded 5 4 1 
May be consistent with SAH 8 1 7 
Consistent with SAH 5 0 5 
 
 
Table 3.6:  Comparison of UKNEQAS Guidelines reporting status groupings to the 
proposed CSF diazo bilirubin cut-off of < 359 nmol/l. 
 
UKNEQAS reporting status No. CSF diazo 
bilirubin < 359 
nmol/l 
CSF diazo 
bilirubin ≥ 359 
nmol/l 
Controls 
No evidence to support SAH 27 
29 1 
SAH not excluded 3 
Subjects 
No evidence to support SAH 59 58 1 
SAH not excluded 5 4 1 
May be consistent with SAH 8 2 6 
Consistent with SAH 5 0 5 
 
 
With the UKNEQAS Guidelines three controls were reported as ‘SAH not 
excluded’ whereas when the CSF diazo bilirubin cut-offs are applied, in both cases, 
there is only one control which would be reported as ‘may be consistent with SAH’.  
If we compare  the  subjects  reported  as  ‘No  evidence  to  support  SAH’  (n = 59) 
under UKNEQAS Guidelines to the results obtained with the two cut-offs; at 300 
nmol/l three subjects are now reported as ‘may be consistent with SAH’ and at 359  
nmol/l one subject is reported as ‘may be consistent with SAH’.  In the ‘SAH not 
excluded’ (n = 5) group according to UKNEQAS Guidelines the application of the 
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two CSF diazo bilirubin cut-offs results in four out of five being reported as ‘not 
consistent with SAH’ at both levels.  For the ‘may be consistent with SAH’ (n = 8) 
group according to UKNEQAS Guidelines; at a CSF diazo bilirubin cut-off of 300 
nmol/l one subject would be reported as ‘not consistent with SAH’ and at 359 nmol/l 
two subjects would be reported as ‘not consistent with SAH’.  In the final group, 
‘consistent with SAH’ (n = 5) according to UKNEQAS Guidelines, all subjects at 
both cut offs would be reported as ‘may be consistent with SAH’.  
 
3.4.5. CSF ferritin 
Precision and linearity studies were performed to confirm the suitability of the 
Roche assay for analysis of ferritin in CSF.   For the precision studies, CSF samples 
were assayed in replicates of five and the coefficient of variance (CV %) calculated.  
Each of the five replicates was performed on separate days to give an intra-assay CV.  
Figure 3.5, shows there is scatter, but the range of CVs is 1.0 – 3.2% indicating good 
precision for the analysis of CSF. 
 The linearity study was performed using doubling dilutions of the low level 
quality control material (Biorad) for ferritin, results were calculated using five 
replicate analyses at each level.  Figure 3.6. shows good sensitivity with detection 
limits of 0.8 ng/ml.  The detection limit was the lowest figure obtainable by the 
analyser during the linearity study. 
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Figure 3.5: CSF ferritin precision as performed on the Roche MODULAR
TM
 E unit 
via ELICA..  CSF samples were analysed in replicates of five on separate occasions. 
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Figure 3.6: Ferritin linearity performed on the Roche MODULAR
TM
 E unit (via 
ELICA) using doubling dilutions of the low level QC material (Biorad) using five 
replicates at each level.  Error bars indicate the standard deviation at each point. 
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Table 3.7 Sensitivity and Specificity of cut-off points of CSF ferritin for the detection 
of SAH. 
 
Ferritin cut-off ng/ml Sensitivity Specificity 
< 6.0 100% 33% 
< 12.0  80% 90% 
< 18.0 80% 90% 
 
 
Table 3.7 details the sensitivity and specificity of potential CSF ferritin ‘cut-
off’ points.  It is clear that the cut-off needs to be chosen carefully to achieve an 
appropriate specificity.  The cut-off of 12 ng/ml was selected for comparison purposes 
based on the normal reference range for CSF ferritin (Keir et al. 1993, p.160; 
O’Connell & Watson, 2003, p.271) of < 12 ng/ml. 
Included in Table 3.7 is the cut-off value used in the research of O’Connell 
and Watson (2003, p.271) of 12 ng/ml.  The sensitivity and specificity of this cut-off 
in this work, 80% and 86% respectively, is quite different to the 100% sensitivity and 
78% specificity obtained by O’Connell and Watson.  Further work by Watson et al. 
(2008, p.191) had a sensitivity of only 81% and specificity of 91% at 12 ng/ml, which 
corresponds with the results achieved in this research.  In the research of Watson et al. 
(2008. p.191) a cut-off of 6.4 ng/ml was also examined with a sensitivity of 100% and 
a specificity of 48% which are comparable to the 100% sensitivity and 51% 
specificity found in this research with a cut-off of 6.0 ng/ml. 
In order to compare the diagnostic capability of CSF ferritin with the 
UKNEQAS Guidelines, the cut-off value of 12 ng/ml was applied to the results 
obtained in this research (Table 3.8), and CSF ferritin results < 12 ng/ml reported as 
‘not consistent with SAH’ and those ≥ 12 ng/ml reported as ‘may be consistent with 
SAH’.  
With the UKNEQAS Guidelines three controls were reported as ‘SAH not 
excluded’ and when the CSF ferritin cut-off is applied the results remained  
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Table 3.8; Comparison of UKNEQAS reporting status groupings to the CSF ferritin 
cut-off of < 12 ng/ml. 
 
UKNEQAS reporting status No.s CSF ferritin  
< 12 ng/ml 
CSF ferritin  
≥ 12 ng/ml 
Controls 
No evidence to support SAH 27 
27 3 
SAH not excluded 3 
Subjects 
No evidence to support SAH 57 55 2 
SAH not excluded 3 2 1 
May be consistent with SAH 8 1 7 
Consistent with SAH 7 1 6 
   
unchanged.  If we compare the subjects reported as ‘no evidence to support SAH’ (n 
= 57) under UKNEQAS Guidelines to the results obtained with the CSF ferritin cut-
off two subjects are now reported as ‘may be consistent with SAH’.  In the ‘SAH not 
excluded’  (n = 3)  group  according  to  UKNEQAS  Guidelines the application of the 
CSF ferritin cut-off results in two out of three being reported as ‘not consistent with 
SAH’.  For the ‘may be consistent with SAH’ (n = 8) group according to UKNEQAS 
Guidelines one subject would be reported as ‘not consistent with SAH’.  The final 
group, ‘consistent with SAH’ (n = 7) according to UKNEQAS Guidelines, one 
subject would be reported as ‘not consistent with SAH’. 
 
3.4.6. Protein S100 
A linearity study was performed to confirm the suitability of the Roche assay 
for analysis of protein S100 in CSF.  The linearity study was performed using 
doubling dilutions of the low level quality control material (Roche) for protein S100.  
The data shown in Figure 3.7. shows good linearity with detection limits of 0.28 μg/l.  
The detection limit was the lowest figure obtainable by the analyser during the 
linearity study. 
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Figure 3.7: Protein S100 linearity performed on the Roche MODULAR
TM
 E unit (via 
ELICA) using doubling dilutions of the low level QC material (Roche). 
 
 
Table 3.9: Sensitivity and specificity of cut-off points of CSF protein S100 for the 
detection of SAH. 
 
CSF protein S100 cut off (μg/l) Sensitivity Specificity 
0.20 100% 1% 
0.40 80% 4% 
0.80 40% 40% 
1.60 40% 94% 
3.20 20% 97% 
 
 
Table 3.9 details the sensitivity and specificity of a number of potential ‘cut-
off’ points for CSF protein S100.  It is clear from the sensitivity and specificity 
achieved at each of these cut-offs that CSF protein S100 is ineffective in determining 
the occurrence of an SAH.  At acceptable sensitivity (80%) the specificity is too low 
(4%), and with acceptable specificity of 94% the sensitivity is only 40%. 
Upon closer examination of the CSF protein S100 results, the control group 
mean values were 1.01 ± 0.67 μg/l and in those subjects with confirmed SAH the 
mean values were 8.52 ± 17.05 μg/l.  These results are similar to those obtained by 
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Kay et al. (2003, p.241) where the control group had mean CSF protein S100 levels of 
0.26 ± 0.1 μg/l and the SAH group mean values of 7.0 ± 5.3 μg/l seven days post 
SAH.   
Table 3.10 details the sensitivity and specificity of a number of potential ‘cut-
off’ points for serum protein S100.  It is clear from the sensitivity and specificity 
achieved at each of these cut-offs that serum protein S100 is ineffective in 
determining the occurrence of an SAH.  At acceptable sensitivity (100%) the 
specificity is too low (56 or 67%), and with acceptable specificity of 85% the 
sensitivity is 33%.  In addition to this there is too much overlap between the control 
group (mean values 0.36 ± 1.44 μg/l) and the subject group (with confirmed SAH 
mean values 0.09 ± 0.01 μg/l) therefore making this an unsuitable analyte to include 
further in the comparison.  These results are quite different to those obtained by 
Wiesmann et al. (1997, p.1156) where the control group had serum protein S100 
mean values of 0.05 ± 0.08 μg/l and the SAH group levels were 0.26 ± 0.44 μg/l 
seven days post SAH.  The results of Yoon et al. (2008, p.310) were also quite 
different for the control group having a median serum protein S100 of 0.05 (0.036 – 
0.066) μg/l but did show good correlation with the SAH group with levels of 0.092 
(0.052 – 0.163) μg/l on admission. 
 
Table 3.10: Sensitivity and specificity of cut-off points of serum protein S100 for the 
detection of SAH. 
 
Serum protein S100 cut off (μg/l) Sensitivity Specificity 
0.07 100% 56% 
0.08 100% 67% 
0.09 66% 73% 
0.10 33% 75% 
0.20 33% 85% 
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3.4.7. Effects of oxyhaemoglobin on alternative methods 
The results of the initial oxyhaemoglobin interference study show that there 
was no interference with CSF diazo bilirubin below a NOA of approximately 0.7 AU 
(or 1.3 µg/l), no interference with CSF ferritin even at very high NOA levels of > 3.0 
AU (or 5.3 µg/l and above) and CSF protein S100 levels showed a slight decrease as 
oxyhaemoglobin levels increased (Figure 3.8.).  
The second oxyhaemoglobin interference investigation used a CSF pool.  CSF 
diazo bilirubin showed a positive bias at NOAs of approximately 0.80 AU (or 1500 
µg/ml), but there was little interference with CSF ferritin and CSF protein S100 levels 
(Figure 3.9). 
 
 
 
Figure 3.8: Doubling dilutions of oxyhaemoglobin with HPLC grade water to 
investigate interference with the CSF diazo bilirubin (nmol/l), ferritin (ng/ml) and 
protein S100 (μg/l) assays. 
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Figure 3.9: Doubling dilutions of a CSF pool with oxyhaemoglobin added to 
investigate interference with the CSF diazo bilirubin (nmol/l), ferritin (ng/ml) and 
protein S100 (μg/l) assays.  The y axis is on a log scale in order that data points can 
be viewed easily. 
 
3.4.8. Sample stability 
 Figure 3.10. shows that CSF ferritin remains stable in samples refrigerated 
over a period of 4 days at 4-8 ºC and that CSF protein S100 is stable over a period of 
3 days but levels do begin to deteriorate beyond 3 days of refrigeration. 
 Figure 3.11. shows that CSF ferritin remains stable in samples frozen at -40 
ºC over a period of eighteen months and that CSF protein S100 shows considerable 
deterioration after just six months. 
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Figure 3.10: Percentage change in CSF ferritin and protein S100  refrigerated  at 4-8 
ºC and light protected over a period of 4 days, using two separate pools of CSF.   
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Figure 3.11: Percentage change in CSF ferritin and protein S100 frozen at -40 ºC 
over a period of eighteen months and light protected, using two separate pools of 
CSF.  Pool 1; Ferritin 1 and protein S100 1, Pool 2; Ferritin 2 and  protein S100 2. 
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3.4.9. Suitable CSF sample type 
 As discussed in section 3.1.4. it is essential to establish if both plain CSF and 
fluoride oxalate preserved CSF are equally suitable in all alternative analyses.  It 
would be simpler and less time consuming if all analyses could be carried out on one 
sample alone, potentially reducing overall turnaround time and protecting the plain 
sample from unnecessary light degradation. 
In order to assess which was the most suitable sample type, both a plain CSF 
sample and a fluoride oxalate CSF sample were analysed for each subject and control 
for CSF diazo bilirubin, ferritin and protein S100 (Figures 3.12 a-c). 
 The coefficient of determination (R
2
) for the analytes CSF diazo bilirubin, 
ferritin and protein S100 are respectively 0.997, 0.999 and 0.587.  These are close to 1 
for both CSF diazo bilirubin and ferritin, which indicates a strong relationship 
between ‘x’ and ‘y’ i.e. between plain CSF results and fluoride oxalate CSF results 
indicating that CSF diazo bilirubin and ferritin analysis can be performed equally well 
on either sample type.  The coefficient of determination for protein S100 indicates 
that there is a relatively weak relationship between the plain CSF results and the 
fluoride oxalate CSF results, which means that protein S100 analysis could only be 
performed on the plain CSF sample. 
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 Figure 3.12c  
Figures 3.12 a-c; comparison of results of plain CSF samples and fluoride oxalate 
CSF samples in order to determine if both sample types are equally suitable for 
analysis: a = CSF diazo bilirubin, b = ferritin, c = protein S100.  Figures a and b 
have a logarithmic scale on both the x and y axis.  
 
3.5. Discussion 
3.5.1. Subjects 
 It was originally estimated that one hundred patients with suspected SAH and 
one hundred controls would be included in this research. The estimate for the patients 
suspected of having an SAH was almost reached (81%), but the number of controls 
included was disappointingly low (30%).  This appears to have occurred due to the 
reduced sample volumes received for oligoclonal band requests as compared to 
xanthochromia requests.  As CSF sample volumes are not routinely recorded it was 
not identified as a potential restriction upon sample collection for this research. 
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3.5.2. Visual inspection of CSF for xanthochromia 
The poor sensitivity (40%) with a specificity of 92% for this method of 
assessing CSF for the presence of xanthochromia is reflected in the results of other 
research.  Perry et al. (2006, p.2470) reported visual inspection to have a sensitivity of 
50% and a specificity of 97% and Arora et al. (2008, p.14) found that visual 
inspection had a sensitivity of only 47%.  Neither report provides details of the 
protocol followed for visual estimation of CSF xanthochromia so it is difficult to 
directly compare the results to this study, and in the work of Perry et al. it is unclear if 
centrifugation of the CSF sample occurred prior to visual examination (2006, p.2468).   
In contrast, Sidman et al. (2005, p.54) achieved much better results with a 
sensitivity of 55% and a specificity of 98%, but it is apparent  that the analysts were in 
fact assessing the presence of oxyhaemoglobin rather than the presence of 
xanthochromia and it is therefore not an ideal comparison.  Linn et al. (2005, p.1452) 
achieved a sensitivity of 100% but the method used to determine if the CSF sample 
was positive for xanthochromia (absorbance >0.05 AU at 450-460 nm) is not 
consistent with the UKNEQAS Guidelines and would appear to underestimate the 
presence of xanthochromia. 
The poor sensitivity of this study is supported by the findings of other work in 
which the detection limits of the human eye were investigated.  Bradley et al (2003, 
p.73) investigated inter-observer variability of visual xanthochromia and found; 100% 
of analysts reported an NBA of 0.011 AU (positive according to UKNEQAS 
Guidelines) as negative visually, 40% of analysts reported an NBA of 0.03 AU as 
visually positive and 100% of analysts reported an NBA of 0.074 as visually positive.  
In the work of Marden et al (2001, p.53) the lowest point of visual detection was 
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0.029 AU and it was only at an NBA ≥ 0.139 that > 95% of analysts reported the CSF 
samples as visually positive for xanthochromia. 
 
3.5.3. Spectrophotometric assessment of xanthochromia 
The sensitivity (100%) and specificity (81%) achieved in this research for 
spectrophotometric assessment of xanthochromia in determining the occurrence of 
SAH is comparable to the results of others.  Perry et al. (2006, p.2470) achieved a 
sensitivity of 100% and a specificity of 83%.  They claimed to use UKNEQAS 
guidelines but did not use scanning spectrophotometry, instead using the absorbances 
at four wavelengths to give an approximation of the results that would be obtained by 
scanning spectrophotometry which does not produce the correct results (Beetham & 
Lhatoo, 2007, p.86).  In addition samples were frozen over an uncertain time frame 
prior to spectrophotometric analysis and freezing changed absorbances on average by 
0.010 AU, which could be enough to provide a positive result under UKNEQAS 
Guidelines. 
The term xanthochromia is derived from the Greek, xanthos meaning yellow 
and is by definition the yellow discolouration indicating the presence of bilirubin in 
the CSF.  Regardless of its definition many research articles use the term 
xanthochromia in reference to any discolouration of the CSF.  Foot and Staib (2001, 
p.327) refer to xanthochromia as a ‘loose term’ which encompasses the presence of 
bilirubin and oxyhaemoglobin.  It is on this basis that the term ‘xanthochromia index’ 
is referred to in the literature as synonymous with xanthochromia, when in truth it is 
an assessment of the presence of oxyhaemoglobin alone (Foot & Staib, 2001, p.328; 
Wood et al, 2005, p.143).  This confusion over terms has lead to a number of studies 
dismissing spectrophotometric determination of xanthochromia as a useful tool in 
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determining the occurrence of SAH on the basis of its poor sensitivity and specificity, 
when they are actually looking at the wrong CSF pigments.  Perry et al.  (2006, 
p.2470) found the xanthochromia index to have a sensitivity of 100% with a 
specificity of only 29%. 
 
3.5.4. CSF diazo bilirubin 
The intra assay CV of 7.9% at 280 nmol/l (just below the cut-off) 
demonstrates that this modified assay is sufficiently sensitive.  In addition the assay is 
linear from 70 nmol/l to 4024 nmol/l which encompasses the area of interest.  
There is still a discrepancy of around 130 nmol/l to be reconciled for the 
difference between the cut-off employed in this research (300 nmol/l) and the 
calculated CSF bilirubin from the UKNEQAS guidelines cut-off (167 nmol/l - based 
upon 0.007 AU and using the extinction coefficient of bilirubin at 476 nm).  The 
difference between the limits of detection of the assay using saline (60 nmol/l) and 
using bilirubin free CSF (158 nmol/l) would indicate that this issue may be matrix 
related, although this difference could be due to bacterial growth in the sample, and 
that the CSF samples contain an unspecified analyte which interferes with the CSF 
diazo bilirubin assay.   
Although CSF is sterile when sampled and it is placed into a sterile specimen 
container, consideration needs to be given to bacterial growth and its potential effects 
on the CSF diazo bilirubin method limits of detection exercise discussed above.  
Bacterial contamination of the sample, and subsequent growth, could increase the 
alkalinity of the sample.  As the sample volume in the CSF diazo bilirubin method has 
been increased seven fold compared to a serum bilirubin assay, this change in pH 
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could potentially overwhelm the buffering system within the reagent and therefore 
affect the assay results.   
There is also the possibility of pharmacological interference with the CSF 
diazo bilirubin method.  Rifampicin (an antibiotic used in the treatment of 
tuberculosis, meningitis prophylaxis and methicillin-resistant Staphylococcus aureus 
and as a chemotherapeutic) has a positive effect on bilirubin measurements.   Meisel 
et al. (1980, p.206) report that this is a small effect with no clinical significance for 
serum bilirubin levels, whereas Sonntag & Scholer (2001, p.379) found it to give a 
13% increase, this may be problematic with the low levels being analysed in the CSF 
diazo bilirubin method. 
This discrepancy has remained fairly consistent across two research groups 
(This research and the work of Ungerer et al, 2004 & Chao et al., 2007) utilising two 
separate analytical platforms and two different diazo methods which would further 
support the theory that an unspecified analyte is causing interference.   
The sensitivity (100%) and specificity (86%) achieved in this research at a cut-
off of 300 nmol/l for CSF diazo bilirubin in determining the occurrence of SAH, is 
superior to the results of other studies.  Chao et al. (2007, p.142) reported a sensitivity 
of 100% and a specificity of 75% with a cut-off at 300 nmol/l, although they 
determined that the optimal cut-off would be 359 nmol/l with a sensitivity of 100% 
and a specificity of 92%.  Using this higher cut-off in this research would have missed 
one sample determined as suggestive of SAH which had an NBA of 0.008 AU and a 
CSF diazo bilirubin of 303 nmol/l.  In order for CSF diazo bilirubin to be effective at 
determining the occurrence of SAH then this lower cut-off of 300 nmol/l needs to be 
employed.  The research of Ahmed et al. (2009) provided insufficient information to 
draw a direct comparison with this research.  
  
 
78 
The research of Chao et al. (2007) is a further extension of the original work 
undertaken by Ungerer et al. (2004), in which the CSF diazo bilirubin method 
employed is a modified Jendrassik & Gróf method (Ungerer et al., 2004, p.1854; 
Chao et al., 2007, p.141) which, according to the UKNEQAS Clinical Chemistry 
Scheme returns, is not employed in United Kingdom laboratories.  The CSF diazo 
bilirubin method employed in this study i.e. that of Whalefeld et al. (1972, p.11), 
suffers from less interference from oxyhaemoglobin and may account for differing 
choices of cut-off. 
 
3.5.5. CSF ferritin 
The intra assay CV of 2.7% at 15 ng/ml (just above the 12 ng/ml suggested 
cut-off) demonstrates that this assay is sufficiently sensitive for the analysis of CSF 
Ferritin.  The assay was shown to be linear for Ferritin CSF, Figure 3.5, between 0.8 
and 14 ng/ml, encompassing the area of interest. 
Using a cut-off of 12 ng/ml, CSF ferritin achieves a sensitivity of 80% and a 
specificity of 86% in determining the occurrence of SAH.  In the initial work by 
O’Connell and Watson (2003, p.273) they concluded that CSF ferritin could be used 
to objectively exclude the diagnosis of SAH, but this needed to be examined further 
through the investigation of larger numbers of cases.  A follow up study (Watson, 
2008, p.192) could not recommend using CSF ferritin for the exclusion of SAH due to 
the number of false positives resulting in patients undergoing unnecessary 
angiography, but reported that ferritin did have the advantage of being a simpler assay 
(as compared to scanning spectrophotometry) available on automated analysers in 
most laboratories.   The identification of false positives could be attributed to variable 
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levels of ferritin synthesis in response to a bleed (Watson et al., 2008, p.191) or the 
elevated levels seen in siderosis (O’Connel & Watson, 2003, p.273). 
 
3.5.6. Protein S100; CSF and serum 
 It is clear from the poor sensitivity and specificity (Tables 3.9 and 3.10) of 
protein S100 achieved in CSF and serum at various cut-off points that it would be an 
unsuitable alternative or adjunct to the UKNEQAS Guidelines in determining the 
occurrence of SAH.  This is further supported by the excessive overlap in CSF and 
serum protein S100 results seen between both the subjects and the controls. 
 
3.5.7. Effects of oxyhaemoglobin 
 As indicated in the UKNEQAS Guidelines (2003, p.487) oxyhaemoglobin 
causes an underestimation of NBA by approximately 0.001 AU for every 0.030 AU of 
NOA.  This would mean that at an NOA of only 0.030 AU a positive NBA of 0.007 
AU could well be missed as the NOA level could reduce the NBA to only 0.006 AU.  
It is in these instances that an alternative to the UKNEQAS Guidelines would be 
invaluable, particularly if the alternative suffered less from interference from 
oxyhaemoglobin. 
There appears to be little interference at relatively high levels of 
oxyhaemoglobin for CSF diazo bilirubin (up to 0.80 AU) and CSF ferritin (> 3.0 AU) 
whereas CSF protein S100 showed a slight decrease as oxyhaemoglobin levels 
increased.  Since only 9% of samples in this research reported as not negative under 
UKNEQAS Guidelines had a NOA of over 0.80 AU then this provides further support 
for the applicability of either CSF ferritin or CSF diazo bilirubin in the determination 
of SAH. 
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3.5.8. Sample stability 
 The sample stability studies were carried out in order to establish if the storage 
conditions and batch analysis of CSF ferritin and protein S100 employed in this 
research had any detrimental effect upon results.  Due to the already proven labile 
nature of CSF bilirubin (UKNEQAS, 2003, p.486; Foroughi, 2010, p.401) this was 
not included as part of the sample stability study. 
 The initial stability study concentrated on the refrigerated storage of samples, 
as samples received out of hours and at weekends would not be frozen until the 
following Monday (or Tuesday for bank holiday weekends).  The results indicate that 
no detrimental effect would occur for ferritin over a period of four days and protein 
S100 over a period of three days.  As a consequence, only CSF samples less than four 
days old upon freezing were analysed for ferritin and only CSF samples less than 
three days old upon freezing were analysed for protein S100. 
The second phase of the stability study was carried out in order to establish if 
the freezing and subsequent batching of ferritin and protein S100 analysis had an 
effect on the results obtained.  This phase demonstrated that the practice of analysing 
samples every five months had no detrimental effect upon results. 
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3.5.9. Suitable sample type 
 Under UKNEQAS Guidelines the clinical biochemistry laboratory receives 
two separate CSF samples.  One is collected into fluoride oxalate preservative for the 
analysis of glucose and protein, this is the first sample collected from the lumbar tap.  
The other sample is collected into a plain sample container which is light protected for 
scanning spectrophotometry, this is the fourth sample collected from the lumbar tap 
(samples two and three are sent to microbiology).  Examining the suitability of both 
sample types was an important part of this research as it would be simpler and less 
time consuming if an alternative to UKNEQAS recommendations could be carried out 
on the same sample used for ‘routine’ CSF investigations.   
The results of this part of the research clearly indicate that either a plain or a 
fluoride oxalate CSF sample could be used for the analysis of CSF diazo bilirubin and 
ferritin, but that protein S100 analysis would possibly need to be carried out on the 
plain sample alone.  This gives ferritin and CSF diazo bilirubin an advantage, as using 
the fluoride oxalate sample would ensure that the plain sample was kept intact for 
possible scanning spectrophotometry and that all analyses required, including protein 
and glucose, could be carried out on the same sample.  This also addresses the 
concerns raised by the UKNEQAS special advisory group about the potential for 
delayed reporting of results (Cruickshank, 2008, p.618). 
 
3.6. Conclusion 
In order to establish which and indeed if any of these suggested alternatives 
would be suitable to replace or supplement the current UKNEQAS Guidelines they 
need to be compared directly to each other using specified criteria.  The chapter which 
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follows carries out this comparison under objective 3 (see 1.3. Aims and objectives of 
research project) ‘To compare the alternative laboratory test(s) with existing 
laboratory practice i.e. the UKNEQAS National Guidelines’. 
It was decided to include visual inspection in the comparison as it is still the 
only estimation of xanthochromia available in some UK laboratories (Holbrook et al., 
2007, p.444).  Spectrophotometry would be examined under the 2003 UKNEQAS 
Guidelines (2003, p.481) used in this research and the more recently released update 
(Cruickshank et al., 2008, p.238).  CSF diazo bilirubin and CSF ferritin were also 
included in the comparison, as the results found in this research indicate that they had 
a potential role to play.  CSF and serum protein S100 were not considered further in 
this research due to their poor performance in detecting the occurrence of SAH. 
Some research groups have suggested that CSF diazo bilirubin (Chao et al., 
2007, p.143; Ungerer et al., 2004, p.1855) and CSF ferritin (O’Connel & Watson, 
2003, p.273; Watson, 2008, p192) could be utilised as a screening test prior to 
scanning spectrophotometry.  A screening test is not a diagnostic test, its primary 
purpose is to detect early disease or risk factors for disease in a population of 
seemingly healthy individuals e.g .the cervical screening programme.  There is a need 
therefore, to be cautious regarding terminology.  A two step process i.e. testing 
samples for CSF diazo bilirubin or CSF ferritin followed by scanning 
spectrophotometry, if deemed necessary, is a ‘rule-in/rule-out’ scheme of testing 
rather than screening.  CSF diazo bilirubin or CSF ferritin could therefore be used to 
rule out a diagnosis of SAH, based upon their sensitivity, which is then being 
followed up by scanning spectrophotometry to rule in which of the subjects are likely 
to have suffered an SAH, based upon the specificity of the test (Lee, 1999, p.521). 
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In the following chapter CSF diazo bilirubin and CSF ferritin were considered 
as part of a two step scheme of testing in which they were utilised as an initial rule out 
test to be followed up by scanning spectrophotometry where appropriate.  In this 
respect the absence of false negatives using the rule in/rule out test is the primary 
concern as false negatives could mean a diagnosis was missed and a patient 
potentially discharged. 
All of the assays considered in the comparison have their attributes, from the 
ease and accessibility of visual inspection to the objectivity of CSF ferritin and CSF 
diazo bilirubin, they also have their drawbacks, such as the time consuming and 
technically difficult scanning spectrophotometry.  Aspects such as these will also be 
deliberated in the ensuing chapter to ensure that the proposed alternatives have been 
examined from all angles. 
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Chapter 4 
Comparison of CSF diazo bilirubin and 
CSF ferritin with the current practices of 
visual inspection and scanning 
spectrophotometry (UKNEQAS Guidelines) 
in the determination of xanthochromia in 
CSF 
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4.1. Introduction 
In order to satisfy objective three (see section 1.3.) of this research ‘to directly 
compare the alternative laboratory tests with existing laboratory practices’, this 
chapter will compare the use of the proposed alternatives, CSF diazo bilirubin and 
CSF ferritin, with the current practices of visual inspection and scanning 
spectrophotometry (UKNEQAS Guidelines). This will establish how the proposed 
alternative laboratory tests compare with existing practices and what place they could 
have in the laboratory diagnosis of SAH.   
The laboratory tests, investigated in this research, that will be considered in 
the following comparison have their attributes, from the ease and accessibility of 
visual inspection to the objectivity of CSF ferritin and CSF diazo bilirubin, they also 
have their drawbacks, such as the time consuming and technically difficult scanning 
spectrophotometry and the subjectivity of visual inspection.  Aspects such as these 
will also be discussed in the ensuing chapter to ensure that the proposed alternatives 
have been thoroughly examined. 
When this research was initiated the scanning spectrophotometry method 
employed for SAH diagnosis using CSF analysis was that recommended in the 2003 
UKNEQAS Guidelines (2003, p.481).  In May 2008, after the collection and analysis 
of samples had been completed for this research, revised national Guidelines for 
analysis of cerebrospinal fluid for bilirubin in suspected SAH were published by 
UKNEQAS (Cruickshank et al., 2008, p.238).  
Not only do these revised Guidelines need to be included in the comparison, 
but an evaluation of the two sets of Guidelines is essential to determine the impact of 
the modifications. 
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4.1.1.  Comparison of UKNEQAS 2003 and 2008 Guidelines 
 There have been some subtle changes to the introduction of the Guidelines in 
the 2008 version and some minor points have been omitted, such as the ‘small but 
definite risk of morbidity and mortality’ of angiography (UKNEQAS, 2003, p.481), 
see 1.1.4 Diagnostic investigation of SAH p.9, and the explanation of how 
‘spectrophotometry to detect bilirubin in CSF is a reliable method of distinguishing 
between an SAH and a traumatic lumbar puncture if there is a high red cell count or if 
the patient presents late’ (UKNEQAS, 2003, p.482).  Additions to the 2008 revision 
have emphasised the effect of CSF protein and serum bilirubin on CSF bilirubin 
(Cruickshank et al., 2008, p.238), which is only implied via the reporting pathway in 
the 2003 Guidelines (UKNEQAS, 2003, p.485). The 2008 Guidelines thoroughly 
discourage the use of direct analysis of CSF diazo bilirubin (Cruickshank et al., 2008, 
p.239) as it has not been adequately validated.  One research group has published two 
papers, to date, which have validated the CSF diazo bilirubin method (Ungerer et al., 
2004, p.1854; Chao et al., 2007, p.140) but the authors of the UKNEQAS guidelines 
2008 do not yet have sufficient confidence in the performance of this method to 
recommend it as a screening method (Cruickshank, 2008, p.618).  There are also 
concerns that the CSF diazo bilirubin methods have not been validated by the 
manufacturers for this purpose in Europe and they require CE marking. 
 The specimen requirements and transport section has some surprising 
additions in the 2008 revision (Cruickshank et al., 2008, p.239) such as ‘CSF samples 
should always be analysed if sufficient sample is received’.  This would seem to 
imply unreferenced/unpublished research which reveals that samples are not always 
analysed.  This may be a reference to the information gleaned from the national audit 
of cerebrospinal fluid analysis published in 2007 (Holbrook et al., 2007, p.444) in 
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which laboratories reported that they rejected CSF samples for a variety of reasons.  
There is also a modification of opinion over the use of pneumatic tube systems to 
transport samples.  In the 2003 Guidelines it was stated that these should be avoided 
(UKNEQAS, 2003, p.483) whereas in the 2008 revision they are not recommended 
but it is suggested that the overriding consideration should be rapid transport to the 
laboratory (Cruickshank et al., 2008, p.239). 
 The reporting and interpretation of CSF spectrophotometry has changed 
significantly between the 2003 Guidelines and the 2008 revision (see Appendix 7) 
with regard to the significance of low oxyhaemoglobin levels, but with no real 
explanation as to the basis of this revision (Cruickshank et al., 2008, p.239).  
Additionally at the end of the 2003 Guidelines there are two additional comments to 
‘bear in mind’ when reporting on spectrophotometry (UKNEQAS, 2003, p.486) 
which are omitted from the 2008 revision; 
1. a normal erthyrocyte count in a CSF taken definitely between 12 and 72 hours 
after an event is evidence against a SAH 
2. spectrophotometric findings on a CSF taken at a second or subsequent lumbar 
puncture some hours or more after the previous puncture only reflect the 
probablility that blood has been introduced traumatically into the subarachnoid 
space at an earlier puncture. 
These two points were put to the corresponding author, Dr Anne Cruickshank, 
who stated that it was the view of the UKNEQAS panel that erythrocyte counts had 
no place in the diagnosis of SAH.  It was also felt that any lumbar puncture may 
introduce blood into the subarachnoid space and the significance of a positive result 
some hours after a previous lumbar puncture is unclear.  It could indicate SAH, but it 
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may reflect only the previous lumbar puncture and a negative result would always be 
clinically useful. 
In both the original 2003 Guidelines and the 2008 revision, a ‘decision tree’, a 
type of flow chart, is included to guide the user to the appropriate interpretation of 
results.  In the 2008 revision the decision tree has been simplified by the removal of 
sample requirements, making it less ‘busy’ and easier to follow.  There are very few 
other changes other than those to accommodate the new NOA ‘rules’.  Interestingly 
there is no option in this revised decision tree for samples with an NBA of > 0.007 
AU and no oxyhaemoglobin, not an impossible situation especially if the subject 
presents late. 
There have been concerns raised (Absalom, 2009, p.177; Griffiths et al., 2009, 
p.1052) regarding the removal of the correction for serum bilirubin in the presence of 
increased NOA and the potential for patients to undergo cerebral angiography 
unnecessarily.  Under the revised guidelines regardless of how high the patient’s 
serum bilirubin is, if NOA is increased the statement ‘Consistent with SAH’ is issued.  
This is justified by the authors of the 2008 UKNEQAS guidelines under the principal 
aims of the guideline revision i.e. to emphasise the clinical significance of increased 
bilirubin with a visible oxyhaemoglobin absorbance peak, and to simplify the 
reporting of results in this group of patients (Cruickshank, 2009, p.178).  Additionally 
the UKNEQAS Specialist Advisory Group which developed the guidelines had access 
to unpublished data in which only two out of a total of 2304 cases over a five year 
period had NBA >0.007 AU, NOA >0.02 AU and serum bilirubin concentration >20 
µmol/L (Cruickshank, 2009, p.178).  In this research which includes a much smaller 
group of patients and over a much shorter time frame there was one patient who had 
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an NBA  0.614 AU, NOA 0.455 AU and a serum bilirubin concentration >20 µmol/L; 
41 µmol/L. 
An audit comparing the original 2003 and revised 2008 guidelines concluded 
that the revised 2008 guidelines for the analysis of CSF in suspected SAH offered less 
ambiguous reports (interpreting comments have been reduced from 14 to 9) to 
clinicians and did not adversely affect patient outcome for at least one year (Griffiths 
et al., 2010, p.377).  The authors do admit that the adverse patient outcome may have 
been underestimated as it is possible that a patient could have been admitted to 
another hospital with an SAH or died out in the community without reaching hospital. 
 
4.2. Method 
4.2.1.  Analytical methods for comparison 
The tests used in the comparison were divided into two groups.  Those that are 
current laboratory practice i.e. visual inspection and scanning spectrophotometry 
using the UKNEQAS Guidelines (Holbrook et al., 2007, p.444), and the suggested 
alternatives from this research i.e. CSF diazo bilirubin (cut-off 300 nmol/l) and 
ferritin (cut-off 12 ng/ml). 
Neither CSF nor serum protein S100 were used in the comparison due to their 
poor performance in detecting the occurrence of SAH. 
 
4.2.2. Comparison criteria 
In order to compare these analytical methods for the determination of SAH a 
robust set of criteria needed to be formulated. 
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An essential component for any diagnostic test is the ability to differentiate 
between disease positives (sensitivity) and disease negatives (specificity).  The ideal 
diagnostic test would have sensitivity and specificity of 100%, but in reality this 
rarely occurs and therefore a compromise must be made to achieve the best overall 
performance.  Sensitivity was based upon results from subjects who had suffered an 
SAH and specificity was based upon results from subjects who had not suffered an 
SAH, as determined from patients’ clinical notes. 
Rarely is analytical testing for disease cut and dried and in many circumstances 
there is a ‘grey’ area in which the result is neither truly positive nor truly negative e.g. 
with UKNEQAS Guidelines (inconclusive i.e. may be consistent with SAH) and 
visual (blood stained).  Grey areas more often than not lead to further investigations, 
for example with the UKNEQAS Guidelines when a result is ‘inconclusive’ this leads 
to the patient, potentially, undergoing cerebral angiography.  Further investigations 
involve more work and careful consideration therefore needs to be given to what 
benefits would be realised by changing to a new set of ‘guidelines’ and any potential 
workload implications. 
All of the methods included in this comparison suffer with interference from 
oxyhaemoglobin to some extent.  Due to the traumatic nature of the procedure used to 
obtain CSF (lumbar puncture) the presence of oxyhaemoglobin is a very real 
possibility in any sample arriving in the laboratory.  Therefore the effect of 
oxyhaemoglobin is an important consideration in selecting the most appropriate 
method for determining the occurrence of SAH. 
Dependent upon which analyte is selected it may not be possible or appropriate to 
carry out analysis 24 hours a day.  This fits with current practice in more than half of 
laboratories now using the UKNEQAS Guidelines (Holbrook et al., 2007, p.448).  
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Additionally many laboratories are tertiary referral centres and therefore receive 
samples via Royal Mail and other transport systems.  In light of this, sample stability 
is an important consideration. 
The ability to perform a test to ‘rule-out’ SAH at the same time as routine CSF 
requests i.e. protein and glucose, would greatly improve turnaround time and 
accommodate the changing skills mix within pathology.  This would not only be of 
great benefit to the patient but would also have an impact on potential bed blocking 
and could allow testing to occur 24 hours a day. 
Another important consideration is the cost of introducing a new method for the 
determination of SAH as compared to current practice.  The cost benefit analysis 
should not only concern the cost of the test itself, but also the cost implications of 
keeping  patients in acute beds until the analysis is complete.  
Therefore in order to compare the alternative tests with current laboratory practice 
the following criteria were used: 
 Sensitivity and specificity 
 ‘Grey’ areas and further investigations 
 Interference from oxyhaemoglobin 
 Stability of the analyte under various storage conditions   
 Turn-around-time 
 Cost:benefit analysis  
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4.3. Results 
4.3.1. Sensitivity and specificity 
 If the sensitivities of the laboratory tests under consideration are examined, it 
is clear that visual inspection is the weakest at only 40% (Table 4.1).  If we 
subsequently disregard visual inspection then the remaining tests are equally 
sensitive, at 100%, apart from Ferritin at 80%, and have similar specificities with only 
a 5% difference (range 81–86%, Table 4.1).  It is interesting to note that visual 
inspection has the best specificity.  
 
Table 4.1: Sensitivity and specificity of the tests under consideration for the 
determination of SAH utilising CSF analysis; visual inspection, scanning 
spectrophotometry (2003 and 2008 UKNEQAS Guidelines), CSF diazo bilirubin and 
CSF ferritin. 
 
Method Sensitivity (%) Specificity (%) 
Visual inspection 40 92 
UKNEQAS 2003 100 81 
UKNEQAS 2008 100 82 
CSF diazo bilirubin 100 86 
CSF Ferritin 80 86 
 
4.3.2. Grey areas and verification 
 For visual inspection an inconclusive result, i.e. where interpretation is 
prevented, would arise if the CSF protein was > 1 g/l or if the sample was 
bloodstained, as both of these circumstances interfere with the visual interpretation of 
the CSF’s colour.   Within this research a total of eleven (13.5%) subjects had a CSF 
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protein of > 1 g/l; and a further three (3.7%) were visually bloodstained.  All of these 
were reported as ‘inconclusive’. 
The UKNEQAS Guidelines, original 2003 and revised 2008, require 
interpretation of an inconclusive nature on all CSF samples with a protein of > 1 g/l 
and increased levels of oxyhaemoglobin (see Appendix 7 for details).  The details in 
Table 4.2 demonstrate that there are less inconclusive reports using the 2008 
guidelines revision, going from 17.3 % with the 2003 Guidelines down to 9.9 % under 
the revised 2008 Guidelines.  
Using CSF diazo bilirubin analysis with a cut-off of < 300 nmol/l and 
reporting those subjects above this cut-off as inconclusive, results in 20.8% of 
subjects being reported as inconclusive.  If the same procedure is applied to CSF 
ferritin analysis with a cut off of < 12 ng/ml, 21.1% subjects are reported as 
inconclusive. 
 The only method available for verifying visual results and those obtained from 
the UKNEQAS Guidelines is cerebral angiography, but for CSF diazo bilirubin and 
ferritin a verification step could be added within the laboratory setting.  In order to 
clarify the ‘grey area’ further, the UKNEQAS Guidelines could be applied to all those 
samples found to be inconclusive using the CSF diazo bilirubin and ferritin cut-offs. 
 
Table 4.2: Inconclusive CSF analysis results using the original UKNEQAS 
Guidelines, 2003, and the 2008 revision. 
 
 Inconclusive 
2003 
Guidelines 
14 (1)*    [17.3%] 
2008 
Revision 
8 (1)*    [9.9%] 
*Confirmed SAH, not the same patient 
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 Using the CSF diazo bilirubin cut-off of < 300 nmol/l followed by UKNEQAS 
Guidelines 2008 would result in three (3.9%) subjects being reported as inconclusive.  
If the same procedure is applied to CSF ferritin analysis with a cut off of < 12 g/l 
followed by UKNEQAS Guidelines 2008; two (2.6%) subjects would be reported as 
inconclusive. 
 
4.3.3. Oxyhaemoglobin interference 
 The impact of the presence of oxyhaemoglobin can not truly be assessed for 
the visual examination of CSF other than that visually bloodstained CSF is reported as 
inconclusive.  It must be noted however that the ability of the human eye to determine 
the presence of oxyhaemoglobin is variable (Bradley et al., 2003. p.74).  In this 
research only three subjects were reported as visually blood stained, with NOA of 
0.065 AU, 0.141 AU and 1.627 AU.  If these results are compared to the NOA of all 
samples reported as visually clear (NOA range; 0.000 AU to 0.410 AU) there is 
clearly considerable overlap. 
 In order to assess the impact of oxyhaemoglobin levels on the UKNEQAS 
Guidelines the final reporting comments directly influenced by the sample’s 
oxyhaemoglobin levels were examined in more detail.  Under the 2003 UKNEQAS 
Guidelines a total of 10 (12.5%) subjects were reported as inconclusive i.e. ‘may be 
consistent with SAH’; all ten subjects had NBAs of zero and the NOAs range from 
0.042 AU to 0.445 AU.  A similar picture was seen with the 2008 UKNEQAS 
Guidelines under which a total of seven (8.8%) subjects were reported as inconclusive 
i.e. ‘may be consistent with SAH’; all seven subjects had NBAs of zero and the NOAs 
ranged from 0.108 AU to 0.445 AU. 
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Above an NOA of 0.800 AU there is interference seen with the CSF diazo 
bilirubin assay.  Only two (2.5%) subjects included in this research had an NOA of > 
0.800 AU, both of which were reported as ‘consistent with SAH’ under the 2008 
UKNEQAS Guidelines 
There appears to be little effect on CSF Ferritin even at NOA > 3.0.  Only one 
(1.3%) subject included in this research had an NOA even approaching this (reported 
as NOA > 2.0) and they were reported as ‘consistent with SAH’ under the 2008 
UKNEQAS Guidelines. 
 
4.3.4. Analyte stability 
For the purposes of a service to establish the presence of xanthochromia in a 
CSF sample, analyte stability is of utmost importance, even more so when 
accommodating different levels of service across a wide geographical area.  For 
example in South West Wales the laboratory at Morriston hospital provides a service 
for five surrounding hospitals (Figure 4.1), the furthest of which (Bronglais Hospital) 
is 76 miles away. 
These referral samples make up over one third (35.9%; June 2008 to May 
2009) of the department’s xanthochromia workload making stability during transport 
an important issue.  The transport time for these samples is quite variable; 76.5% 
arrive within one day, 12.3% within two days (over half of these are sampled over a 
weekend), 9.2% take three to four days (all of which were sampled over a weekend) 
and a worrying 2% take six days to arrive (again all of these were sampled over a 
weekend). 
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Figure 4.1: Map of South West Wales indicating the locations of the five hospitals 
which refer xanthochromia requests to Morriston Hospital 
 
Sample stability studies carried out for the 2003 UKNEQAS Guidelines show 
that CSF stored in a plastic tube and exposed to daylight shows a bilirubin decay rate 
of at least 0.005 AU/h (UKNEQAS, 2003, p.486) making light protection of the CSF 
sample an important issue for those xanthochromia referral requests. 
 Previous work carried out by the researcher (Appendix 8) has shown that CSF 
bilirubin (ascertained by scanning spectrophotometry) is stable for a minimum of 72 
hours if sufficiently light protected and the results of the sample stability study carried 
Princess of Wales Hospital, 
Bridgend (26 miles) 
Morriston 
Hospital, Swansea 
Prince Philip Hospital, 
Llanelli (11 miles) 
West Wales General Hospital, 
Carmarthen (27 miles) 
Bronglais Hospital, 
Aberystwyth (76 miles) 
Withybush Hospital, 
Haverfordwest (55 miles) 
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out in this research indicate that no detrimental effect would occur for ferritin over a 
period of four days (see Figure 3.9).  
 
4.3.5. Sample turn around times 
 Due to the acute nature of SAH any requested analyses should, under ideal 
conditions, be ‘turned around’ within the shortest time frame possible.  If we examine 
the individual tests and estimate a turn around time from receipt into the laboratory to 
reporting of results (Table 4.3) it is clear that this would vary considerably. 
These estimated turnaround times demonstrate that under ideal circumstances 
all the methods of analysis under investigation could provide results within 40 
minutes or less.  It is only when potential hindrances to reporting of results are taken 
into account that there is any real discernable difference, CSF diazo bilirubin and CSF 
ferritin being the quickest, followed by visual inspection and lastly scanning 
spectrophotometry.  The turnaround times for CSF ferritin and scanning 
spectrophotometry would vary the most as ferritin is likely to be available on a 
separate analyser platform to standard CSF tests (protein and glucose) and scanning 
spectrophotometry would be dependent upon the local service provided. 
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Table 4.3: Estimated turnaround time (TAT) for: visual inspection, scanning 
spectrophotometery (2003 and 2008 Guidelines), CSF ferritin and CSF diazo 
bilirubin.  Based upon known preparation times, method dependent analysis times 
and estimated reporting time. 
 
Method Preparation time 
(min) 
Analysis 
time 
(min) 
Additional 
time  
Reporting 
time 
Total TAT  
 
Visual inspection 6  
(centrifugation) 
1 
 
20–40 min 
(protein & 
glucose 
analysis) 
3 min 
(manually 
entering 
results) 
27–47 min 
Scanning 
spectrophotometry 
(2003/2008) 
20 
(centrifugation and 
spectrophotometer 
warm up) 
10 20 min if re-
run CSF 
protein 
10 min 
30 min to 
113* hours 
(dependant 
upon level 
of service 
provided) 
113 hours for 
trained 
operator 
CSF ferritin 6 
(centrifugation) 
20-40  
N.B. 
Method 
dependent 
 
No additional 
time if assay 
on same 
platform and 
QC already 
performed 
Automated, 
potentially 
4-5 min for 
technical 
and clinical 
validation 
26 min to  
>2 hours 
Two hours (or 
more) if assay 
on separate 
platform 
which requires 
QC 
CSF diazo 
bilirubin 
6 
(centrifugation) 
20 
N.B. 
Method 
dependent 
No additional 
time if QC 
already 
performed 
26–46 min 
20 minutes if 
QC not 
already 
performed 
* Data obtained via departmental audit  
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4.3.6. Cost:benefit analysis 
 If the costs of individual tests are scrutinised, it is clear from the figures 
presented in Table 4.4 that visual inspection alone is the most economical option 
followed by CSF diazo bilirubin and CSF ferritin which have comparable costs.  
Scanning spectrophometry is the most expensive test by a factor of sixteen compared 
to its nearest contender (CSF ferritin), and the major contributor is staffing costs 
which make up over 90% of the total, this reflects the specialist training and skills 
required to analyse and interpret these requests. 
 To fully examine the benefit of these individual tests the average analysis time 
needs to be explored in relationship to occupied bed days, potential bed blocking and 
the cost of occupying a bed (Table 4.5).  The figures used in Table 4.5 are based upon 
the number of subjects recruited into this research and the average turn-around time 
for individual tests; estimated (visual inspection, CSF diazo bilirubin and CSF 
ferritin) and those established during audit (scanning spectrophotometry).  Cost is 
based upon figures quoted by ABMU Health Board’s finance department for an acute 
bed at approximately £150 per day.  These figures reveal that there would be little 
impact with regard to potential occupied bed days for visual inspection, CSF diazo 
bilirubin and CSF ferritin with total bed days for analysis of all samples within this 
research ranging from 2–3.3 days at a cost of £300 - £495.  It is a very different 
picture when the figures for scanning spectrophotometry are examined where almost 
90 bed days are potentially taken up in analysis time and at a significantly higher cost 
of over £13,000. 
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Table 4.4: Cost analysis for the individual tests investigated in this research; 
including reagent, consumables, staff costs and the total cost for the 80 requests 
recruited into this research 
 
Test Reagent cost 
(£) 
Staff cost  
(£) 
Cost per test 
(£) 
Total cost 
for 80 
requests   
(£) 
Visual inspection 0 0.36 0.36 28.80 
CSF diazo bilirubin 0.32 0.36 0.68 54.40 
CSF ferritin 0.36 0.36 0.72 57.60 
Scanning 
spectrophotometry 
1.06 10.70 11.75 940.00 
 
 
Table 4.5: Potential occupied ‘bed days’ due to analysis time for individual tests, 
based upon the 80 requests received during this research and the average turn 
around time (TAT) for individual tests; estimated (visual inspection, CSF diazo 
bilirubin and CSF ferritin) and those established during audit (scanning 
spectrophotometry).Cost is based upon an acute bed costing approximated at £150 
per day. 
 
Test Average 
TAT per 
test (h) 
TAT for 
80 tests 
(h) 
Bed days Cost (£) 
Visual inspection 0.6 48 2 300 
CSF diazo bilirubin       
(≥ 300 nmol/l) 
0.6 48 2 300 
CSF ferritin         (> 
12 ng/ml) 
1 80 3.3 495 
Scanning 
spectrophotometry 
26 2080 86.7 13,005 
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4.4. Discussion 
 The sensitivity and specificity of the analytes (excluding visual inspection) 
compared in this research are comparable; all had sensitivities ranging from 80 – 
100%, with specificity ranging from 81-86%.  Visual inspection was excluded due to 
its poor sensitivity of only 40%.  Therefore all of the analytes (apart from visual 
inspection) are suitable for determining the occurrence of SAH with respect to 
sensitivity and specificity. 
 With ‘grey areas’, or reporting of inconclusive results, the UKNEQAS 
Guidelines 2008 have the best performance with only 9.9% of requests reported as 
‘inconclusive’ with the other analytes ranging from 17.2–21.1%.  If a verification 
stage is added for CSF diazo bilirubin and CSF ferritin using the UKNEQAS 
Guidelines 2008, then requests reported as ‘inconclusive’ for CSF ferritin are only 
2.6% and for CSF diazo bilirubin only 3.9%.  If the extra verification step were to be 
included as part of the analysis pathway then CSF ferritin would provide the best 
performance in determining the occurrence of SAH, with respect to ‘grey’ areas. 
 Oxyhaemoglobin interference can have a considerable impact on the ability of 
the different investigations to produce a result and due to the traumatic nature of CSF 
sampling is a very real possibility in any CSF sample received in the laboratory.  CSF 
ferritin has the least interference from oxyhaemoglobin with only 1.3% of requests 
reported as inconclusive due to oxyhaemoglobin interference alone and CSF diazo 
bilirubin comes a close second with 2.5% of requests reported as inconclusive due to 
oxyhaemoglobin interference alone.  With the UKNEQAS Guidelines however there 
is a much larger impact; 2003: 12.5% and 2008: 8.8%.  This would therefore make 
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CSF ferritin the most suitable analyte for SAH determination if oxyhaemoglobin 
interference was the most important consideration. 
 There is no discernable difference between the analytes when it comes to 
storage stability if samples are stored under appropriate conditions (i.e. light 
protection and separated from cells). 
 The current laboratory service provides CSF analysis for the detection of sub-
arachnoid haemorrhage over a large geographical area (Figure 4.1) and therefore 
sample turnaround times are an important factor in determining which is the most 
suitable analyte.  If we examine the estimated turn around times of the analytes (Table 
4.3) it is clear that all analytes, apart from scanning spectrophotometry, could be 
provided on site at individual laboratories within 30 min to 2 hours.  With scanning 
spectrophotometry this can take, on average, 26 hours with some samples taking up to 
six days. 
 The cost benefits of the individual analytes is variable with visual inspection 
being the cheapest at £0.36 per test, and having the least impact on potential occupied 
bed days i.e. only two days for all subjects included in this research and only £300 for 
the bed.  CSF diazo bilirubin came a close second costing only £0.68 per test and only 
resulted in, potentially, two occupied bed days for all the subjects included in this 
research at a cost of £300.  Scanning spectrophotometry (UKNEQAS 2003 and 2008) 
had the biggest impact, costing £11.75 per test and potentially 86.7 occupied bed days 
for all subjects included in this research at a cost of £13,005.  If we examine the cost 
further, combining the cost of the tests and the cost of the potential occupied bed 
days, then remaining with scanning spectrophotometry alone would cost almost 
£14,000 for the subjects recruited into this research.  If CSF ferritin or CSF diazo 
bilirubin where to be adopted as a screening method with scanning spectrophotometry 
  
 
103 
as final step then this could potentially reduce the cost by almost £10,000 for the 
subjects recruited into this research. 
 
4.5. Conclusion 
Thus far the performance of individual analytes for each comparison criteria 
has been examined in isolation.  In order to determine which analyte would be the 
most suitable overall then the top performing analyte for each comparison criteria 
needs to be considered (Table 4.6).  
It is clear from the figures presented in Table 4.6 that CSF diazo bilirubin 
would be the analyte of choice as it is either the top or second performer for each 
comparison criteria. 
 
Table 4.6: Top performing and second place analytes for individual comparison 
criteria considered in this research 
 
Comparison criteria Top performing 
analyte 
Second 
Sensitivity and specificity CSF diazo bilirubin UKNEQAS 2008 
Grey areas and 
verification 
CSF ferritin CSF diazo bilirubin 
Oxyhaemoglobin 
interference 
CSF ferritin CSF diazo bilirubin 
Analyte stability No clear winner 
Turn around time CSF diazo bilirubin Visual inspection 
Cost Visual inspection CSF diazo bilirubin 
Occupied bed days Visual inspection and CSF diazo bilirubin; joint winners 
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 If CSF diazo bilirubin were to be introduced in laboratories as a viable 
alternative, or supplement, to scanning spectrophotometry then a robust set of 
guidelines needs to be available.  The ensuing chapter develops these guidelines for 
the laboratory diagnosis of SAH utilising CSF diazo bilirubin analysis (Objective 1.4 
of this research).  Ensuring that they are accessible to all laboratories; timely, feasible 
and employ, where possible, commonly used laboratory equipment. 
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Chapter 5 
Alternative guidelines for the determination 
of sub-arachnoid haemorrhage utilising 
CSF 
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5.1. Introduction 
The fundamental objective of this research was to produce guidelines which 
are accessible for all clinical biochemistry laboratories to use as an alternative, or 
supplement, to those currently recommended by UKNEQAS (Cruickshank et al., 
2008, p. 238).  The aim was that they should be more user friendly for both the 
service providers and the requesting clinicians. 
In order for these guidelines to be more user friendly, laboratories’ current 
service provision needed to be taken into consideration.  There exists a wide variety in 
service provision, with some laboratories not offering on-site scanning 
spectrophotometry for xanthochromia determination.  These laboratories still rely on 
visual inspection alone or refer requests to other laboratories.  Although this does 
provide almost instantaneous results it has already been proven that this is an 
inadequate indicator for the presence of xanthochromia (Bradley et al., 2003, p. 74).  
Those laboratories that do provide a scanning spectrophotometry service may or may 
not do so 24 hours a day or may even post samples to a referral laboratory, therefore 
introducing a significant time delay for results. 
Another important consideration is the availability of equipment.  All clinical 
biochemistry laboratories will have an analyser platform upon which serum bilirubin 
can be measured, but methods employed will differ from site to site, as will required 
sample volumes and the ability to modify methods to suit individual requirements. 
Laboratories must also determine the number of xanthochromia requests that 
are dealt with annually.  The UNKEQAS guidelines recommend that a minimum of 
25 samples be analysed annually (Cruickshank et al., 2008, p. 242) in order to build 
up and maintain sufficient proficiency, this principle should also be applied to the new 
guidelines.  The minimum number of samples to be analysed annually must be 
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considered with regard to the ‘two-step’ process of the new guidelines i.e. the first 
consideration should be are there sufficient requests to warrant running a CSF diazo 
bilirubin assay service and are there enough resultant spectrophotometery requests to 
warrant this separate service?  Some smaller laboratories may well find that they 
receive enough requests to justify having a CSF diazo bilirubin service but need to 
refer any spectrophotometry requests to another laboratory.  
The laboratories within ABMU health board received a total of 533 
xanthochromia requests between April 2012 and March 2013 which would mean 
around 44 CSF diazo bilirubin tests per month and 107 referrals for scanning 
spectrophotometry per year (based on approximated 20% of samples being referred 
for further testing).  This level of requests provides sufficient number to warrant the 
CSF diazo bilirubin method and to maintain analysts skill levels with the UKNEQAS 
guidelines (Cruickshank et al., 2008, p. 242). 
All of these factors need to be considered to ensure that the proposed 
guidelines are accessible to as many laboratories as is practical. 
 
5.2. Proposed guidelines 
 As has already been discussed in Chapter 4, an integral part of the proposed 
guidelines will be the 2008 revised UKNEQAS Guidelines (Cruickshank et al., 2008, 
p. 238) and how the analysis of CSF diazo bilirubin can complement these.  The 
following section provides details of the proposed modified guidelines.   
Sample requirements and transport: 
i. CSF samples should ALWAYS be analysed if sufficient sample is received. 
ii. The specimen for spectrophotometry should be the least blood-stained fraction 
of CSF to be taken (usually the last and ideally the fourth). 
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iii. The volume requested must be that which enables the analysis to be 
undertaken without dilution, and will be determined by local requirements. 
iv. Both the specimen for scanning spectrophotometry and the specimen for 
protein analysis should be protected from light. 
v. Use of pneumatic tube systems to transport the specimen to the laboratory is 
best avoided, but the overriding consideration is rapid transport of the sample 
to the laboratory. 
vi. A simultaneous blood specimen should be taken for serum bilirubin and total 
protein measurement. 
vii. The timing of sampling relative to that of possible haemorrhage should be 
recorded.  This should be no less than 12 hours post event. 
 
It is clear that these points are almost identical to those required in the UKNEQAS 
Guidelines (Cruickshank et al., 2008, p. 239) except for one minor addition in point 
iv, which states that ‘the sample for protein analysis should also be protected from 
light’.  This is to ensure that CSF diazo bilirubin can be measured accurately whilst 
still preserving the integrity of the sample which may be destined for scanning 
spectrophotometry. 
 
Specimen handling: 
Both the specimen designated for scanning spectrophotometry and the sample 
designated for CSF protein analysis should be centrifuged at > 2000 rpm for five 
minutes as soon as possible after receipt in the laboratory and within one hour of 
collection.  The supernatant from the specimen designated for scanning 
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spectrophotometry should be aliquoted into a secondary container, protected from 
light and stored at 4°C along with the specimen designated for CSF protein analysis. 
Analysis: 
Stage 1: CSF protein analysis sample 
 Analyse for CSF diazo bilirubin, CSF protein and any other requested tests 
using available methods and analyser platforms. 
 If CSF diazo bilirubin is < 300 nmol/l, go straight to reporting and 
interpretation. 
 If CSF diazo bilirubin  is ≥ 300 nmol/l go to analysis stage 2. 
Stage 2: Scanning spectrophotometry 
 Follow UKNEQAS Guidelines (Cruickshank et al., 2008, p. 239) for CSF 
scanning spectrophotometry. 
Reporting and Interpretation: 
CSF diazo bilirubin interpretation comments: 
 < 300 nmol/l 
‘CSF bilirubin not increased.  No evidence to support SAH.’ 
 ≥ 300 nmol/l 
‘CSF bilirubin is present in sufficient concentration that SAH can not be 
excluded.  Sample referred for further analysis.’ 
Note: these results and accompanying interpretative comments could be available 
within an hour of receipt, and for samples referred for scanning 
spectrophotometry could be issued as an interim report. 
CSF scanning spectrophotometry comments: 
 Follow UKNEQAS guidelines (Cruickshank et al., 2008, p. 239) 
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N.B. See Appendix 9 for an interpretation flowchart (combining the proposed 
guidelines with those recommended by UKNEQAS). 
 
5.3. Method of dissemination 
Dissemination has been defined as ‘a planned process that involves consideration 
of target audiences and the settings in which research findings are to be received’ 
(Wilson et al., 2010, p.92) and is based upon persuasive communication which covers 
five variables; source of communication, message to be communicated, channels of 
communication, the characteristics of the audience (receiver) and the setting 
(destination) in which the communication is received. 
In this research the source of communication is the researcher and the message to 
be communicated is the new guidelines.  Channels of communication will be broadly 
similar i.e. published articles, electronic communication and scientific meetings but 
due to the information needs (i.e. characteristics) of the two separate audiences 
(laboratory based and clinically based) there will be subtle differences in application.  
The two groups of staff work in dissimilar settings within the healthcare system and 
this will influence the channels of communication which they access. 
Suggested channels of communication for the two audiences are detailed below; 
1. Publishing articles in journals relevant to the laboratory community.  These 
were identified through relevant professional bodies.   
2. Slightly different articles, aimed at requesting clinicians, would be published 
in journals more suited to their profession, which have a wide audience and a 
big impact factor.  These were identified through an internet search for general 
medicine, neurology and emergency medicine journals. 
3. Electronically i.e. the ACB Mailbase and the IBMS discussion forum. 
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4. Scientific meetings; identified through professional bodies. 
The journal articles need to contain enough detailed information so that other 
laboratories can readily duplicate the work, and so that requesting clinicians can 
identify the benefits of one set of guidelines over the other. 
As a prelude to publishing these guidelines a telephone survey of Local Health 
Board laboratory services (formerly NHS Trusts) in South Wales was conducted to 
get an insight into the attitudes of individual laboratories to introducing alternative 
guidelines.  The survey covered such issues as xanthochromia method currently in 
use, and available equipment (see Appendix 10). 
 The laboratories surveyed were distributed across four Local Health Boards 
covering ten individual hospitals with accident and emergency departments (Table 
5.1).  Only hospital sites with accident and emergency departments were contacted as 
this would be the first point of contact for the majority of SAH cases.  The ten 
hospitals contacted covered  a  wide  range  of  services;  from those provided by sites 
with limited accident and emergency services (Caerphilly and District Miners 
Hospital) to those provided at a regional neurology centre (University Hospital of 
Wales). 
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Table 5.1: Hospitals with accident and emergency departments within South Wales 
Local Health Boards contacted for a telephone survey to determine opinion for 
changes to xanthochromia analysis guidelines.  
 
Local Health Board Hospital 
Aneurin Bevan Caerphilly & District Miners (Caerphilly) 
Nevil Hall (Abergavenny) 
Royal Gwent (Newport) 
Cardiff & Vale University University Hospital of Wales (Cardiff) 
Cwm Taf Prince Charles Hospital (Merthyr Tydfil) 
Royal Glamorgan (Llantrisant) 
Hywell Dda Prince Phillip (Llanelli) 
West Wales General (Carmarthen) 
Withybush (Haverfordwest) 
Bronglais (Aberystwyth) 
 
 
 
5.4. Results 
5.4.1 Journal selection 
In order to select appropriate journals for the clinical biochemistry laboratory 
‘community’ the two separate professions need to be considered; biomedical scientists  
and clinical scientists with chemical pathologists.  The two professional bodies 
associated with these professions are the Institute of Biomedical Science and the 
Association of Clinical Biochemistry, both of which have their own respective 
journals.  Also included in the selection of journals for laboratory professionals is 
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‘Clinical Chemistry’ as this is the journal in which the original work on CSF 
xanthochromia (Chalmers & Kiley, 1998, p.1740), which led to the production of the 
original UKNEQAS guidelines (UKNEQAS, 2003, p.481), was published. 
The Biomedical Scientist – is the monthly magazine received by all members 
of the Institute of Biomedical Science (IBMS), and is described on the IBMS website 
(Institute of Biomedical Science, 2010) as ‘the major professional publication for 
news, science, articles and job adverts.’ Articles are featured on a wide range of 
subjects including education, laboratory practice, training and management, reports on 
scientific and technological developments, members' correspondence and Institute 
activities. There are also special articles and expert contributions on laboratory safety 
and management. 
Currently there are 21,786 biomedical scientists registered with the Health 
Professions Council (Health Professions Council, 2010), this being a legal 
requirement for individuals to practice as a biomedical scientist, and membership of 
the IBMS, which is entirely voluntary, is currently almost 17,000.  This means that up 
to 80% of biomedical scientists receive the professional publication ‘The Biomedical 
Scientist’.  This is not a peer reviewed journal, therefore there is no impact factor 
available. 
Annals of Clinical Biochemistry – a bimonthly journal received by all 
members of the Association of Clinical Biochemists, is described on its website as 
‘One of the world's foremost in its field ..... contributes to existing knowledge in all 
fields of clinical biochemistry, especially that pertaining to the understanding, 
diagnosis and treatment of human disease’ (Association of Clinical Biochemists, 
2010).  In 2008 this particular journal had an impact factor of 1.788. 
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 There are currently 4,394 clinical scientists registered with the Health 
Professions Council (Health Professions Council, 2010), but it is impossible to 
ascertain how many of these are clinical biochemists, and this would not provide 
figures for chemical pathologists (Medical staff working within clinical biochemistry 
laboratories). 
Clinical Chemistry – a monthly journal published by the American 
Association for Clinical Chemistry, described on its website (American Association 
for Clinical Chemistry, 2010) as the ‘…leading forum for peer-reviewed, original 
research on innovative practices in today’s clinical laboratory……has the highest 
impact factor among journals of clinical chemistry.’  In 2008 this journal had an 
impact factor of 5.579. 
In order to select appropriate journals to reach all relevant clinicians there 
needs to be a three pronged approach in order that the distinct groups can be targeted; 
General Medicine, Neurology and Accident & Emergency.   
British Medical Journal – The British Medical Journal’s (BMJ) vision is 
described on its website (British Medical Journal, 2010) as ‘The BMJ’s vision is to be 
the world’s most influential and widely read medical journal. Our mission is to lead 
the debate on health and to engage, inform, and stimulate doctors, researchers, and 
other health professionals in ways that will improve outcomes for patients. We aim to 
help doctors to make better decisions.’ It has a weekly print circulation of 122,000, of 
which 10,000 are distributed outside the United Kingdom.  International editions 
reach a further 55,000 readers.  In addition to the print circulation, around 1.5 million 
unique users download somewhere in the region of 6 million pages per month from 
bmj.com.  In 2008 this journal had an impact factor of 12.827.  An article published in 
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this, or a similar journal (e.g. The Lancet) would reach a wide general audience of 
clinicians. 
Journal of Neurology, Neurosurgery & Psychiatry - The Journal of 
Neurology, Neurosurgery, and Psychiatry describes itself on its website (Journal of 
Neurology, Neurosurgery & Psychiatry, 2010) as a journal which ‘publishes original 
articles, short reports, editorials, commentaries and more; covering the whole field of 
clinical neurological practice, neurosurgery & neuropsychiatry. Emphasis is given to 
common disorders such as cerebrovascular disease, multiple sclerosis, Parkinson's 
disease, peripheral neuropathy, epilepsy, and subarachnoid haemorrhage.’  This 
journal has a print circulation of 2,860, 22% of which is to the United Kingdom.  In 
2008 this journal had an impact factor of 4.622.  An article published in this journal 
would reach a wide audience of clinicians in neurology. 
Emergency Medicine Journal – The Emergency Medicine Journal describes 
itself on its website (Emergency Medicine Journal, 2010)  as ‘a leading international 
journal of developments and advances in emergency medicine and critical care. 
Representing all specialties involved in emergency care in the hospital and pre-
hospital environment.’  It has a print circulation of 3410, 84% of which is to the 
United Kingdom.  In 2008 this journal had an impact factor of 1.347. An article 
published in this journal would reach a wide audience of clinicians working in an 
accident and emergency environment. 
 
5.4.2 Electronic dissemination 
The ACB Mailbase is a discussion group at acb-clin-chem-gen@jiscmail.ac.uk 
which has ‘brought together clinical chemists around the world’ (Association of 
Clinical Biochemistry, 2012).  Participants can view mailings via the internet or 
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subscribe to take part and receive e-mails directly.  The IBMS discussion forum is 
available to members within the IBMS members’ forum at 
http://www.ibms.org//forum/?forum=success&rc=0  (Institute of Biomedical Science, 
2012).  Discussions are grouped into different topics and any member can create a 
new discussion thread. 
Both of these discussion groups would provide an invaluable platform to 
promote the proposed new guidelines and provide information to laboratories wishing 
to implement them. 
 
5.4.3 Scientific meetings 
The ACB holds an annual conference ‘Focus’ which consists of a scientific 
programme presenting new and innovative ideas, backed up by an exhibition of all the 
latest technologies.  The IBMS congress has a similar structure but is held biennially.  
Submission for presentation at both of these scientific meetings would be an excellent 
opportunity to raise awareness of the proposed new guidelines within the laboratory 
community. 
The Royal Society of Medicine, one of the largest providers of continuing 
medical education in the UK, holds various conferences throughout the year.  The 
College of Emergency Medicine, which was established to advance education and 
research in Emergency Medicine, holds an annual conference each November.  The 
Association of British Neurologists holds an annual conference each May which 
supports neurologists and neurological trainees in their clinical practice.  Submission 
for presentation at any or all of these conferences would be an ideal method of 
making the clinical community aware of the proposed new guidelines. 
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5.4.4 Telephone survey 
All 10 laboratories contacted were willing to participate in the telephone 
survey.  Staff answering the questions were a mixture of senior biomedical scientists 
(60%) and clinical scientists (40%). 
Question 1. What method if any do you employ for xanthochromia determination in 
CSF? 
 Half of all respondents (n = 5) did not provide an on-site service for the 
determination of xanthochromia in CSF and half used the UKNEQAS Guidelines 
2008 (Cruikshank et al, 2008, p.238). 
Question 2. How is the service provided? 
 Half of all respondents (n = 5) referred xanthochromia requests to another 
laboratory, two provided an on-site service 24 hours a day, one provided an on-site 
service within normal working hours only, and two provided an on-site service during 
normal working hours and could call staff in if required out of hours. 
Question 3. If using UKNEQAS Guidelines, when did you introduce them i.e. were 
you an early adopter? 
 The majority of respondents who provided a xanthochromia service (n = 4), 
reported that they were early adopters.  One respondent had only started providing a 
xanthochromia service within last 12 months, prior to this xanthochromia requests had 
been referred to another laboratory. 
Question 4. If using UKNEQAS Guidelines, do you use any modifications? 
 Of those respondents who provided an on-site xanthochromia service, only 
two had made no modifications to the 2008 guidelines (Cruikshank et al, 2008, 
p.238), one had developed their own algorithm for reporting comments which ‘made 
more sense’, one had simplified the wording of the reporting comments and one did 
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not request a blood sample with every xanthochromia request, only using blood 
results to calculate a corrected NBA if a sample had been taken on the patient within 
the previous 24 hours. 
Question 5. What platform do you currently perform serum bilirubin analysis on? 
 The platforms used by respondents for serum bilirubin analysis can be divided 
into four groups; 
1. Roche Modular P units; three respondents 
2. Vitros (dry chemistry); two respondents 
3. Abbott instrumentation; two Architect and one Aeroset 
4. Olympus: one respondent 
Question 6. Can you create user definable chemistries on this platform?  
All respondents could create a user definable chemistry, eight on their routine 
platform and two who used dry chemistry would need to use their separate wet 
chemistry platform. 
Question 7. Would you consider using a modification to the UKNEQAS Guidelines 
which incorporated an initial ‘rule-out’ step of analysing CSF diazo bilirubin directly 
on the sample provided for protein analysis? 
 Nine respondents in total would consider using a modification to the 
UKNEQAS Guidelines which incorporated an initial ‘rule-out’ step.  The tenth 
respondent received too few requests to warrant this approach. 
 
5.5. Discussion 
In order for the new guidelines to become widely accepted and used they need 
to be disseminated appropriately.  Publishing articles in the Biomedical Scientist and 
the Annals of Clinical Biochemistry should, according to circulation figures and HPC 
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registration figures, reach the widest possible audience of individuals working in 
clinical biochemistry laboratories.  Publishing in Clinical Chemistry will reach the 
original audience from whence this line of research commenced in 1998. 
Inclusion of the proposed new guidelines on the ACB Mailbase and the IBMS 
discussion forum and submission for presentation at the conferences associated with 
these professional bodies would be an ideal opportunity to promote the proposed new 
guidelines to laboratory professionals. 
 Dissemination of information on the new guidelines must go beyond the 
borders of laboratory service providers.  Requesting clinicians need to be provided 
with sufficient and appropriate information in order that they can request the tests 
most appropriate for their patients’ clinical needs.  Publishing in the British Medical 
Journal or The Lancet will reach the widest range of clinicians across all specialties, 
so this will provide good general information.  But in order to reach the intended 
target audience articles should be published in journals aimed at neurologists and 
clinicians working in A&E departments; Journal of Neurology, Neurosurgery & 
Psychiatry and Emergency medicine journal. 
 If the amended guidelines were published in the proposed journals then all 
parties who might have an interest in, or wish to use the amended guidelines, could be 
reached with the potential for them to become widely accepted. 
 It is particularly important to publish the guidelines in journals such as the 
British Medical Journal as not all clinician’s may be aware that there are laboratory 
guidelines.  An article published in 2011 in the British Medical Journal ‘Investigating 
suspected subarachnoid haemorrhage in adults’ (Brown, et al., 2011, p.2645) 
discusses lumbar punctures following a negative CT scan, but fails to mention the 
laboratories involvement or reference the UKNEQAS guidelines. 
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 Presenting the proposed new guidelines at scientific meetings aimed at 
laboratory professionals and clinicians would be an excellent platform for 
dissemination.  It would be prudent to present at scientific meetings aimed at 
laboratory professionals first so that they could field questions from clinicians. 
 Only half of the respondents to the telephone survey provided an on-site 
service for the determination of xanthochromia in CSF.  But all had the equipment in 
place to undertake CSF diazo bilirubin analysis and therefore provide the ‘rule-out’ 
step of the new guidelines. 
 Of those sites using the UKNEQAS Guidelines the majority (80%) had been, 
in their own opinion, early adopters.  Additionally 90% of all of those surveyed 
indicated that they would consider using a modification to the UKNEQAS Guidelines 
which incorporated an initial ‘rule-out’ step.  This suggests that given sufficient 
information regarding the proposed guidelines those laboratories surveyed would be 
willing to adopt them and this is further supported by the fact that only two sites 
surveyed had made no ‘in-house’ modifications to the 2008 guidelines reporting 
structure (Cruikshank et al, 2008, p.238).  These frequent modifications also suggest 
that a better, simpler set of guidelines would be desirable to laboratories. 
 
5.6. Conclusion 
 The evidence gleaned from the telephone survey supports the introduction of 
the proposed new guidelines and suggests that laboratories would be willing to adopt 
them; the next step is to provide a resilient framework which ensures that the service 
is provided to a consistent standard. 
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 The subsequent chapter considers the procedures which need to be put in place 
to ensure that the guidelines are implemented in a robust manner.  This will include 
the standard operating procedure for CSF diazo bilirubin, in-depth training for those 
staff who will undertake analysis of the samples and for those reporting the results 
and the communication that will need to occur to ensure that those working in the 
laboratory and the service users have sufficient information. 
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Implementation of new guidelines 
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6.1. Introduction 
It is important that SAH is detected in all patients in whom it has occurred to 
ensure the best possible outcome for the patient.  There is currently a two stage 
diagnostic pathway for determining SAH which involves neuroimaging (CT scans) 
and laboratory investigation of CSF, both of which have drawbacks.   Modern CT 
imaging of patients fails to detect approximately 2% of those who have suffered SAH 
(Morgenstern et al., 1998, p.303) and the UKNEQAS Guidelines appear to place too 
much emphasis upon the presence of oxyhaemoglobin and could overestimate serum 
bilirubin’s contribution to CSF bilirubin by up to 15%, which could lead to false 
negatives (Chalmers, 2003, p.132). 
The proposed new laboratory guidelines would not only address some of the 
issues related to the presence of oxyhaemoglobin but would additionally improve 
laboratory turnaround times, reduce the number of CSF samples reported as 
inconclusive, accommodate the changing skills mix within pathology and reduce the 
overall cost of providing a service.  In order for the new guidelines to be introduced in 
an efficient manner a number of areas need to be addressed.  These include 
maintenance of the CSF diazo bilirubin assay, training of laboratory staff and 
communication with clinicians. 
Maintenance of the CSF diazo bilirubin assay will be imperative as this assay 
will be used less frequently than routine tests performed in the laboratory, around 44 
tests per month.  Maintenance will include keeping track of reagent ‘on-board’ 
stability and ensuring that calibration and quality control is performed in a consistent 
manner, whatever time of day or night analysis is required. 
In order for the new guidelines to be implemented there will be certain 
elements of training for all individuals involved.  All clinical biochemistry staff 
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undertaking the analysis and reporting of CSF xanthochromia requests will need to 
have appropriate understanding of how results are interpreted, and how the ‘new’ 
service fits in with the UKNEQAS Guidelines.  This will ensure staff are able to deal 
with any queries from requesting clinicians, which will be particularly important 
throughout the initiation phase during which clinicians may not always know exactly 
what they need to request or how to interpret the ‘interim’ reports following a CSF 
diazo bilirubin  of > 300 nmol/l.  This will be achieved through a training package and 
subsequent competency assessment in line with the Knowledge and Skills Framework 
and National Occupational Standards. 
Good communication with clinicians will be of utmost importance regarding 
the ‘new’ guidelines.  Information about the new requesting and reporting procedure 
will need to be conveyed to all concerned well in advance of any changes.  If this is 
also accompanied by an emphasis on the benefits of the new guidelines this will assist 
with a smoother transition.  This information could readily be incorporated into the 
various educational interactions which occur between the laboratory service and 
clinical staff i.e. Grand rounds, medical school lectures and laboratory bulletins. 
 
6.2. Assay maintenance 
It is proposed that the CSF diazo bilirubin assay will be installed on a high 
throughput general chemistry analyser upon which high serum protein and bilirubin 
levels, compared to the CSF samples, will be analysed.  In order to account for this 
individual laboratories will need to undertake carry over studies.  In this research 
using the Roche MODULAR P units the carry over varied between 0.02% and 0.06% 
dependent upon the sample volume required for the prior test.  Based upon a normal 
serum bilirubin of 20 µmol/l, this would represent a CSF diazo bilirubin carry over of 
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between 4 and 12 nmol/l i.e. of no clinical significance.  This is a much different 
picture if the prior sample had a serum bilirubin of 200 µmol/l, which would represent 
a carryover of 40 nmol/l or more i.e. of clinical significance.  If however an alkaline 
wash of the measuring cell to be used is undertaken prior to each CSF diazo bilirubin 
measurement then the carry over is reduced to only 0.001%. 
The CSF diazo bilirubin assay, will in general, be used less frequently than 
other assays on general chemistry analysers.  It is therefore imperative that the 
maintenance of this assay is carefully laid out and strictly adhered to.  For the 
purposes of this discourse the use of Roche reagents and equipment will be covered.  
This could easily be adapted by other users to suit local needs and available 
equipment. 
CSF diazo bilirubin is a user defined assay using Roche liquid stable reagents 
for serum bilirubin estimation; this means that the reagent is not supplied ready to use 
with a specific analyser set up, but that this needs to be determined by the user and 
programmed into the analyser.  The specific details of the reagent and analyser set up 
are laid out in the CSF diazo bilirubin standard operating procedure (Appendix 11).  
The reagents should be replaced regularly e.g. once per fortnight, to ensure that assay 
integrity is not affected by reagent integrity.  This can be assured by setting up a 
routine maintenance schedule within the Roche analyser software.  There should be a 
full 2-point calibration every 24 hours which can be imposed by setting up a time-out 
facility on the analyser which would prevent analysis occurring until the calibration 
has been performed.  Quality control (QC) samples should be run at a minimum of 
every eight hours which can be assured by setting up a time-out facility as part of the 
routine QC procedure within the Roche result handling software which effectively 
prevents any results being released until the QC has been performed.  The assay needs 
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to be enrolled on a suitable external quality assurance scheme e.g. the UKNEQAS 
scheme ‘CSF Haem Pigments’, which is issued bimonthly.  Currently participants in 
this scheme can report CSF diazo bilirubin concentration but there is no external 
quality assurance evidence available on the performance of CSF diazo bilirubin 
assays (Beetham et al., 2011, p. 495). 
This UKNEQAS scheme is for laboratory determination of CSF 
xanthochromia in the determination of SAH and incorporates quantitative 
measurements of CSF bilirubin.  This particular EQA scheme was launched in 2002 
as a pilot, initially it was a challenge to produce samples containing bilirubin and 
oxyhaemoglobin, particularly at low levels, which were stable enough for transport to 
participating laboratories i.e. via post.  As such the first distributions had poor 
reproducibility of added bilirubin.  Subsequently a bilirubin ‘stabiliser’ was added 
which resulted in satisfactory linearity (Patel et al., 2005).  However there are still 
issues regarding sample stability as demonstrated by the April 2011 report which 
stated that one of the EQA samples appeared to have deteriorated during transit. 
There are currently 171 participants in this UKNEQAS scheme.  The returns 
for this scheme do not consistently report how many participants returned CSF diazo 
bilirubin results, with only four laboratories returning quantitative results in April 
2012. 
It should also be recognised that the assay is not CE marked for the analysis of 
CSF and that the analysing laboratory would therefore take on the risks associated 
with this.  It would be preferable for the diagnostic companies to have the assay CE 
marked but as individual laboratories would be analysing relatively small numbers of 
samples it may not be a financially attractive venture. 
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6.3. Training 
 There are different groups of staff who will be involved with the handling and 
subsequent analysis of CSF samples for xanthochromia determination.  These include 
support workers who may receive the sample and carry out pre-analytical preparation 
(i.e. centrifugation); biomedical scientists, who may receive the sample, carry out pre-
analytical preparation, undertake the analysis of the CSF sample and report results.  
There is also a third group, clinical scientists and chemical pathologists, who will 
report results and provide clinical advice.  These three separate groups will need to be 
trained in different areas regarding the new guidelines. 
 Support workers will need to be aware of the changes to pre-analytical 
preparation in that the CSF sample traditionally used only for protein and glucose 
analysis will now also be analysed for CSF diazo bilirubin and therefore requires light 
protected storage post centrifugation if analysis is not to occur immediately.  This will 
be achieved through ‘in-house’ training sessions followed up with e-mail 
communication, laboratory meetings and posters to ensure that all staff have been 
provided with the correct information and explicit instructions as to where CSF 
samples should be stored prior to analysis. 
The biomedical scientists will need a thorough understanding of the ‘new’ 
guidelines and how they fit with the UKNEQAS guidelines.  This will include the 
maintenance of the CSF diazo bilirubin assay, calibration protocols, QC procedures, 
analysis of samples and how to progress samples through the guidelines and the 
reporting process.  This will be achieved via a comprehensive training package, and to 
ensure that staff have understood the training package a competency assessment will 
be required, followed up by regular training updates.  Appendix 12 details the training 
package to be provided and the accompanying competency assessment. 
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The training of clinical scientists and chemical pathologists will be through a 
similar training package and competency assessment to that provided for the 
biomedical scientists although this training will focus more on the reporting process. 
 
6.4. Communication with clinicians 
In order for the new guidelines to be communicated effectively to clinicians an 
appropriately staged programme of information needs to be constructed.  This needs 
to ensure that all of the relevant clinicians are reached and over an appropriate 
timeframe.  The timing of such a programme is critical, as there should only be about 
four weeks between the provision of information and the implementation of the new 
guidelines.  If too much time elapses the information becomes forgotten. 
It is imperative that this information reaches the relevant groups of clinicians 
who will be using the service.  For example, although general practitioners will find 
the new guidelines interesting and information from the laboratory will be welcome 
they are unlikely to use this service directly.  Any information for clinicians should 
initially be aimed at those working in Accident and Emergency departments, 
Neurology departments, Intensive Care units and Medical Admissions units.  Once 
this has been achieved it can then be conveyed to the wider clinical community.   
Information for clinicians would initially be conveyed via personal 
communication from the laboratory to individual consultants in order that they can 
cascade the information to their teams.  This would primarily be aimed at those 
consultants most likely to be involved with the diagnosis of SAH (e.g. those working 
in A&E departments, Neurology departments, Intensive Care units and Medical 
Admissions units) and then expanded out to the wider clinical community.  Specific 
‘Grand round’ presentations at all hospital sites would provide further information 
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and the opportunity for individual clinicians to ask specific questions about the 
change in service.  Additional ‘vehicles’ for the distribution of information would be 
the pathology information portal (accessible to all health board staff via the intranet) 
and information leaflets which could be made available in all clinical areas.  
Additionally, during the changeover period all CSF collection packs provided by the 
Hospital Sterilisation and Disinfection Unit would contain information regarding the 
changes. 
 
6.5. Conclusion 
In order to achieve a full and comprehensive implementation programme the 
elements discussed in this chapter must be brought together around a central 
implementation date.  This would be assured through comprehensive training of all 
grades of clinical biochemistry staff and sufficient information for requesting 
clinicians, supported by a regimented assay maintenance programme.  This would 
result in a smooth transition from the current guidelines to the new guidelines. 
Additionally the information provided to clinicians would tackle the lack of 
understanding regarding the use of CSF samples in the diagnosis of SAH identified by 
the questionnaire issued regarding UKNEQAS guidelines.  The new guidelines would 
also improve access to the service due to the availability of round the clock analysis 
compared to the current ‘office-hours’ service still operating in some areas. 
Chapter seven, which follows, provides an overall conclusion to this research 
and presents recommendations, including future work. 
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conclusion 
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7.1. Introduction 
This research has explored the clinical biochemistry laboratory determination of 
SAH using CSF samples.  It has investigated current service provision and the perception 
of this service by users.  It has then explored alternative methods for laboratory 
determination of SAH using pre-determined criteria. 
This chapter summarises the findings of the research, initially in relation to the 
research objectives put in place at the outset, and then outlines the recommendations that 
have emerged as a consequence.  Suggestions for future research in the field will also be 
considered. 
 
Research Objectives 
The research was guided by the objectives below and the following conclusions drawn: 
 
1. To examine processes and identify problems with the current laboratory 
service for detection of SAH, through surveying requesting clinicians and 
examining the current UKNEQAS National Guidelines. 
 The findings of the questionnaire made it clear that general awareness of the 
UKNEQAS guidelines with clinicians was not as extensive as it needed to be and that 
this would need to be addressed in order to ensure that users access the service 
correctly e.g. correct timing of lumbar punctures.  The UKNEQAS guidelines discuss 
the hours of service that should be available i.e. that it should be determined by: 
 Local need 
 Tertiary centre’s referral policy 
 Access to beds 
 Availability of angiography 
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The results of the questionnaire suggested that the service provided at the time 
of the survey (Monday – Friday 9am-5pm) did not meet local need.  An alternative or 
supplement to scanning spectrophotometry could address this. 
 
2. To develop an alternative laboratory test(s), which could be used to identify 
patients who have suffered an SAH, utilising cerebrospinal fluid and/or serum 
samples. 
In order to identify potential alternative laboratory tests the nature of SAH was 
considered i.e. blood is released into the subarachnoid space and the brain is damaged.  
Therefore laboratory analysis needed to focus on detecting the presence of blood 
and/or its breakdown products, any change in CSF constituents that arises as a direct 
consequence of blood being introduced in to the subarachnoid space or a specific 
analyte which would only be present if brain damage occurred. 
Through exploration of the nature of SAH three potential alternatives to the 
UKNEQAS Guidelines were identified: CSF ferritin, CSF diazo bilirubin and protein 
S100 in CSF and serum.  All three alternatives were compared with the current 
practices of visual inspection and scanning spectrophotometry. 
Visual inspection had a poor sensitivity (40%) for assessing the presence of 
xanthochromia in CSF which appeared in part to be due to the detection limits of the 
human eye (Bradley et al., 2003, p.73; Marden et al., 2001, p.53).  
The sensitivity (100%) and specificity (81%) achieved with scanning 
spectrophotometry compared well with the findings of other research (Perry et al., 
2006, p.2470).  However it is clear from the literature that there is more than one 
definition of ‘xanthochromia’ (Foot & Staib, 2001, p.328; Wood et al, 2005, p.143), 
and that this confusion over terms has led to a number of studies dismissing 
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spectrophotometric determination of xanthochromia as a useful tool in determining 
the occurrence of SAH on the basis of its poor sensitivity and specificity, when they 
were actually looking at the wrong CSF pigments. 
CSF diazo bilirubin achieved a sensitivity of 100% and specificity of 86% at a 
cut-off of 300 nmol/l which compares well to the findings of other research (Chao et 
al., 2007, p.142) using a similar cut-off. 
 At a cut-off of 12 ng/ml, CSF ferritin achieved a sensitivity of 80% and a 
specificity of 86% in determining the occurrence of SAH.  Although this is backed up 
by the work of others they could not recommend using CSF ferritin for the exclusion 
of SAH (Watson et al., 2008, p.192) due to uncertainty over the reliability of 
appearance of ferritin in the CSF following an SAH. 
 It was clear from the poor sensitivity and specificity (Table 3.7) of protein 
S100 achieved in CSF at various cut-off points and the overlap of results with the 
control and subject groups for serum that it was an unsuitable alternative or adjunct to 
the UKNEQAS Guidelines in determining the occurrence of SAH.  
 The UKNEQAS Guidelines (2003, p.487) indicate that oxyhaemoglobin 
causes an underestimation of NBA.  An alternative to the UKNEQAS Guidelines 
would therefore be invaluable, particularly if the alternative suffered less from 
interference from oxyhaemoglobin.  In this research both CSF diazo bilirubin and 
CSF ferritin suffered from little interference from oxyhaemoglobin at levels seen in 
over 90% of samples received in the laboratory.  
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3. To compare the alternative laboratory test(s) with existing laboratory practice 
i.e. the UKNEQAS National Guidelines. 
 If sensitivity and specificity are considered in isolation then all the alternative 
laboratory tests (excluding visual inspection) are suitable for determining the 
occurrence of SAH (sensitivities ranged from 80 - 100% with specificity ranging from 
81-86%).  For the reporting of inconclusive results, the UKNEQAS Guidelines 2008 
has the best performance (9.9% of requests reported as inconclusive) although with a 
verification step added CSF ferritin has the best performance with only 2.6% of 
requests reported as inconclusive.  CSF ferritin was found to have the least 
interference from oxyhaemoglobin with only 1.3% of requests reported as 
inconclusive due to oxyhaemoglobin interference alone, making CSF ferritin the most 
suitable analyte for SAH determination if oxyhaemoglobin interference was the most 
important consideration.   
There was found to be no discernable difference between the analytes when 
considering storage stability, if samples are stored under appropriate conditions (i.e. 
light protection and separated from cells).  Estimated turnaround times of the analytes 
(Table 4.3) indicate that, apart from scanning spectrophotometry, all analytes could be 
provided on site at individual laboratories within 30 min to 2 h.  If the cost benefits of 
the individual analytes were the most important factor then visual inspection would be 
the cheapest, £0.36 per test, and have the least impact on potential occupied bed days. 
If the top performing analyte for each comparison criteria is examined (Table 
4.6) then CSF diazo bilirubin is the analyte of choice as it is either the top or second 
performer for each comparison criteria i.e. reduced turnaround times and reduced 
‘inconclusive’ results. 
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4. To present an alternative or supplement to the current UKNEQAS National 
Guidelines for the laboratory diagnosis of SAH which is accessible to all 
laboratories: timely, feasible and employs commonly used equipment. 
In order for the new guidelines to become widely accepted and used then they 
need to be disseminated appropriately.  In order to reach the widest possible audience 
of individuals working in clinical biochemistry laboratories the guidelines should be 
presented in journals which have a wide circulation in this field.  From the figures 
obtained as part of this research this would indicate that the Biomedical Scientist, 
Annals of Clinical Biochemistry and Clinical Chemistry would be the most 
appropriate.  
Additionally the inclusion of the proposed new guidelines on the ACB 
Mailbase and the IBMS discussion forum and submission for presentation at the 
conferences associated with these professional bodies would be an ideal opportunity 
to promote the proposed new guidelines to laboratory professionals. 
 Requesting clinicians also need to be provided with sufficient and appropriate 
information about the new guidelines in order that they can become widely accepted.  
This could be achieved by publishing in journals such as The British Medical Journal 
and The Lancet.  A more targeted approach could be achieved through publishing 
articles in journals aimed at neurologists and clinicians working in A&E departments 
(the intended target audience) e.g. Journal of Neurology, Neurosurgery & Psychiatry 
and the Emergency medicine journal.  Additionally submission for presentation at the 
conferences associated with these areas of medicine would be an ideal opportunity to 
promote the proposed new guidelines to the medical community. 
 The telephone survey of laboratories in South Wales provided evidence which 
supports the introduction of the proposed new guidelines, not least the frequency with 
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which laboratories modify the reporting structure of the current guidelines, and more 
importantly would suggest that laboratories would be willing to adopt them. 
 
7.2 Limitations of the research approach 
One limitation of this research was that only opinion from clinicians working 
in Wales was included in the clinicians’ questionnaire on service provision.  It was 
originally envisaged that opinion would be gathered from clinicians in Salisbury as 
well, for comparison.  Unfortunately the results from the Salisbury questionnaires 
were lost in the post, although this may well have made little difference, as medical 
training across the United Kingdom is the same and SAH management guidelines are 
the same.   
Another limitation regarding the relatively small survey was that although it 
gathered some significant and interesting data it would have better served the role of a 
pilot study.  The information gathered from this ‘initial’ questionnaire could then have 
been used to produce a more detailed questionnaire with a robust method of 
distribution to the target audience.  This would have produced results of greater 
impact to this research.  
A further limitation was the number of subjects and controls included.  It was 
originally estimated that one hundred patients with suspected SAH and one hundred 
controls would be included in this research. The estimate for the patients suspected of 
having an SAH was almost reached (81%), but the number of controls included was 
disappointingly low (30%).  This appears to have occurred due to the reduced sample 
volumes received for oligoclonal band requests as compared to xanthochromia 
requests.  As CSF sample volumes are not routinely recorded it was not identified as a 
potential restriction upon sample collection for this research.  If the numbers of 
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subjects and controls included in this research had been higher this would have 
provided results with greater statistical significance. 
 
7.3 Recommendations 
 This research has provided an opportunity to examine the current laboratory 
service provision for the analysis of CSF in relation to the determination of SAH and 
the impact a ‘rule-out’ step could have on this service.  As a result of this research a 
number of areas in which there is cause for concern and possible changes that may be 
required have been identified and are summarised below. 
1. Issues with current UKNEQAS guidelines; 
The introduction of the UKNEQAS Guidelines has removed 
the inaccuracies of visual examination in that the human eye cannot 
differentiate between a xanthochromia negative CSF sample and a 
‘borderline’ positive sample (Bradley et al., 2003, p.74).  It has also 
consolidated the variety of different methods of spectrophotometry that 
were being employed by a number of laboratories. 
Scanning spectrophotometry is still not the answer; it is still 
subjective and has a possibility of inter-operator variability; dependent 
upon which system is used within the laboratory the baseline is 
positioned manually following spectrophotometric scanning of the 
CSF sample (Figure 1.2).  This could have a major impact when 
dealing with borderline samples in that there is a very real potential for 
the laboratory to report both false positives and false negatives.  There 
are systems available now which will position the baseline and suggest 
the appropriate interpretative comment automatically, but these are 
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more expensive and are not CE marked.  There is also concern that 
when employing the UKNEQAS Guidelines, too much emphasis is 
placed upon the presence of oxyhaemoglobin and its possible 
interference and that the calculation (Equation 1.1) used to estimate 
serum bilirubin’s contribution to CSF bilirubin overestimates by up to 
15%, this could lead to false negatives (Chalmers, 2003, p.132).  There 
are also issues relating to high CSF proteins which result in the 
interpretive comment ‘interpret with caution’ being issued.  These high 
CSF proteins are seen in cases of meningitis and as the clinical signs of 
SAH and meningitis are not dissimilar there is a very real possibility of 
xanthochromia requests being undertaken on patients with meningitis 
and the results clouding the diagnostic process. 
 
2. Issues with perception of current service; 
 The two main concerns raised through individual comments 
received as part of the clinicians’ questionnaire were the lack of an out 
of hours service, therefore increasing turnaround time, and the general 
feeling that reporting a sample as ‘equivocal’ was not good enough 
especially if this would mean putting a patient at risk while under 
going angiography. 
Information provided to clinicians as part of the roll out of new 
guidelines would tackle the lack of understanding regarding the use of 
CSF samples in the diagnosis of SAH identified by the clinicians’ 
questionnaire.   
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3. Suggested changes to guidelines; 
 If CSF diazo bilirubin were to be introduced in laboratories as a 
viable supplement to scanning spectrophotometry then a robust set of 
guidelines need to be available.  These guidelines for the laboratory 
diagnosis of SAH utilising CSF diazo bilirubin analysis need to ensure 
that they are accessible to all laboratories, timely, feasible and employ, 
where possible, commonly used laboratory equipment. 
4. Implementation of new guidelines; 
Implementation of the new guidelines would be assured 
through comprehensive training of all grades of clinical biochemistry 
staff and sufficient information for requesting clinicians, supported by 
a regimented assay maintenance programme.  This would achieve a 
smooth transition from the current guidelines to the new guidelines. 
The new guidelines would also improve access to the service 
due to the availability of round the clock analysis compared to the 
current ‘office-hours’ service. 
 
7.4 Impact on the profession 
 If these Guidelines were to be adopted then there would be a big impact on 
laboratories nationwide in terms of training and the skill level of staff required to 
undertake different stages of the analysis process.  In order to afford the Guidelines 
appropriate nationwide promotion pilot sites could be selected to run with the new 
Guidelines for a minimum of six months before roll out across the UK.  An audit of 
these pilot sites and the impact of the new guidelines could then be presented at the 
ACB annual national meeting ‘Focus’ and the IBMS biennial conference. 
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7.5 Future research 
 Areas for potential further investigation, which would build on the work 
already undertaken in this research are summarised below; 
1. UK wide survey of clinicians; this would provide invaluable information of 
the expectations of clinicians with respect to the provision of diagnostic 
services for the determination of SAH. Any future survey should place greater 
emphasis on clinical practice, examples of questions which could be used can 
be found in appendix 13, 
2. Closer examination of the comparability of the total absorbance at 476nm, the 
NBA and the CSF diazo bilirubin. 
3. UK wide survey of current laboratory service provision and their willingness 
to adopt the amended guidelines, 
4. Formal audit of service provision once the amended guidelines have been in 
place for twelve months, including patient outcomes and bed blocking, and 
therefore more accurate cost:benefit analysis and comparison pre and post 
amended guidelines, 
5. Continue to look for other alternatives which may provide a less subjective 
method of SAH determination. 
 
7.6 Conclusion 
 SAH is an emergency situation in the A&E department and a diagnosis needs 
to be made rapidly.  SAH diagnosis is notoriously difficult (Chapter 1.1.4) and the 
clinical biochemistry service has a significant role to play.  This research sought to 
examine current practices and attempt to identify areas for improvement of the service 
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provided.  In order to do this the current service was examined and alternative 
approaches to analysis investigated.  The current laboratory service was perceived by 
users to be taking too long and an alternative to the current service was deemed to be 
a modification to the UKNEQAS Guidelines which incorporated an extra step of CSF 
diazo bilirubin analysis. 
 The original lead author of the UKNEQAS Guidelines, Dr Robert Beetham 
(retired), was contacted for his opinion on this research, which combined with an 
editorial regarding the direct analysis of CSF diazo bilirubin (Beetham, 2007, p. 99) 
gives rise to three points; 
1. The proposed new guidelines would not pick up those CSFs that have a high 
NOA  (> 0.1 AU) but apparently normal NBA. 
2. An NBA of 0.007 AU should not be equivalent to a CSF diazo bilirubin of 300 
nmol/l but more like 180 nmol/l. 
3. The system should be really well controlled ensuring stability of calibrants. 
In answer to these points; 
1. If the NOA is > 0.1 AU and the NBA is ‘normal’ this would lead to the 
conclusion that the CSF diazo bilirubin is < 300 nmol/l and under the 
proposed new guidelines the result would go out as ‘no evidence to support 
SAH’ rather than under the current UKNEQAS Guidelines ‘Inconclusive 
(NOA may mask low NBA)’.  Only four of the subjects studied in this 
research, were reported as inconclusive under the current guidelines due to an 
NOA > 0.1 AU, all of these had a CSF diazo bilirubin of < 300 nmol/l and 
none had experienced an SAH.  Although these are small numbers and would 
need further study they do support the proposed new guidelines. 
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2. The discrepancy raised in point 2 was investigated by looking at the limits of 
detection of the assay.  There is around 130nmol/l to be reconciled for the 
difference between the cut-off employed in this research (300nmol/l) and the 
calculated CSF bilirubin from the UKNEQAS guidelines cut-off (167nmol/l - 
based upon 0.007 AU and using the extinction coefficient of bilirubin at 
476nm).  The difference between the limits of detection of the assay using 
saline (60nmol/l) and  using bilirubin free CSF (158nmol/l) would indicate 
that this issue may be matrix related and that the CSF samples contain an 
unspecified analyte which interferes with the bilirubin assay. 
3. The rigorous ‘house-keeping’ of the assay, detailed in assay maintenance 
(Chapter 6, section 2), will satisfy this point. 
 This research has satisfied all of the aims and objectives set out in chapter one 
and has, additionally, set out the means by which the new guidelines would be 
implemented.  All that remains with regard to these new guidelines is to undertake a 
formal audit once they have been in use for twelve months in order to ascertain how 
the changes have affected service users i.e. clinicians and patients and the overall 
cost:benefit outcome. 
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Chapter 8 
Reflections 
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8.1. Introduction; a brief history of my career 
 
 
What follows is a critical review of my learning prior to starting the Doctorate 
in Biomedical Science (DBMS), including my formal education, training and 
development as a biomedical scientist. 
 
Education and Training 
On the job training; 
I entered the biomedical science profession in September 1992 when I gained 
a trainees post at Southport and Formby District General Hospital.  My training was 
multi-disciplinary across biochemistry, haematology and transfusion (I finally 
specialised in biochemistry).   
My training started in the haematology department, my first day was a real 
shock to the system, loads of words I did not understand (technical jargon) and by the 
end of the day my brain had shut down due to information overload.   
I spent six months in haematology learning all the basics, how to operate the 
full blood count analyser, making blood films and performing coagulation assays.  
These all came with their challenges.  I started with the full blood count analyser 
learning all about quality control, how important it was and how to remedy faults.  
Running the machine was a challenge; it was very easy to get tied up in knots if you 
did not concentrate.  Making blood films was an art in itself but luckily I was a 
natural.  Coagulation was all about timing, to start off with I would only have one test 
set up at a time but as I gained confidence I would have whole rows of them on the 
go.  This was great until there was a patient with a long clotting time which then 
meant starting all the others again. 
  145 
Six months in haematology was followed by a six month rotation in 
biochemistry, initially I did not find this quite as interesting as haematology.  I spent 
the first 4 weeks numbering up samples and secondary tubes which was quite dull 
after a very short time, but looking back I realise how necessary it was to my 
understanding of how the laboratory worked.  After that I was shown how to run the 
urea and electrolyte analyser (assessing kidney function).  This was the most 
complicated analyser I had ever come across (at the time), after my training I could 
make up the reagents, calibrate and quality control (checking everything was 
measuring what it should), run patient samples, print out results and stick them onto 
the request forms (yes we actually used sticky labels!).  Then one of the senior 
members of staff would go through the results with me before they were sent out to 
the wards. 
During my next rotation in haematology I spent a few months in transfusion.  
This I really enjoyed.  I was extremely slow to start with, blood groups, which 
everyone else could do in a couple of hours, took me all day, but with good 
instruction and lots of patience from the head of department I was soon flying through 
them. 
During each session in the departments over my four years of training I learnt 
more and more.  By the time I had completed my degree it had been a long time since 
I had been considered as a trainee who could not be left to get on with anything 
unsupervised.  I was considered to be a valuable member of the team and had even 
gained a reputation for being able to fix the majority of the analysers. 
 
 
 
  146 
My degree: 
My formal education in biomedical science began with a part-time degree in 
Clinical Biomedical Science at Liverpool John Moore’s University.  I started in 
September 1992 and attended University one or two days a week for four years while 
doing ‘on the job’ training at Southport and Formby District General Hospital. 
I found the course stimulating and exciting, I love to learn and it was all new 
to me, the theory, the experiments, everything.  It gave me a really good broad base of 
biomedical science, all of the disciplines were covered to a certain degree, and much 
more depth in my chosen specialty – biochemistry.  Moreover it was excellent doing 
the degree part time while working in a pathology laboratory as I could go to work the 
next day and put my newly learned theory into practice.  For my project I was asked 
by the department to set up, evaluate and run a quality assurance (QA) scheme for 
ward-based glucose meters.  This I really enjoyed, it gave me a lot of contact with 
other healthcare professionals involved with the use of glucose meters. 
I gained my BSc in Clinical Biomedical Science in May 1996, achieving a 2.1. 
which I was extremely proud of. 
 
The log book: 
The log book was provided by the Council for Professions Supplementary to 
Medicine (CPSM), it covered all aspects of my training as a BMS and was specific to 
my chosen discipline – biochemistry.  Every couple of months myself and the training 
officer would sit down and discuss my recent training.   In order for the log book to be 
signed off I had to thoroughly explain my understanding and the application of each 
section.  Until the log book was complete I could not undertake the state registration 
examination. 
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The state registration exam; 
Upon completion of my log book and degree I applied for state registration 
with the CPSM.  It was an oral examination and an external examiner appointed by 
the CPSM attended the laboratory.  I had to give them a tour of the laboratory 
explaining what all of the analysers did, how they worked and how the results were 
interpreted.  I was then ‘interrogated’ for one hour to determine the extent of my 
knowledge.  I was extremely nervous but according to my training officer I did very 
well. 
 
Continuing Professional Development; 
Attaining my degree and passing my state registration examination was only 
the beginning of my professional development.  Since then I have continued with my 
formal education and development of my skills as a biomedical science practitioner, 
selecting courses and training which suit both my interests and needs. 
 
Post-graduate education; 
During the final year of my BSc I enrolled with the Institute of Biomedical 
Science (IBMS) to do a CPD diploma.  This was a relatively new concept within 
Biomedical Science, but I really enjoyed doing it.  I gained most of my credits 
through journal based learning (20 multiple choice questions set by the IBMS on 
selected papers), instrument training sessions, meetings and conferences. In all it took 
me about 18 months to complete.  It was relatively straightforward to achieve as I 
read all the papers anyway and attended numerous training sessions and meetings in 
relation to my work on the glucose meter quality assurance scheme. 
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January 2000 saw me ‘emigrating’ to Wales and in the September I enrolled at 
the University of the West of England, Bristol, to do an MSc in Biomedical Science 
specialising in clinical chemistry.  It was a block release course, three weeks at a time 
at the University, it was great and I really enjoyed my time there.  It was very 
intensive but I gained such a great deal out of the sessions due to their intensity.   
For my MSc project I looked at CSF xanthochromia analysis for the detection 
of sub-arachnoid haemorrhage.  This was a great project which I really enjoyed, and 
was adopted by the department as standard practice (in line with national guidelines).  
May 2003 saw me passing my MSc with flying colours gaining a distinction for my 
project. 
 
Professional Development: 
My professional development really commenced when I started my training 
along-side my degree, but once I gained my state registration it took on a whole 
different ‘flavour’.  It was now really down to me, what I wanted to do with my career 
and what opportunities presented themselves. 
I carried on developing the glucose meter quality assurance scheme, 
expanding it to include general practitioners surgeries.  I also introduced ‘patient 
days’, where patients could come in to have their glucose meter checked, and their 
technique.  Just before I left Southport (December 1999) I got all of the district nurses 
on board too.  I also managed to get a poster accepted regarding glucose meter QA at 
the IBMS international congress in 1995, Birmingham.  While at Southport I also 
became heavily involved in gas analyser maintenance and training ward based staff, 
which I really enjoyed.  
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It was at Southport that I became involved with looking after work experience 
students (I had actually done my work experience in the lab at Southport when I was 
16!).  It started out just because I was the youngest in the lab, therefore closer to the 
students, but I really enjoyed it.  This developed further once I arrived at Swansea 
where I was asked to fulfill the same role.  Eventually I became the work experience 
co-ordinator for the entire pathology department. 
I was instrumental in changing the way Swansea examine CSF for 
xanthochromia, my MSc project provided the evidence we needed to adopt the 
national guidelines and I had a major role in setting up the procedure in the laboratory 
and the sample handling for clinicians.  I also had a poster accepted regarding this for 
FOCUS (Annual Congress for the Association for Clinical Biochemistry) in 2003 
(Bradley et al., 2003, p.73). 
Following my MSc I became more involved in training, starting in 2005, with 
being a mentor to one of our trainees who was with us for 12 months on a sandwich 
degree course.  I was there for her to ask questions about anything she did not 
understand and closely supervised the completion of her HPC/IBMS competence to 
practice portfolio, which was required for registration and the right to practice 
biomedical science. 
I subsequently went on to successfully mentor a further three trainee BMSs 
through their portfolios culminating with my appointment as the departmental training 
officer in 2008. 
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8.2. Why a doctorate? 
 
The accepted knowledge base within the biomedical science profession is like 
‘shifting sands’ i.e. it is forever changing due to the almost constant introduction of 
new techniques and theories, therefore individuals need to constantly update their own 
knowledge. 
Undertaking a professional doctorate seemed to be the next logical step in my 
professional education following my MSc.  It would also allow me to expand my 
research into xanthochromia which I had initiated whilst undertaking my MSc and 
would also satisfy a personal need to undertake further education as this is something 
I really enjoy (I already have my eye on the next educational ‘challenge’). 
 
 
8.3. Reflections on the DBMS taught element 
The aim of the taught element of the DBMS is to prepare the student to 
undertake doctoral research.  This is achieved through three individual units: 
1. Advanced research techniques 
2. Publication and dissemination 
3. Professional review and development 
  
Advanced research techniques: 
This module gave me the tools that I needed to apply the appropriate research 
approach, critically evaluate associated published work and select the most 
appropriate statistical method.  The taught element of this unit was enhanced with 
three assignments in the following areas: 
1) Analysis of data, 
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2) Critical appraisal of literature for evidence based practice, 
3) Applying theory to practice: A research resource pack for 
professionals. 
Each of these assignments has directly contributed to the completion of my 
thesis.  The analysis of data assignment provided me with the opportunity to re-
familiarise myself with statistical analysis.  Critical appraisal demonstrated to me that 
not all published research is of good quality and how to identify deficiencies in 
scientific literature.  The final assignment ‘A research resource pack for professionals’ 
allowed me to understand how I should pick my research methodology. 
 
Publication and dissemination: 
 I really enjoyed this unit and feel that I learnt a vast amount about publication 
and the politics of publication.  I had no idea it was fraught with so many pitfalls or so 
many choices.  This encouraged me to try and get one of my Advanced Research 
Techniques assignments published.  It was a research resource pack for biomedical 
scientists, so I selected a professional publication – The Biomedical Scientist – as this 
would be the best way of reaching my target audience.  The article was accepted and 
published in May 2005. 
 As a direct result of this unit I feel I could now advise fellow biomedical 
scientists and trainees, by both commenting on their article (style, weak points etc) 
and advise them as to the best place to publish their work. 
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Professional review and development: 
 Although reflection is now becoming an essential tool for the biomedical 
scientist and is a mandatory part of the IBMS Certificate of Competence this unit was 
my first experience of reflection.  After the first couple of lectures I was very 
unimpressed and felt it was much too ‘fluffy’ and unscientific, how could I possibly 
benefit from this?  As I explored the theory of reflection and examined it in 
conjunction with my professional practice I realised it was something that I was 
already doing, just not formally.  This unit helped me to develop my skills as a 
reflective practitioner and pass this knowledge on to others. 
 
8.4. Reflections on part 2 of the DBMS 
Part 1 of the DBMS gave me the necessary skills to undertake the research 
part of the doctorate but putting it into practice was still a challenge.  This started with 
the research proposal which underwent several version changes to ensure that my 
aims and objectives were realistic and relevant.   
The statistical skills I had gained in the Advanced Research Techniques unit 
were invaluable when analysing the data gained via the questionnaire and the analysis 
of the CSF samples.  I really enjoyed developing the questionnaire, something which I 
had not done before.  It made me really think about the role of the clinical 
biochemistry service within the NHS and highlighted to me that my vision of how 
pathology functions had an element of a stand-alone nature to it.  The collection and 
analysis of samples allowed me to stretch my knowledge with regard to automated 
analysers as I needed to install a completely new method and provide the analyser 
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with specific instructions as to the required volume of reagents and the wavelengths at 
which to measure. 
The writing of the thesis brought its own challenges.  This is where the 
Advanced Research Techniques unit assisted through the development of my critical 
appraisal skills which allowed me to select suitably robust scientific literature to 
support my arguments. 
The Publication and Dissemination unit has assisted me with my presentation 
skills.  As part of this unit I was given a topic for a presentation.  I had given a few 
presentations at work and always felt they were fine, but as part of the marking 
scheme we were given feedback not only from the tutors but also from the audience.  
This was a completely new experience to me and provided me with some excellent 
pointers as to how I could improve my presentation performance.  I will rely heavily 
upon my change in presentation ‘style’ when I ‘present’ my thesis. 
 
8.5. Summary 
Both the taught element of the DBMS and the research element have enabled 
me to develop as a professional.  The skills that I have learned have already had a 
direct impact on my career progression as they were essential in gaining my 
promotion to departmental training officer.  Now I have the opportunity to pass on my 
knowledge and skills not only to existing members of staff but also to a new 
generation of Biomedical Scientists who face unique challenges with the ever 
changing face of the NHS. 
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Literature search development; 
Initial literature searches centred on review articles on SAH and the seminal 
work of Chalmers and Kiley (1998, p.1740) and the UKNEQAS guidelines 
(UKNEQAS, 2003, p.481; Cruickshank et al., 2008, p.238).   Using these papers the 
snowball method of gathering further data from references in these articles was 
employed.   
In order to further develop the literature review and ensure that it was up to 
date a variety of search engines where examined and searches undertaken using key 
words.  The searches were restricted to the year 2000 and onwards to ensure the 
searches current and not too unwieldy. 
In order to develop an effective and efficient literature search it was important 
to select keywords which would answer the questions posed by each chapter and how 
these keywords could work together to refine the search.  Each area for review was 
broken down into its essential elements and the keywords required identified. 
For example in chapter one subarachnoid haemorrhage was entered into the 
search engine to identify subject headings to include in the search then using Boolean 
logic ‘AND’ further keywords and associated subject heading were included in the 
searches.  Details of the keywords used to identify subject headings are provided in 
the table overleaf. 
The articles returned by the searches were ordered ‘most recent publication first’ 
and then the first 50 articles were further investigated for inclusion and articles 
deemed suitable where critiqued to establish their relevance. 
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Chapter Keywords utilised 
Database/records retrieved 
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1 
 Subarachnoid haemorrhage 
AND 
14990 6286 1033 6413 12500 961 
o Aetiology 80 34 3 7 385 2 
o Epidemiology 41 57 5 82 306 13 
o Diagnosis 343 930 3 113 
 
1711 11 
o Headache 1601 207 93 189 
 
814 20 
o Incidence 693 251 43 41 1036 4 
o Investigation 427 180 20 14 488 40 
o Laboratory 270 103 1 5 221 1 
o Outcome 4335 1092 205 120 3166 86 
o Prevalence 299 62 12 19 340 5 
o Risk 3263 69 273 115 2689 20 
o Treatment 5877 2372 280 117 4016 32 
2 
 Subarachnoid haemorrhage 
AND 
14990 6286 1033 6413 12500 961 
o Questionnaire 152 63 11 5 141 8 
o Survey 314 40 13 5 143 7 
o Audit 51 12 3 1 30 0 
 Xanthochromia 
AND 
118 53 11 258 87 4 
o Questionnaire 1 2 0 0 1 0 
o Survey 2 1 1 0 3 0 
o Audit 2 2 0 0 4 
 
0 
3  
 Subarachnoid haemorrhage 
AND 
14990 6286 1033 6413 12500 961 
o Laboratory diagnosis 
o  
28 4 10 3 64 4 
 Brain damage marker 
o  
14 7 0 0 88 3 
o Haemoglobin metabolite 0 0 0 0 5 1 
o Blood metabolites 1 1 0 0 67 5 
o CSF Bilirubin 
o  
35 41 1 0 46 3 
 CSF Ferritin 
o  
5 7 1 1 11 0 
o Protein S100 26 28 0 3 20 0 
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Databases; 
 
In order to undertake a comprehensive literature search a number of different 
databases were utilised.  Details of the individual databases and the most recent dates 
the searches were reviewed are provided below. 
 
Embase; 
Embase is a biomedical and pharmacological database containing bibliographic 
records with citations, abstracts and indexing derived from biomedical articles in peer 
reviewed journals.  It contains over 22 million records spanning 1974–present.  The 
Embase journal collection is international with over 7,500 active peer-reviewed 
journals in more than 90 countries. 
Broad biomedical scope covering the following areas: 
o Drug therapy and research, including pharmaceutics, pharmacology and 
toxicology 
o Clinical and experimental (human) medicine 
o Basic biological science relevant to human medicine 
o Biotechnology and biomedical engineering, including medical devices 
o Health policy and management, including pharmacoeconomics 
o Public, occupational and environmental health, including pollution control 
o Veterinary science, dentistry, and nursing 
Date of last review – 23rd July 2012 
 
Medline; 
Medline covers the international literature on biomedicine, including the allied health 
fields and the biological and physical sciences, humanities, and information science as 
they relate to medicine and health care.  Information is indexed from approximately 
5.400 journals published world-wide from 1946-present. 
Date of last review – 25th July 2012. 
 
CINAHL; 
CINAHL provides indexing for more than 3,000 journals from of the fields of nursing 
and allied health.  The database contains more than 2.6 million records dating back to 
1981.  CINAHL covers nursing, biomedicine, health sciences librarianship, 
alternative/complementary medicine, consumer heath and 17 allied health disciplines. 
Date of last review – 20th July 2012. 
 
Wiley; 
Wiley-Blackwell is the international scientific, technical, medical, and scholarly 
publishing business of John Wiley & Sons. Wiley-Blackwell publishes nearly 1,500 
peer-reviewed journals and 1,500+ new books annually in print and online, as well as 
databases, major reference works and laboratory protocols. Wiley Online Library is 
one of the world's most extensive multidisciplinary collections of online resources, 
covering life, health, social and physical sciences, and humanities.  
Date of last review – 14th August 2012. 
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Web of Science; 
Web of Science is an online academic citation index provided by Thomson Reuters.  
It provides access to multiple databases and cross-disciplinary research.  The 
multidisciplinary coverage encompasses over 11,000 journals, which are selected on 
the basis of impact evaluations. This includes Open access journals and over 12,000 
conference proceedings each year, spanning multiple academic disciplines. Coverage 
includes the sciences, social sciences, arts, and humanities. 
Date of last review – 20th August 2012. 
 
Science Direct; 
Science Direct is a leading full-text scientific database offering journal articles and 
book chapters from more than 2,500 peer-reviewed journals and more than 11,000 
books. There are currently more than 11 million articles/chapters, a content base that 
is growing at a rate of almost 0.5 million additions per year. Science Direct covers 
around one quarter of the world’s full-text scientific, technical and medical literature 
published in 24 fields of science. 
Date of last review – 14th August 2012. 
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Appendix 2 
United Kingdom National External Quality 
Assessment Scheme (UKNEQAS) 
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What is UKNEQAS? 
UKNEQAS is an external quality assessment scheme which assists with 
implementing and maintaining an optimal level of quality in clinical laboratory 
services.  Steering committees deal with policy and strategy issues while specialist 
advisory groups provide clinical and scientific support.  It holds full Clinical 
Pathology Accreditation.  Traditionally UKNEQAS only dealt with analytical 
results produced by laboratories but have recently started examining interpretative 
comments, which first piloted in clinical biochemistry laboratories.  They also 
provide international services for specialised assays, some of which are sponsored 
by the World Health Organisation. 
 
UKNEQAS and quality assurance 
Quality assurance is a fundamental element of the clinical laboratory’s 
provision of precise and accurate results.  It is not just about the potential 
variability within the analytical methods employed to produce the results, it also 
encompasses potential biological variation. 
‘Quality assurance seeks to guarantee the right result from the right test, at 
the right time, on the right specimen from the right patient, interpreted using the 
right reference data’ (UKNEQAS, p.11). 
There are three constituent elements: 
1. Quality assurance (QA); 
Includes all efforts taken to verify that those investigations carried out within the 
laboratory are reliable.  This is a multi-step process encompassing the sentiment of 
the statement above i.e. it starts with selecting the appropriate test, acquiring a 
suitable sample from the correct patient, analysing it and documenting the result 
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promptly and accurately, providing appropriate interpretation and reporting to the 
correct clinician for action. 
2. Internal quality control (IQC); 
Assesses the precision of investigations carried out within individual laboratories 
in real time and facilitates continuity of patient care over time.  The majority of 
IQC procedures involve the analysis of control material and evaluate results 
against predetermined limits.  Results outside these limits indicate that action 
needs to be taken before patients results are reported. 
3. External quality assessment (EQA); 
QA and IQC are procedures used within discrete testing locations, whereas EQA 
examines variation between different locations testing the same analyte with the 
overarching aim of ensuring geographical continuity of results.  UKNEQAS 
achieves this by sending identical samples to all enrolled laboratories and 
comparing the results to the expected result.  
 
History of UKNEQAS 
 IQC procedures were not widely introduced into UK clinical laboratories until 
the 1960’s.  Several keen groups pursued this further by carrying out 
geographically local research to determine comparability of results.  These evolved 
into local and regional schemes, which increased awareness of QA within 
laboratories.  In the late 1960’s the Ministry of Health oversaw the introduction of 
National Quality Control schemes for Clinical Chemistry and Haematology with 
the first distribution of samples occurring in 1969.  Over the next two decades 
further schemes were established, eventually covering all major pathology 
disciplines.
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Cerebrospinal fluid 
Xanthochromia audit 
 
 
The cerebrospinal fluid (CSF) of healthy individuals is optically clear, but for over a 
century it has been recognised that it can become coloured following a 
cerebrovascular incident such as sub-arachnoid haemorrhage (SAH). 
Until the mid 1950’s xanthochromia could only be assessed qualitatively by visual 
interpretation.  The introduction of spectrophotometry brought with it the ability to 
measure pigments present in coloured CSF. 
Xanthochromia is by definition the yellow discolouration indicating the presence of 
bilirubin in the CSF.  Following haemorrhage, red cells lyse and release 
oxyhaemoglobin which is metabolised by heme oxygenase in the arachnoid and 
choroid plexus to form bilirubin.  At least 12 hours are required to reach peak enzyme 
activity following SAH
1
, therefore the minimum period for CSF xanthochromia 
detection is 12 hours after onset of symptoms.  Xanthochromia  indicates in-vivo 
haemorrhage, whereas detection of red blood cells and oxyhaemoglobin cannot 
differentiate in-vivo haemorrhage from a traumatic lumbar puncture. 
Until recently CSF xanthochromia in the clinical biochemistry department of Swansea 
NHS trust was assessed visually, this at the time being the norm.  In 1998 Chalmers 
and Kiley
2
 published a paper, which simplified the process of scanning 
spectrophotometry for CSF xanthochromia, this was quickly followed by a further 
paper from Chalmers
3
, which simplified the process even further.  Following the 
publication of these two papers UKNEQAS introduced national guidelines in 2003 for 
the analysis of CSF for bilirubin in suspected SAH
4
. 
The clinical biochemistry department of Swansea NHS trust adopted these guidelines 
in 2003 soon after publication, following rigorous in-house validation. 
 
This audit covers a twelve month period (1
st
 April 2004 – 31st March 2005) during 
which a total of 170 xanthochromia requests were received in the clinical 
biochemistry department of Swansea NHS Trust. 
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Patient demographics; 
 
Of the 170 requests received 41 % (69) were male and 59 % (101) were female.  The 
age distribution of the patients is detailed in Table A3.1. 
 
Table A3.1: Age distribution of patients 
 
Age (years) No. requests 
≤ 20 10 
21 – 30 35 
31 – 40 42 
41 – 50 25 
51 – 60 26 
61 – 70 17 
71 – 80 10 
81 – 90 4 
> 90 1 
 
The clinical details provided are summarised in Table A3.2.  The two most common 
clinical details were SAH/?SAH (30 %) and headache (26 %). 
 
Table A3.2: clinical details provided 
 
Clinical details No. Clinical details No. 
No details entered 52 Meningitis 1 
? encephalitis 1 Memory loss 1 
? meningitis 12 No clinical details 6 
? SAH 30 ? MS 2 
? meningitis/?SAH 2 SAH 10 
?SAH/Headache 7 SAH/headache 1 
Cerebral ataxia 1 SAH/meningitis 1 
Dementia 1 See form 1 
Headache 34 Septic 1 
Headache/?meningitis 1 SLE 1 
Headache/numbness 1 Unlabelled 1 
Headache/odd behaviour 1 Visual disturbance 1 
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Requesting locations and clinicians; 
 
There were a total of 46 different locations that requested xanthochromia analysis, the 
top 10 are listed in Table A3.3. 
  
Table A3.3: top ten requesting locations 
 
Site Ward  type No. requests 
Morriston Neurology 23 
Morriston Admissions 21 
Neath Port-Talbot Admissions 13 
Singleton Medical Admissions 12 
Singleton General Medicine 8 
Morriston Neurology 7 
Singleton Accident and Emergency 7 
Neath Port-Talbot Local Accident Centre 6 
Llanelli Admissions 6 
Singleton Haematology 5 
 
 
There were a total of 51 different clinicians who requested xanthochromia analysis, 
the top 10 are listed in Table A3.4. 
  
Table A3.4: Top 10 requesting clinician’s specialities 
 
Clinician speciality No. of requests 
1 - Not stated 17 
2 - General Medicine 8 
3 - General Medicine 8 
4 - Geriatrics 8 
5 - General Medicine 7 
6 - Accident and Emergency 7 
7 – Chest Medicine 6 
8 - General Medicine 6 
9 – Chest Medicine 6 
10 - Cardiology 6 
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Xanthochromia results; 
 
The reported results of the 170 xanthochromia requests can be divided into 7 different 
categories (Table A3.5). 
 
Table A3.5; xanthochromia results categories 
 
Result Number % 
Insufficient 1 0.59 
Not available 2 1.18 
Not tested 2 1.18 
See below 3 1.76 
Equivocal 33 19.41 
Negative 124 72.94 
Positive 5 2.94 
 
Insufficient; 
Sample leaked in storage, therefore unable to analyse 
 
Not available; 
1 sample consisted of mostly clotted blood and therefore was unsuitable for analysis 
1 sample request for oligoclonal bands, after discussion with requesting clinician it 
was agreed that xanthochromia analysis was unnecessary. 
 
Not tested; 
1 not tested as xanthochromia analysis is not available on neonates 
1 not requested on original form, NT (not tested) entered into each field rather than 
the xanthochromia request being deleted. 
 
See Below; 
1 sample – ‘moderately blood stained sample, CSF sample may be consistent with 
SAH … …’ 
2 samples – ‘CSF sample may be consistent with SAH … …’ 
 
Equivocal; 
24 (72.8 %)  - Low levels of oxyhaemoglobin, low predictive value for SAH 
6 (18.2 %) - Concentration of oxyhaemoglobin may mask bilirubin, SAH not 
excluded 
1 (3.0 %) - Oligoclonal band comments only 
1 (3.0 %) - Not light protected, low levels of OxyHB, low predictive value for 
SAH 
1 (3.0 %) - Low levels of methhaemoglobin, low predictive value for SAH 
 
Xanthochromia negative; 
All had low oxyhaemoglobin and low net bilirubin absorbances 
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Xanthochromia positive; 
5 all visually yellow in colour (NBA - 0.032 – 0.205) 
1 – no clinical details 
1 – query SAH 
1 – headache 
2 – SAH  
 
Visual versus calculated assessment of bilirubin; 
 
Visual assessment of the CSF sample is recorded in the laboratory information 
management system (MASTERLAB) but not reported to the requesting clinician.  
Comparisons of visual results to the calculated net bilirubin absorbance (NBA) are 
shown below (Table A3.6).  
N.B. an NBA of > 0.007 is considered to be indicative of SAH (consideration of 
other factors e.g. serum bilirubin and CSF protein must first be taken into account). 
 
Table A3.6; visual versus calculated assessment of CSF bilirubin 
 
Visual assessment No of samples NBA Reported result 
Blood stained 2 0.000 Equivocal 
  0.016 See Below 
Clear 130 0.000 22 Equivocal/108 Negative 
 9 0.001 3 Equivocal/6 Negative 
 6 0.002 2 Equivocal/4 Negative 
 2 0.003 2 Negative 
 2 0.005 2 Negative 
 2 0.006 1 Equivocal/1 Negative 
 1 0.007 Negative 
 1 0.010 See Below 
Clotted blood 1 Not tested  
Haemolysis 3 0.000 3 Equivocal 
 1 0.001 1 Equivocal 
Not available 2 Not tested  
Not tested 2 Not tested  
Yellow 6 0.010 See below 
  0.032 Positive 
  0.061 Positive 
  0.118 Positive 
  0.157 Positive 
  0.205 Positive 
 
 
 
 
 
 
  179 
Turn-around times; 
 
Turn-around times have been calculated based upon the time that the sample was 
‘booked-in’ to MASTERLAB and the time that the results were reported.  It does not 
take into account sampling time as this is not always provided and transport delays to 
the laboratory are outside the laboratories control (Table A3.7). 
 
Ideal maximum turn-around times:- 
 Monday – 16:00 Friday < 24 hours 
 Friday received by 16:00 < 17 hours 
 Friday received after 16:00 < 72 hours 
 Saturday < 65 hours 
 Sunday < 41 hours 
 
Table A3.7: sample turn-around times (based upon the 165 samples reported) 
 
Day No. Average(h) Min(h) Max(h) No. outside ideal limits 
Monday 14 22.4 1 63 5 
Tuesday 30 19.0 1 63 5  
Wednesday 40 17.9 1 132 5  
Thursday 19 14.6 1 89 2  
Friday (by 16:00) 17 18.2 1 72 4  
Friday (after 16:00) 17 63.7 1 163 4  
Saturday 13 53.7 43 68 2 
Sunday 15 28.4 14 61 3 [1 bank holiday 
Monday] 
 
Overall average turn around time for all requests 26 hours. 
 
A total of 30 samples (18 %) were reported outside the ideal maximum turnaround 
times. 
 
As these figures show a total of 45 samples (27 %) were received over the weekend 
period i.e. Friday after 16:00 hours till Sunday 00:00 hours. 
 
 
Discussion 
 
The annual incidence of SAH in the UK is about 1:10,000.  It is more frequent in 
females than males with a ratio of 3:2, this ratio is reflected in the xanthochromia 
analysis requests; 59% female as compared to 41% male.  The incidence of SAH does 
increase with age, but this has not been reflected in this audit as only 35% of requests 
were on patients over 50 years of age.  On closer examination of the demographics of 
those patients reported as positive for xanthochromia, and therefore suggestive of 
SAH, the figures fit more with those expected (see Table A3.8 below). 
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Table A3.8: Demographics of xanthochromia positive requests 
 
Age Sex 
34 M 
45 F 
58 F 
58 M 
63 F 
 
The clinical details provided with each xanthochromia request were relatively diverse 
(Table A3.2), this reflects the variety of clinical presentations of SAH.  On closer 
examination the vast majority (75%) of clinical details provided do refer to symptoms 
of SAH, e.g. headache, or SAH itself. 
 
The requesting locations and clinicians reflect the serious nature and clinical 
presentation of SAH in that the majority are referred to the laboratory via neurology 
and acute admissions. 
 
Of the 170 xanthochromia specimens received only 5 (2.9%) were unsuitable for 
analysis and only 1 (0.6%) was received ‘not light protected’.  This reflects the great 
pains the laboratory has gone to in order to communicate the sample requirements to 
clinicians through the provision of CSF kits, which have been designed to provide all 
the sample collection tubes and the necessary information. 
 
Almost 20% of requests were reported as equivocal (inconclusive), this is new ground 
for requesting clinicians as until the introduction of scanning spectrophotometry in 
2003 the laboratory did not report xanthochromia as ‘inconclusive’ only as positive, 
negative or blood stained.  This ‘new’ reporting class is accompanied by a brief 
explanation; 
‘Low levels of oxyhaemoglobin present, this has a low predictive value for SAH’ 
From the number of queries, regarding these results, made to clinical scientists (no 
statistical data available) it would appear that this information might not be sufficient. 
 
On examination of the comparison of visual results to the calculated assessment of 
bilirubin, it is evident that no false negative would have been reported by visual 
assessment alone, but one false positive would have been reported.  This again 
confirms scanning spectrophotometry to be the superior method for xanthochromia 
analysis. 
 
Currently xanthochromia analysis within the clinical biochemistry department of 
Swansea NHS trust is performed by scanning spectrophotometry according to the 
UKNEQAS guidelines
4
.  This is a technically difficult and subjective method and as a 
result is only carried out by a relatively small number of staff.  As a consequence this 
service is only provided within core laboratory opening hours i.e. 9am – 4pm Monday 
to Friday.  This is reflected in the average turnaround time of 26 hours, although this 
could be affected by transport delays from satellite laboratories. 
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Turnaround times vary widely (Table A3.6) due to the extended period over the 
weekend (Friday 4pm – Monday 9am) when xanthochromia analysis can only be 
arranged at the discretion of a Clinical Biochemist and by calling in a suitably trained 
member of staff. 
It must be recognized that these turn-around times do not take into consideration any 
delay caused by requesting clinicians not providing the laboratory with all the 
required samples, this most often being a serum sample which is necessary to 
calculate the impact of serum bilirubin on any bilirubin present in the CSF. 
 
Conclusion; 
Are the results that we are providing clinicians produced within a clinically relevant 
time frame?  Lumbar punctures cannot be performed until 12 hours after the onset of 
symptoms, combine this with the average turn-around time (26 hours) and on average 
xanthochromia results are not available until 38 hours after onset of symptoms.  How 
does this fit with the standard protocol for SAH diagnosis? 
 
Further work; 
Design a questionnaire directed at requesting clinicians to see where xanthochromia 
results fit in to their diagnostic strategy for SAH diagnosis, in particular are they 
provided within a clinically useful timeframe. 
Look into alternative methods of determining SAH from CSF samples (CSF ferritin, 
direct analysis of bilirubin in CSF, CSF S100).  These could be used as ‘rule-out’ 
tools 24/7 therefore reducing the average turn-around time.  
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Clinical biochemistry laboratory service 
provision for the detection of sub-arachnoid 
haemorrhage using cerebrospinal fluid. 
 
 
The objective of the attached questionnaire is to determine 
how clinicians who have requested cerebrospinal fluid (CSF) 
xanthochromia analysis perceive the provided service.  The responses 
to this questionnaire will have a pivotal role in a research project, 
which aims to improve service provision. 
 
Your participation in this survey will be greatly appreciated 
and may well result in an enhanced service with direct benefits for 
your patients. 
 
If you have any questions or queries regarding this 
questionnaire please contact the Chief Investigator; Mrs V. A. 
Bradley:- 
 
Email:- victoria.bradley@swansea-tr.wales.nhs.uk  
 
Tel:-  01792 703052 
 
Address Clinical Biochemistry 
  Morriston Hospital 
  Morriston 
  Swansea 
  SA6 6NL 
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(please mark the appropriate boxes with an X) 
 
 
1. Grade  ___________________________ 
 
2. Speciality  ___________________________ 
 
3. Hospital Base ___________________________  
 
4. Are you aware that there are United Kingdom National External 
Quality Assessment Scheme (UKNEQAS) guidelines regarding the 
laboratory investigation of CSF xanthochromia? 
 
 
                               YES                    NO 
 
5. Are you aware of the recommended minimum time from onset of 
symptoms to lumbar puncture? 
 
Please state minimum amount of time in hours:________ 
 
6. Was CSF xanthochromia requested as part of a diagnostic protocol 
(patient pathway)? 
 
 
                               YES                    NO 
  Please give brief details: 
  _______________________________________ 
  _______________________________________ 
  _______________________________________ 
  _______________________________________ 
 
7. How many times over the past twelve months would you estimate 
that you have requested CSF xanthochromia analysis? 
 
 
    1                2                3                4                5 or more 
(please specify number)
   
8. Did the patient have a negative or equivocal CT scan result before 
undergoing lumbar puncture? 
 
 
                               YES                    NO 
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9. Was there a CSF collection kit for xanthochromia readily available in 
the ward/department? 
 
 
                               YES                    NO 
 
10. Where the instructions on the CSF collection kit for xanthochromia 
clear and easy to follow? 
 
 
                               YES                    NO 
 
  If NO, which part/s need to be clarified? 
  _______________________________________ 
  _______________________________________ 
  _______________________________________ 
  _______________________________________ 
  _______________________________________ 
 
11. Was the turn-around time of the results within a clinically acceptable 
time frame? 
 
 
                               YES                    NO 
 
If NO, what would be acceptable? 
  _______________________________________ 
  _______________________________________ 
  _______________________________________ 
  _______________________________________ 
 
12. Where the results provided and the accompanying interpretation clear 
and informative? 
 
 
                               YES                    NO 
 
If NO, which parts need to be clarified? 
  _______________________________________ 
  _______________________________________ 
  _______________________________________ 
  _______________________________________ 
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13. Did you receive all of the results that you expected? 
 
 
                               YES                    NO 
 
If NO, which additional results where expected? 
  _______________________________________ 
  _______________________________________ 
  _______________________________________ 
  _______________________________________ 
 
 
 
Any additional comments or information you feel may be of use; 
______________________________________________ 
______________________________________________ 
______________________________________________ 
______________________________________________ 
______________________________________________ 
______________________________________________ 
______________________________________________ 
______________________________________________
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Thank you for participating in this questionnaire. 
 
Completed questionnaires can be returned via e-mail to:- 
 
victoria.bradley@swansea-tr.wales.nhs.uk 
 
Alternatively they can be posted to:- 
 
  Mrs V. A. Bradley 
  Clinical Biochemistry 
  Morriston Hospital 
  Morriston 
  Swansea 
  SA6 6NL 
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Appendix 5 
Medical Staff Questionnaire results 
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A5.1. Analysis of Questionnaire  
A5.1.1. Questionnaire returns 
A total of 24 questionnaires were returned, 23 via the postal service and 1 
via e-mail (a further 5 responses from Salisbury were lost in transit); 5 responses 
were received from Bro Morgannwg NHS Trust and 19 from Swansea NHS 
Trust. 
 
A5.1.2. Evaluation of returns by staff group and speciality 
 The majority (58%) of respondents were consultants and the most 
common area of expertise of all respondents (67%) was medicine. 
 
A5.1.3. Evaluation of Questions 
Question 1.  Are you aware that there are United Kingdom National External 
Quality Assessment Scheme (UKNEQAS) Guidelines regarding the laboratory 
investigation of CSF xanthochromia?  
In total 33% (n = 8) of respondents were aware of UKNEQAS Guidelines 
regarding the laboratory investigation of CSF xanthochromia and 67% (n = 16) 
were not (Figure A5.1).  
 
Question 2. Are you aware of the recommended minimum time from onset of 
symptoms to lumbar puncture? (respondents were requested to state the 
minimum amount of time in hours) 
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Figure A5.1 – Respondents awareness of the existence of UKNEQAS Guidelines 
for the laboratory investigation of CSF xanthochromia, including respondent’s 
specialism. 
 
 
Figure A5.2 – Respondents opinion of the recommended minimum time frame 
from onset of symptoms of SAH to lumbar puncture. 
 
In total 33.4% (n = 8) of respondents stated that the minimum time from 
onset of symptoms to lumbar puncture was less than 12 hours, 45.9% (n = 11) 
stated that it was 12 hours, 12.6% (n = 3) stated that it was greater then 12 hours 
and 8.4% (n = 2) did not know the minimum time (Figure A5.2). 
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Of those respondents who reported that the recommended minimum time 
from onset of symptoms to lumbar puncture was less than 12 hours, 37.5% (n = 
3) were from neurosurgery and 62.5% (n = 5) were from medicine (Figure A5.3). 
Of those respondents who reported that the recommended minimum time 
from onset of symptoms to lumbar puncture was 12 hours, 9.1% (n = 1) were 
from neurosurgery, 63.6% (n = 7) were from medicine, 9.1% (n = 1) were from 
cardiology, 9.1% (n = 1) were from geriatrics and 9.1% (n = 1) were from 
integrated medicine (Figure A5.3).  
Of those respondents who reported that the recommended minimum time 
from onset of symptoms to lumbar puncture was greater than 12 hours, 66.5% (n 
= 2) were from medicine and 33.5% (n = 1) were from cardiology (Figure A5.3). 
The two respondents who reported that they did not know what the 
recommended minimum time from onset of symptoms to lumbar puncture was, 
were both from medicine (Figure A5.3). 
 
Question 3. Was CSF xanthochromia requested as part of a diagnostic protocol 
(patient pathway)?  
In total 37.5% (n = 9) of respondents stated that the CSF xanthochromia 
was requested as part of a diagnostic protocol, 54% (n = 13) stated it was not and 
8.5% (n = 2) did not understand (Figure A5.4) the question. 
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Figure A5.3 – Respondents awareness of recommended minimum time from 
onset of symptoms of SAH to lumbar puncture and their interpretation of the 
minimum time, including respondent’s specialism. 
 
 
Figure A5.4 – Xanthochromia requests made as part of a diagnostic patient 
pathway, including respondent’s site distribution. 
 
 Of those respondents who stated that the CSF xanthochromia was 
requested as part of a patient pathway 22.2% (n = 2) were from neurosurgery, 
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66.7% (n = 6) were from medicine and 11.1% (n = 1) were from integrated 
medicine (Figure A5.5). 
 Of those respondents who stated that the CSF xanthochromia was not 
requested as part of a patient pathway 15.4% (n = 2) were from neurosurgery, 
61.5% (n = 8) were from medicine, 15.4% (n = 2) were from cardiology and 
7.7% (n = 1) were from geriatrics (Figure A5.5).  Both respondents who did not 
understand the question were from neurosurgery (Figure A5.5).  
 
Question 4. How many times over the past twelve months would you estimate 
that you have requested CSF xanthochromia analysis? 
 In total 8.5% (n = 2) of respondents had requested CSF xanthochromia 
analysis on only one occasion over the previous 12 month period, 29% (n = 7) 
had requested it twice, 16.5% (n = 4) had requested it three times, 21% (n = 5) 
had requested it four times and 25% (n = 6) had requested it five or more times 
(Figure A5.6).  
Of those respondents who had requested CSF xanthochromia on only one 
occasion over the preceding twelve months, one was from medicine and one was 
from cardiology (Figure A5.7). 
Of those respondents who had requested CSF xanthochromia on two 
occasions over the preceding twelve months, 14.3% (n = 1) were from 
neurosurgery, 57.1% (n = 4) were from medicine,  14.3% (n = 1) were from 
cardiology and 14.3% (n = 1) were from geriatrics (Figure A5.7). 
 
  194 
 
Figure A5.5 – Xanthochromia requests made as part of a diagnostic patient 
pathway, including respondent’s  specialism. 
 
 
Figure A5.6; Number of xanthochromia requests made by individual clinicians 
over a twelve month period, including respondent’s site distribution. 
 
 All four of the respondents who had requested CSF xanthochromia on 
three occasions over the preceding twelve months were from medicine (Figure 
A5.7). 
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Of those respondents who had requested CSF xanthochromia on four 
occasions over the preceding twelve months 20% (n = 1) were from 
neurosurgery and 80% (n = 4) were from medicine (Figure A5.7).  
Of those respondents who had requested CSF xanthochromia on five or 
more occasions over the preceding twelve months 40% (n = 2) were from 
neurosurgery and 60% (n = 3) were from medicine (Figure A5.7).  One of the 
clinicians in medicine requested more than 20. 
 
Question 5. Did the patient have a negative or equivocal CT scan result before 
undergoing lumbar puncture? 
All respondents, regardless of speciality or location, responded yes i.e. 
that the patient had had a negative or equivocal CT scan result before undergoing 
lumbar puncture. 
 
 
Figure A5.7 – Number of xanthochromia requests made by individual clinicians 
over a twelve month period, including respondent’s specialism. 
  
  196 
 
Question 6. Was the CSF collection kit for xanthochromia readily available in 
the ward/department? 
In total 63% (n = 15) of respondents stated that the CSF collection kit for 
xanthochromia was readily available in the wards and departments, 25% (n = 6) 
stated it was not and 12% (n = 3) did not know (Figure A5.8). 
 If this is examined further by closer examination of the site-specific 
results it reveals that at Bridgend 40% (n = 2) of respondents stated that the CSF 
collection kit for xanthochromia was readily available in the wards and 
departments, 20% (n = 1) stated it was not and 40% (n = 2) did not know.  
However at Swansea 68.4% (n = 13) of respondents stated that the CSF 
collection kit for xanthochromia was readily available in the ward/department, 
26.3% (n = 5) stated it was not and 5.3% (n = 1) did not know. 
 
Question 7. Were the instructions on the CSF collection kit for xanthochromia 
clear and easy to follow? 
In total 63% (n = 15) of respondents stated that the CSF collection kit 
instructions were clear and easy to follow, 4% (n = 1) stated it was not and 33% 
(n = 8) did not respond (Figure A5.9).  
If this is examined further by closer examination of the site-specific 
results it reveals that at Bridgend 60% (n = 3) of respondents stated that the CSF 
collection kit instructions were clear and easy to follow, and 40% (n = 2) did not 
respond.  Whereas at Swansea 63.1% (n = 12) of respondents stated that the CSF 
collection kit instructions were clear and easy to follow, 5.3% (n = 1) stated they 
were not and 31.6% (n = 6) did not know. 
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Figure A5.8; Availability of CSF collection kits for xanthochromia in wards and 
departments,  including respondent’s site distribution. 
 
 
 
Figure A5.9; Clarity of the instructions within the CSF collection kits for 
xanthochromia and ease of use, including respondent’s site distribution. 
 
Question 8. Was the turn-around time of the results within a clinically 
acceptable time frame? 
In total 63% (n = 15) of respondents stated that the turn-around time of 
the results was within a clinically acceptable time frame and 37% (n = 9) stated 
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that it was not.  If this is examined further by closer examination of the site-
specific results it reveals that at Bridgend 60% (n = 3) of respondents stated that 
the turn-around time of results was within a clinically acceptable time frame and 
40% (n = 2) stated that it was not.  At Swansea 63.2% (n = 12) of respondents 
stated that the turn-around time of results was within a clinically acceptable time 
frame and 36.8% (n = 7) stated it was not. 
 
Question 9. Were the results provided and the accompanying interpretation clear 
and informative? 
In total 84% (n = 20) of respondents stated that the accompanying 
interpretation was clear and informative, 8% (n = 2) stated that it was not and 8% 
(n = 2) did not respond. 
If this is examined further by closer examination of the site-specific 
results it reveals that at Bridgend 80% (n = 4) of respondents stated that the 
accompanying interpretation was clear and informative, and 20% (n = 1) said 
that it was not.  However at Swansea 84.1% (n = 16) of respondents stated that 
the accompanying interpretation was clear and informative, 5.3% (n = 1) stated it 
was not and 10.6% (n = 2) did not respond. 
 
Question 10. Did you receive all of the results that you expected? 
In total 88% (n = 21) of respondents received all of the results that they 
expected, 4% (n = 1) did not and 8% (n = 2) did not respond. 
If this is examined further by closer examination of the site-specific 
results it reveals that at Bridgend all of the respondents received all the results 
that they expected.  At Swansea 84.1% (n = 16) of respondents received all the 
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results that they expected, 5.3% (n = 1) did not and 10.6% (n = 2) did not 
respond. 
 
A5.1.4. Clinicians comments 
 In total nine clinicians provided additional comments at the end of the 
questionnaire regarding the then current service provided for CSF xanthochromia 
analysis. 
 Two clinicians raised concerns over the transport of ‘precious’ samples 
between sites and the potential consequences of them going astray.  There were 
two comments regarding the lack of an out of hours service.  One clinician was 
particularly concerned about ‘equivocal’ samples, this was deemed as ‘fence 
sitting’ and that there were a large proportion of ‘false equivocals’ which were 
‘angiography negative, as expected’. 
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Appendix 7 
UKNEQAS 2003 Guidelines versus 2008 
Guidelines 
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National guidelines for analysis of cerebrospinal fluid for bilirubin in 
suspected Subarachnoid haemorrhage 
2003 guidelines 2008 revised guidelines 
NBA ≤ 0.007 AU and no 
oxyhaemoglobin present 
Report as: ‘No significant bilirubin and 
no oxyhaemoglobin present. No evidence 
to support SAH.’ 
NBA ≤ 0.007 AU  NOA ≤ 0.02 AU 
Report as: ‘Bilirubin and 
oxyhaemoglobin not increased.  No 
evidence to support SAH.’ 
NBA ≤ 0.007 AU and oxyhaemoglobin 
present but NOA < 0.1 AU 
Report as: ‘Oxyhaemoglobin present but 
no significant bilirubin.  
Oxyhaemoglobin on its own has a low 
predictive value for SAH but does not 
exclude.’ 
NBA ≤ 0.007 AU and NOA > 0.02 AU 
but < 0.1 AU 
Report as: ‘Bilirubin not increased.  
Small amount of oxyhaemoglobin 
detected. No evidence to support SAH.’ 
NBA ≤ 0.007 AU and NOA ≥ 0.1 AU 
Report as: ‘Oxyhaemoglobin present but 
no significant bilirubin.  NB The 
concentration of oxyhaemoglobin may 
mask a small but significant increase in 
bilirubin.  SAH not excluded.’ 
NBA ≤ 0.007 AU and NOA ≥ 0.1 AU 
Report as: ‘Oxyhaemoglobin is present in 
sufficient concentration to impair the 
detection of bilirubin.  SAH not 
excluded.’ 
NBA > 0.007 and no oxyhaemoglobin 
present 
NBA > 0.007 and NOA ≤ 0.02 AU or 
NOA > 0.02 AU but with no visible 
oxyhaemoglobin peak 
(a) Serum bilirubin ≤  20 µmol/l and CSF 
protein ≤  1.0 g/l 
Report as: ‘Increased CSF bilirubin but 
no oxyhaemoglobin. Consistent with 
SAH.’ (NB this would be an unusual 
pattern within the first week after and 
event.) 
(a) Serum bilirubin ≤ 20 µmol/l and CSF 
protein ≤ 1.0 g/l 
Report as: ‘Increased CSF bilirubin. 
Consistent with SAH.’ (This would be an 
unusual pattern within the first week after 
an event 
 
(b) Serum bilirubin > 20 µmol/l and CSF 
protein ≤ 1.0 g/l 
Apply formula to calculate an adjusted 
NBA. 
(b) Serum bilirubin > 20 µmol/l and CSF 
protein ≤ 1.0 g/l 
Apply formula to calculate an adjusted 
NBA 
If adjusted NBA ≥ 0.007 AU, report as: 
‘Increased CSF bilurubin but no 
oxyhaemoglobin.’ (NB This would be an 
If adjusted NBA > 0.007 AU report as: 
‘Increased CSF bilirubin. Consistent with 
SAH.’ (This would be an unusual pattern 
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unusual pattern within the first week after 
an event). 
within the first week after an event.) 
 
If adjusted NBA < 0.007 AU, report as: 
‘Increased  CSF bilirubin but probably 
totally accounted for by increase in serum 
bilirubin.  No Oxyhaemoglobin. Not 
supportive of SAH.’ 
If adjusted NBA ≤ 0.007 AU, report as: 
‘Increased CSF bilirubin but probably 
totally accounted for by increase in serum 
bilirubin. Not supportive of SAH.’ 
(c) CSF protein > 1.0 g/l, whatever the 
serum bilirubin. 
Report as: ‘Increased CSF bilirubin, but 
no oxyhaemoglobin.  This finding may be 
consistent with: SAH; an increased 
bilirubin accompanying the increased 
CSF protein; or other source of CSF 
blood. Interpret result with caution in 
relation to SAH, especially if within first 
week of event.’ 
(c) CSF protein > 1.0 g/l, whatever the 
serum bilirubin. 
Report as: ‘Increased CSF bilirubin.  This 
finding may be consistent with: SAH; an 
increased bilirubin accompanying the 
increased CSF protein; or other source of 
CSF blood. Interpret result with caution 
in relation to SAH especially if within 
first week of event.’ 
NBA > 0.007 AU and oxyhaemoglobin 
present but NOA ≤ 0.1AU 
 
(a) Serum bilirubin ≤ 20 μmol/l and CSF 
protein ≤ 1.0 g/l 
Report as: ‘Increased CSF bilirubin with 
oxyhaemoglobin present.  Consistent 
with SAH. 
[No equivalent in 2008 revised 
guidelines] 
(b) Serum bilirubin > 20 μmol/l and CSF 
protein ≤ 1.0g/l 
Apply formula to calculate an adjusted 
NBA. 
If adjusted NBA ≥ 0.007 AU, report as: 
‘Increased CSF bilirubin with 
oxyhaemoglobin present.  Consistent 
with SAH.’ 
If adjusted NBA < 0.007 AU, report as: 
‘Increased CSF bilirubin but probably 
totally accounted for by an increased 
serum bilirubin.  Oxyhaemoglobin 
present which on its own has a low 
predictive value for SAH, although does 
not totally exclude.’ 
(c) CSF protein > 1.0g/l, whatever the 
serum bilirubin. 
Report as: ‘Increased CSF bilirubin with 
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oxyhaemoglobin present.  This finding 
may be consistent with: SAH; an 
increased bilirubin accompanying the 
increased CSF protein; or other source of 
CSF blood.’ 
NBA > 0.007 AU and NOA > 0.1 AU NBA > 0.007AU and NOA > 0.02 with 
visible oxyhaemoglobin peak  
(a) CSF protein ≤ 1.0g/l, whatever the 
serum bilirubin. 
Report as: ‘Increased CSF bilirubin with 
oxyhaemoglobin present.  Consistent 
with SAH.’ 
(b) CSF protein > 0.1g/l, whatever the 
serum bilirubin. 
Report as: ‘Increased CSF bilirubin with 
oxyhaemoglobin present.  This finding 
may be consistent with: SAH; an 
increased bilirubin accompanying the 
increased CSF protein; or other source of 
CSF blood.’ 
Report as: ‘Bilirubin and 
oxyhaemoglobin increased.  Consistent 
with SAH.’ 
Methaemoglobin detected Methaemoglobin detected 
This is an unusual finding and probably 
related to artefactual conversion of 
oxyhaemoglobin.  Therefore when 
methaemoglobin is present the 
significance of the finding is the same as 
if oxyhaemoglobin had been detected.  
When reporting substitute 
methaemoglobin for oxyhaemoglobin 
Identical to original 2003 guidelines 
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CSF bilirubin stability 
 A CSF bilirubin stability study was undertaken.  A large volume CSF sample 
received in the laboratory, which was positive for xanthochromia (i.e. an extra-
ventricular drain sample), was aliquoted once all requested analyses had been 
completed upon the sample.  Two aliquots were placed on a laboratory bench on an 
overcast spring morning under normal strip lighting.  One aliquot was in a clear glass 
tube and the other was light protected in an opaque black specimen bag (Midco 
Labels Limited).  Spectrum analysis (Chalmers, 2001) was performed every hour in 
order to assess the rate of degradation of the bilirubin. 
The rate of degradation of bilirubin in the two CSF samples is shown in Graph 
A8.1.  Additionally the sample that was light protected was also analysed at 72 hours, 
at which point it still had an absorbance (Chalmers, 2001) of 0.075. 
 The light degradation study demonstrated how well the opaque black 
specimen bag (Midco Labels limited) protected the sample from the light, compared 
to the sample being left on the open bench.  It also proved that a sample could be left 
over the weekend, with no detrimental effects to the net bilirubin absorbance, and be 
analysed during normal working hours if necessary. 
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Figure A8.1: CSF bilirubin light degradation: Both samples placed on a laboratory 
bench on an overcast spring morning under normal strip lighting.  One sample was 
protected from the light in an opaque black specimen bag (Midco Labels limited). 
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No 
evidence to 
support 
SAH 
 Inconclusive 
(NOA may 
mask 
decreased 
NBA) 
 No 
evidence to 
support 
SAH 
 Consistent 
with SAH 
 No 
evidence to 
support 
SAH 
 Consistent 
with SAH 
 Interpret 
with 
caution 
 
NO 
CT scan 
SAH 
LP if safe 
> 12h 
CSF diazo bilirubin 
and protein 
Spectrophotometry; 
Chalmers calc NBA 
NBA > 0.007 
NOA > 0.02 + visible OxyHb peak 
YES NO 
Adjust for serum bilirubin if 
appropriate 
Adjusted NBA > 0.007 
YES 
CSF protein < 1.0 g/l 
YES NO 
NBA ≤ 0.007 
NOA < 0.1 
NO YES 
Negative or 
equivocal for blood 
CSF diazo bilirubin 
> 300 nmol/l 
Positive 
for blood 
CSF diazo bilirubin 
< 300 nmol/l 
Key 
CSF – cerebrospinal fluid 
CT – computed tomography 
scan 
NBA – net bilirubin 
absorbance 
OxyHb - oxyhaemoglobin 
SAH – sub-arachnoid 
haemorrhage 
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Telephone survey of laboratory 
xanthochromia services in South Wales 
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Telephone survey questionnaire 
 
 
 
Trust 
 
 
Hospital 
 
 
Department 
 
 
Contact name 
 
 
Grade 
 
 
Responsibility 
 
 
 
 
 
1. What method, if any, do you employ for xanthochromia determination in 
CSF? 
a. UKNEQAS guidelines 2003 
b. UKNEQAS guidelines 2008 
c. Visual examination 
d. Other 
e. No service provided 
 
 
 
2. How is the service provided? 
a. On-site 24/7 
b. On-site within normal working hours 
c. Referred to another laboratory 
d. Other 
 
 
 
3. If using UKNEQAS guidelines when did you introduce them i.e. were you an 
early adopter? 
 
 
 
4. Have you modified procedure to the 2008 revised guidelines 
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5. What platform do you currently perform serum bilirubin analysis on? 
 
 
 
6. Can you create user defineable chemistries on this platform? 
 
 
 
7. Would you consider using a modification to the UKNEQAS guidelines which 
incorporated an initial ‘rule-out’ step of analysing CSF diazo bilirubin directly 
on the sample provided for protein analysis? 
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CSF diazo bilirubin standard operating 
procedure 
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Clinical Biochemistry Service 
 
BIO F2 CSF diazo bilirubin Version No.: 1 
Document Owner: Victoria Bradley Usability Approver: Graham Bishell 
Competency Assessments 
 
 
BIO F2 CSF diazo Bilirubin 
Hazards and Safety Precautions 
Wear gloves 
Contains no known hazard. 
Use the usual precautions when dealing with chemicals. 
See Safety Data sheet for full details 
 Eye Contact: 
Promptly wash eyes with water for at least 15 Mins.  If necessary seek 
medical advice 
Skin Contact: 
Thoroughly wash skin with water 
Ingestion: 
Seek Medical Advice 
R1 Buffer/Solubiliser 
C 2 H 3 NaO 2 (Sodium Acetate Buffer): 85 mmol/l; H 3 NO 3 S (Sulfamic 
Acid): 110 mmol/l; surfactant; solubiliser 
Place in user defined reagent bottle in the pre-designated position 41-1 
on the outer ring of P unit 3.  
R2 Diazonium Ion 
HCl: 100 mmol/l; Diazonium ion: 3 mmol/l 
Place in user defined reagent bottle in the pre-designated position 41-2 
on   the inner ring of P unit 3. 
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Clinical Relevance 
Bilirubin is an organic compound formed by the reticuloendothelial system 
during the normal and abnormal destruction of red blood cells.  The presence 
of bilirubin in CSF is partly due to that which enters the CSF from serum but 
also, if there has been a bleed, formed by the destruction of red blood cells.  
Following haemorrhage (such as SAH) red cells undergo lysis and 
phagocytosis, releasing oxyhaemoglobin, which is metabolised by haem 
oxygenase in the arachnoid and choroid plexus to form bilirubin.   
Since the introduction of the diazo method for bilirubin determination by 
Ehrlich in 1883,1 several modifications have been proposed to enhance the 
reaction. The Malloy and Evelyn method2 employs methanol to catalyze the 
azo-coupling reaction of the indirect bilirubin, as well as to keep the 
azobilirubin in solution. A serious disadvantage of this method lies in the fact 
that protein may be precipitated by the methanol solution to yield falsely 
lowered results. 
In 1938, Jendrassik and Grof3 presented an assay that gave reliable results. 
The method is, however, cumbersome and involves several pipetting steps. 
In the method developed by Wahlefeld et al4 a detergent is used to accelerate 
the reaction and to avoid protein precipitation. The diazo reagent is 2,5-
dichlorophenyldiazonium tetrafluoroborate (DPD) which reacts very rapidly in 
coupling with bilirubin under acidic conditions. The resulting procedure is 
simple, yet exhibits good correlation when compared with the method of 
Jendrassik and Grof. The liquid method used here uses a new diazonium ion 
that gives excellent bilirubin coupling and reduces interference from 
hemoglobin and indican. 
Test Principle 
Total bilirubin, in the presence of a suitable solubilising agent, is coupled with a 
diazonium ion in a strongly acidic medium (pH 1-2).  
                                                Acid 
Bilirubin + diazonium ion      Azobilirubin 
  237 
The intensity of the color of the azobilirubin produced is proportional to the 
total bilirubin concentration and can be measured photometrically. 
Reagents 
Unopened kit components: up to the expiration date at 2 - 8oC. 
R1 Ready for use 
35 days opened and refrigerated on the analyser 
R2 Ready for use 
35 days opened and refrigerated on the analyser 
Calibration 
Calibration  Roche C.f.a.s (general chemistry 
routine calibrator) 
 Performed every 24 h 
Quality Control  
Specimen Collection and Preparation 
Collect CSF using white top universals and fluoride oxalate preservative, both 
of which are provided in CSF collection kits. 
 
Stability 
Protect specimens from light and assay immediately. Centrifuge samples 
containing precipitate before performing the assay. 
Internal Quality Control  Precinorm and Precipath (general 
chemistry routine QC). 
 1:20 dilution 
 Performed every 8 hours 
 N.B. aliquots remain stable at        
-20°C for three days following 
dilution 
External Quality Assurance UKNEQAS pilot scheme ‘CSF Proteins 
and Biochemistry’, received bimonthly 
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Ranges 
 No evidence to support 
SAH 
? SAH refer for scanning 
spectrophotometry 
Reference Range 
(nmol/l) 
< 300 > 300 
Instrument Settings 
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Training package 
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Issues with UKNEQAS guidelines
• Scanning spectrophotometry is subjective
• UKNEQAS guidelines;
• Places too much emphasis on interference of 
oxyhaemoglobin
• Calculation used to estimate serum bilirubin’s
contributions to CSF bilirubin overestimates by up 
to 15% - could lead to false negatives
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CSF bilirubin
• Through research carried out at ABMU 
CSF diazo bilirubin has been identified as 
an aid to the determination of 
xanthochromia;
• Less interference from oxyhaemoglobin
• Combining CSF diazo bilirubin results and 
UKNEQAS guidelines results in fewer inconclusive 
reports
 
 
New guidelines
• The new guidelines incorporate CSF diazo
bilirubin analysis as an initial step;
• < 0.300 µmol/l reported as ‘no evidence to support SAH’
• ≥ 0.300 µmol/l reported as ‘inconclusive, referred for further 
investigation’
• Those CSF samples referred for further 
investigation undergo scanning 
spectrophotometry under the 2008 UKNEQAS 
guidelines.
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CSF diazo bilirubin assay 
maintenance
• Reagents must be replaced once per 
fortnight
• Full 2-point calibration every 24 hours
• QC must be performed every 8 hours
 
 
Guidelines flow chart
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Clinical Biochemistry Service:   
Competency Assessment title: 
CSF diazo bilirubin analysis 
Code: 
SAT:XAN 
 
 
 
 
 
 
 
 
 
 
(For NOS and KSF links, please see task sheet – SAT:XAN) 
 
 
Staff details 
Name (please print)  
Grade  
Assessment details 
Assessor (please print)  
Date of assessment  
Mandatory pre-requisite competency assessments:  
 
1. General H&S 
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Skills: 
 
Performance criteria Signature  Date Evidence 
type 
Load CSF diazo bilirubin reagents on to P-
unit 
   
Calibrate CSF diazo bilirubin    
Prepare CSF diazo bilirubin QC material    
Perform CSF diazo bilirubin QC    
Prepare CSF samples for CSF diazo 
bilirubin analysis 
   
Store CSF samples for potential further 
analysis 
   
 
Suitable evidence: Witness testimony (W), Personal statement (PS), Observation (O) 
 
 
Knowledge: 
 
Please answer the following questions: Date/Signature 
Briefly describe the difference between serum and CSF 
bilirubin reagent; 
 
 
 
 
What dilution of general chemistry QC material is 
required for CSF diazo bilirubin QC? 
 
 
 
 
How long should CSF samples be centrifuged before 
CSF diazo bilirubin analysis? 
 
 
 
 
What is the CSF diazo bilirubin ‘cut-off’ which requires 
that the sample undergo spectrophotometry? 
 
 
 
 
Where are samples stored for spectrophotometry? 
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Member of staff and assessor to sign upon final completion 
 
  Date: 
Assessors signature:   
Staff signature:    
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Future: Medical Staff Questions 
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Potential questions for future survey of clinicians; 
 
1. Do you delay all further investigations whilst you await the results of 
CSF analysis? 
2. Where clinically indicated, do you proceed to angiography before CSF 
results are available? 
3. What is the availability of cerebral angiography out of hours in your 
hospital?  
4. What generation of CT scanner is available in your hospital? 
5. Is expert interpretation of CT scans available 24/7? 
6. What is the average stay of a patient in your hospital with: 
a. CT positive SAH? 
b. CT negative with further investigation. 
7. What proportion of patients who are suspected of having had an SAH and 
are CT negative are discharged before CSF results are available? 
8. What proportions of these are re-admitted with the same complaint? 
9. What proportions of patients who are admitted as suspected of having 
had an SAH and are CT negative are discharged before a lumbar puncture 
is performed? 
 
